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presented	 in	 chapter	 III.	 The	 chapter	 IV	 comprises	 the	 conclusions	 and	 the	
biological	 implications	 of	 the	 results.	 The	 future	 perspectives	 are	 highlighted	 in	
chapter	V.	
JC	 Ribot	 and	DV	 Correia	 developed	 part	 of	 the	 results	 presented	 in	 section	 1	 of	
chapter	 III	 as	 disclosed	 in	 Ribot	 et	 al	 JI	 2014.	 M	 Tesio	 and	 JC	 Ribot	 helped	 the	
development	 of	 the	 results	 presented	 in	 section	 2	 of	 chapter	 III	 as	 disclosed	 in	
Ribeiro	et	al	Leukemia	2016	
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Abstract 
Among	 the	 various	 leukocyte	 populations	 that	 build	 up	 the	 immune	 defense	
against	 infections	 and	 tumors,	 γδ	T	 lymphocytes	 constitute	 an	 enigmatic	 lineage	
whose	 molecular	 mechanisms	 of	 differentiation	 and	 activation	 are	 still	 poorly	
understood.	The	key	 roles	played	by	γδ	T	 cells	 in	 immunity	 critically	depend	on	





In	 this	 PhD	 thesis	 we	 evaluated	 the	 contribution	 of	 cell	 receptor	 signaling	
pathways	to	human	γδ	T	cell	differentiation	and	activation.	Firstly,	we	showed	that	
human	γδ	thymocytes	are	functionally	immature	and	their	differentiation	program	
requires	 additional	 IL-2	 or	 IL-15	 signals	 to	 drive	 their	 differentiation	 into	 IFN-γ	
and	TNF-α	producers	endowed	with	potent	cytotoxicity	against	leukemia	targets.	
We	 further	 elucidated	 the	 signals	 involved	 in	 normal/	 healthy	 γδ	 T	 cell	
maintenance	as	well	as	 in	γδ	T	cell	 tumorigenesis.	We	 identified	 that	 the	protein	
kinase	CK2	(Casein	Kinase	2)	is	overactivated	in	the	γδ	T	cell	lineage	compared	to	
αβ	 counterparts.	We	 further	 showed	 that	 the	 clinical	 grade-inhibitor	of	CK2,	CX-
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Resumo (Portuguese) 
O	 sistema	 imunitário	 consiste	 num	 vasto	 e	 complexo	 conjunto	 de	 moléculas,	
células,	 tecidos	 e	 órgãos	 responsáveis	 pela	 proteção	 de	 um	 organismo	 contra	
agentes	 externos	 ou	 células	 transformadas	 do	 próprio	 organismo.	 Estes	
mecanismos	 de	 proteção	 são	 conceptualizados	 em	 dois	 tipos	 de	 resposta	
imunitária,	 a	 imunidade	 inata	 e	 a	 imunidade	 adquirida	 ou	 adaptativa.	 Estes	
mecanismos	são,	em	larga	media,	baseados	no	principio	básico	da	distinção	entre	o	
“próprio”	 e	 o	 “não	 próprio”.	 Os	 linfócitos	 T,	 ou	 células	 T,	 são	 responsáveis	 pela	
imunidade	 adaptativa	 celular,	 desempenhando	 um	 papel	 fundamental	 no	
reconhecimento	de	organismos	invasores	ou	moléculas	“estranhas”	ou	associadas	







características	 quer	 das	 células	 do	 sistema	 inato	 quer	 do	 sistema	 adquirido.	 Por	
exemplo,	 as	 células	 T	 γδ	 são	 independentes	 do	 complexo	 principal	 de	
histocompatibilidade	 (MHC)	 aquando	do	 reconhecimento	 do	 antigénio	 pelo	TCR.	
As	 células	 T	 γδ	 têm	 a	 capacidade	 de	 reconhecer	 e	 responder	 a	 vários	 estímulos	





se	 encontram	maioritariamente	no	 sangue	 (e	 gânglios	 linfáticos).	As	 funções	das	
células	 T	 γδ	 resultam,	 predominantemente,	 da	 sua	 ativação	 e	 diferenciação	 em	
20  
	
células	 capazes	 de	 produzirem	 citocinas	 e	 induzirem	 a	 morte	 das	 células	 alvo.	
Estas	funções	são	iniciadas	por	sinais	extracelulares,	captados	pelas	células	e	que	
desencadeiam	 diversas	 vias	 de	 sinalização	 no	 interior	 da	 célula.	 Em	 última	




Nesta	 tese	 de	 doutoramento,	 analisamos	 a	 contribuição	 de	 diferentes	 vias	 de	
sinalização	 mediadas	 por	 diferentes	 citocinas	 na	 diferenciação	 de	 timócitos	 γδ	
humanos.	São	ainda	analisados,	com	especial	detalhe,	os	mecanismos	moleculares	
envolvidos	na	sobrevivência	das	células	T	γδ	normais	ou	tumorais.	A	compreensão	
e	 modulação	 destes	 mecanismos	 moleculares	 é	 especialmente	 importante	 na	
medida	em	que	estes	podem	constituir	potenciais	alvos	terapêuticos	em	contexto	
de	 imunoterapia	 envolvendo	 células	 T	 γδ.	 Estas	 vias	 podem,	 por	 exemplo,	 ser	
moduladas	 com	 o	 objectivo	 de	 promover	 as	 funções	 citotóxicas	 das	 células	 γδ	
contra	células	tumorais;	ou	constituir	alvos	terapêuticos	em	situações	de	leucemia	
linfoblástica	aguda	com	origem	nas	células	T	γδ.	
Os	 resultados	descritos	nesta	 tese	mostram	que	os	 timócitos	γδ,	 ao	 contrario	do	
que	se	observa	nos	linfócitos	T	γδ	periféricos,	são	funcionalmente	imaturos.	Isto	é,	
os	 timócitos	 γδ	 (maioritariamente	 do	 subtipo	 Vδ1)	 não	 têm	 a	 capacidade	 de	
produzir	 citocinas	 nem	 a	 capacidade	 de	 induzir	 a	 morte	 celular	 de	 células	
tumorais,	o	que	mostra	que	o	programa	de	diferenciação	das	células	T	γδ	humanas	
não	 é	 finalizado	no	 timo.	Tal	 constitui	 uma	diferença	 importante	 em	 relação	 aos	
timócitos	 γδ	de	murganho.	No	 entanto,	 a	 estimulação	dos	 timócitos	 γδ	humanos	
















de	 CK2,	 através	 do	 inibidor	 CX-4945,	 leva	 a	 um	 bloqueio	 da	 via	 AKT	 e	 a	 um	
aumenta	 da	 morte	 celular	 por	 apoptose	 das	 células	 T	 γδ,	 mas	 não	 das	 T	 αβ	
saudáveis.	 Verificamos,	 ainda,	 que	 a	 hiperativação	 de	 CK2	 é	 uma	 característica	
adquirida	por	células	malignas	de	leucemia	linfoblástica	aguda	(LLA)	com	origem	
na	 linhagem	 T	 γδ.	 Os	 resultados	 obtidos	 em	 amostras	 provenientes	 de	 doentes	
mostram	que	as	células	transformadas	são	do	subtipo	Vδ1,	e	que	o	tratamento	com	
o	inibidor	CX-4945	leva	à	apoptose	destas	células	LLA-T	γδ	primárias.	O	conjunto	
dos	 resultados	 obtidos	 quer	 in	 vitro	 e	 in	 vivo	 (modelo	 xenotransplante	 em	
murganhos	 imunodeficientes)	mostram	que	as	 células	LLA-T	γδ	 são	 sensíveis	 ao	
inibidor	 da	 CK2,	 CX-4945,	 abrindo	 novas	 oportunidades	 à	 sua	 utilização	 no	
tratamento	de	doentes	com	este	tipo	de	leucemia.	
Globalmente,	os	resultados	apresentados	e	discutidos	nesta	tese,	demonstram	que	









células	 transformadas.	 Dada	 a	 hiperativação	 da	 CK2	 em	 células	 transformadas	
LLA-T	 γδ,	 e	 a	 sua	 susceptibilidade	 ao	 inibidor	 CX-4945,	 propomos	 que	 a	 CK2	






























a	 legitimate	 part	 of	 the	 body,	 from	 foreign	molecules	 and	 organisms	 (“nonself”)	
that	might	be	present	 in	 the	organism.	By	complex	cellular	and	molecular	events	
mediated	by	innate	(antigen-nonspecific)	and	adaptive	(antigen-specific)	immune	
response,	 the	 immune	system	eliminates	 those	nonself	 invaders,	which	are	often	
dangerous	bacteria	or	viruses.	In	addition,	the	immune	system	can	recognize,	and	
usually	 eliminate,	 “altered	 self”–cells	 or	 tissues	 that	 otherwise	 could	 originate	
malignancies1.	
Leukocytes	of	 the	 innate	 immune	system	serve	as	sentinels	 for	detecting	general	
signs	 of	 danger.	 These	 cells	 are	 usually	 equipped	 with	 pattern	 recognition	
receptors	 (PRR)	 leading	 to	 a	 fast	 and	 unspecific	 activity	 against	 groups	 of	
pathogens.	 Thus,	 these	 innate	 myeloid	 cells	 (Phagocytes,	 Mast	 cells,	 Basophils,	
Eosinophils)	 and	 innate-like	 lymphocytes	 (NK	 cells,	 NKT	 cells	 and	 γδ	 T	 cells)	




Additionally,	 the	 adaptive	 system	 is	 composed	 of	 B	 cells	 and	 αβ	 T	 lymphocytes,	
which	 react	 specifically	 to	 diverse	 pathogenic	 conditions.	 Adaptive	 immunity	 is	




T	 cell	 receptors	 (TCR)	 for	 T	 cells	 -	 that	 can	 collectively	 recognize	 millions	 of	
distinct	 antigens.	 These	 receptors	 are	 generated	 by	 somatic	 recombination	
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mediated	 by	 recombination	 activating	 gene	 (RAG)	 enzymes,	 an	 extraordinary	




The	anatomic	 sites	where	 the	major	 steps	 in	 lymphocyte	development	occur	are	
called	 primary	 or	 generative	 lymphoid	 organs.	 These	 include	 the	 bone	marrow,	
where	the	precursors	of	all	lymphocytes	arise	and	B	cells	mature,	and	the	thymus,	
where	T	cells	mature.	Following	maturation,	the	lymphocytes	enter	the	circulation	
and	 peripheral	 lymphoid	 organs	 (e.g.	 the	 spleen	 and	 lymph	 nodes)	 where	 they	
survey	for	invading	pathogens	and/or	tumor	cells2.	
The	 thymus	 is	 present	 in	 all	 jawed	 vertebrates,	 present	 similar	 structure	 and	
undergoes	 the	 same	 shrinkage	 with	 age	 and	 plays	 the	 same	 immunological	
function	 as	 in	 human	 beings.	 The	 lymphocytes	 in	 the	 thymus,	 also	 called	




selection,	 thymocytes	 migrate	 toward	 the	 medulla	 where	 medullary	 thymic	
epithelial	cells	(mTEC)	play	a	special	role	in	presenting	self-antigens	to	developing	
T	 cells	 and	 causing	 their	 ablation	 (negative	 selection).	 This	 is	 one	mechanism	of	





in	 human.	 However,	 human	 T	 cell	 development	 appears	 to	 depend	 on	 similar	
mechanisms	(as	in	mice),	and	the	key	factors	in	T	cell	development	may	be	broadly	
conserved	 among	 jawed	 vertebrates.	 Of	 note,	 the	 congenital	 absence	 of	 the	
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thymus,	as	occurs	 in	DiGeorge	syndrome	 in	humans	or	 in	 the	nude	mouse	strain	
(athymic),	 is	 characterized	 by	 very	 low	 numbers	 of	 mature	 T	 cells	 in	 the	




or	 CD8	 receptors.	 These	 double-negative	 (DN)	 thymocytes	 are	 highly	 immature	
progenitors,	 comprising	 about	 1–2%	 of	 thymocytes,	 that	 in	 both	 murine	 and	
human	undergo	successive	stages	of	cell	selection.	T	cell	commitment	corresponds,	
at	 the	molecular	 level,	 to	 productive	 TCR	 rearrangements.	 These	 occurs	 at	 four	
gene	loci,	TCRα,	β,	γ	and	δ,	present	in	all	jawed	vertebrates.	The	protein	products	
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Immature	murine	DN	thymocytes	can	be	separated	into	four	populations	(DN	1-4)	
based	 on	 the	 expression	 of	 CD44	 and	 CD25	 (Ref.	 7).	 However,	 immature	 human	
thymocytes	do	not	express	the	same	surface	markers	and	are	characterized	by	the	
differential	expression	of	CD34,	CD38,	and	CD1a4.	





These	 differentiation	 steps	 are	 controlled	 by	 a	 complex	 system	 of	 several	




of	Notch	 ligands,	Delta-like	 (DL)	and	 Jagged,	have	been	 identified8.	The	activated	
intracellular	 domain	 of	Notch	 proteins	migrate	 to	 the	 nucleus	 and	modulate	 the	
expression	 of	 specific	 target	 genes1,9.	 T	 cell	 development	 depend	 on	 several	




Somatic	 rearrangement	 of	 the	 genes	 encoding	 the	TCRβ,	 TCRγ	 and	TCRδ	 chains,	




is	 selected	 into	 the	γδ	T	cell	 lineage.	Otherwise,	when	a	TCRβ	chain	 is	expressed	
from	 a	 productively	 rearranged	 Tcrβ	 locus	 (V-D-J	 recombination)	 the	 cells	
progress	to	a	αβ	T	cell	lineage.	The	TCRβ	pairing	with	the	invariant	pre-TCRα	chain	
28 general introduction 
	
forms	 a	 pre-TCR12–15.	 Pre-TCR	 signaling,	 coupled	 to	 signals	 from	 cytokine	 and	
possibly	other	receptors,	promotes	cell	survival,	proliferation	and	differentiation.	
Following	 β-selection	 DN4	 cells	 subsequently	 become	 DP	 CD4+CD8+	 population	
that	 comprises	 75–88%	 of	 thymocytes.	 DP	 cells	 complete	 Tcrα	 gene	
rearrangement	 (V-J	 recombination)	 and	 present	 TCRαβ	 heterodimers	 at	 cell	
surface.	 The	 expression	 of	 functional	 TCRαβ	 provides	 the	 substrate	 for	 MHC-
mediated	positive	selection	into	SP	CD4+	or	CD8+	populations	followed	by	negative	
selection	 that	 eliminates	 autoreactive	 αβ	 thymocytes.	 Finally,	 these	 mature	
thymocytes	 proliferate	 shortly	 immediately	 before	migrating	 to	 the	periphery	 to	




Early	 during	 thymocyte	 differentiation	 γδ	 T	 cells	 diverge	 from	 αβ	 T	 cells	 and	
continue	 along	 different	 developmental	 paths.	 The	 bifurcation	 of	 αβ	 and	 γδ	
lineage-commitment	 is	 thought	 to	 be	 complete	 at	 DN3	 and	 these	 decisions	 are	
influenced	 by	 different	 site-specific	 signals,	 derived	 from	 cytokines,	 chemokines,	
TCRs,	Wnt	signaling,	Notch	ligands,	and	others	thymic	microenvironment	stimuli17.		
Successful	 in-frame	 rearrangement	 of	 the	 TCRγ	 and	 δ	 genes	 results	 in	 the	
expression	of	a	TCRγδ	complex	and	favos	differentiation	along	the	γδ	lineage17–19.	
In	 both	 mouse	 and	 humans,	 TCRδ	 rearranges	 first,	 followed	 closely	 by	 TCRγ	
rearrangement17.	
This	recombination	 joins	any	one	of	several	variable	(V)	gene	segments	with	any	
one	 of	 several	 joining	 (J)	 segments	 and,	 in	 TCRδ,	 also	 with	 diversity	 (D)	 gene	
segments.	 	 The	 somatic	 recombination	 of	multiple	 gene	 segments	 contributes	 to	
the	diversity	of	 receptor-structure.	Following	gene	recombination,	only	cells	 that	
make	productive	TCRs	are	selected	to	survive20.	
Factors	 such	 as	 IL-7R	 expression21	 or	 Notch	 signaling22–25	 are	 described	 to	 be	
involved	 in	 γδ	 lineage-commitment26.	 IL-7R	 controls	 the	 recombination	 at	 the	
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TCRγ	 locus	 by	 regulating	 Rag	 accessibility27.	Moreover,	murine	 thymocytes	with	
abundant	 IL-7R	are	more	 likely	 to	give	 rise	 to	γδ	T	 cell	 lineage	 than	 thymocytes	
lacking	IL-7R28.	In	addition,	immature	thymocytes	with	high	levels	of	IL-7R	express	
more	of	the	transcription	factor	SOX13	(sex-determining	region	Y-box	13)	protein.	
SOX13	 is	 a	 putative	 T	 cell	 lineage	 regulator	 that	 promotes	 the	 γδ	 lineage	 and	
impairs	 αβ	 development.	 Mice	 deficient	 in	 SOX13	 expression	 can	 still	 produce	
mature	αβ	T	cells,	whereas	the	development	of	γδ	T	cells	is	impaired17,29.	
Notch	 signaling	 is	 also	 thought	 to	 be	 involved	 in	 αβ	 versus	 γδ	 T	 cell	 lineage	
commitment.	 In	mouse,	 high	 levels	 of	Notch	 signaling	 are	 required	 for	 αβ	T	 cell	
development	compared	to	γδ	T	cells.	Reduced	levels	of	Notch1	gene	in	vivo	favors	
γδ	 T	 cell	 development	 over	 αβ	 T	 cells30,31.	 However	 γδ	 T	 cell	 commitment	may	
require	different	ligands	of	Notch32.	In	humans,	the	involvement	of	Notch	signaling	
in	T	cell	development	is	less	clear	and	paradoxical	to	the	mouse	data.	Toribio	and	
Plum’s	 groups	 showed	 that	 increased	Notch	 activation	 results	 in	 increased	 γδ	 T	
cell	development	at	the	cost	of	αβ	T	cells33–35.	Thus,	the	involvement	of	Notch	in	γδ	
T	cell	commitment	remains	somewhat	controversial.		
The	γδ	T	cell	 lineage	 fate	 is	not	simply	 instructed	by	 the	 type	of	rearranged	TCR	
complex	that	 is	 found	on	the	surface	of	a	given	cell.	 Instead,	the	“strength”	of	the	
signal	that	is	delivered	by	the	TCR	complex	seems	to	be	critical36,37.	Thus,	TCRγδ,	
which	 appears	 to	 signal	 relatively	 strongly,	 directs	 cells	 towards	 the	 γδ	 lineage,	
whereas	the	preTCR,	which	generates	a	weaker	signal	(than	TCRγδ),	promotes	the	
development	 of	 αβ	 lineage	 cells38–41.	 This	 model	 suggests	 that	 a	 strong	 TCRγδ	
signal	 would	 result	 in	 higher	 activation	 of	 the	 extracellular	 signal-regulated	
kinases/	 mitogen-activated	 protein	 kinases	 (ERK-MAPK)	 pathway,	 leading	 to	 a	
higher	induction	of	the	Early	Growth	Response	(EGR1,	EGR3)	transcription	factors	
and	 their	 target	 Inhibitor	 of	 DNA	 binding	 3	 (Id3)	 in	 a	 mouse	 model36,42,43.	 Id	
proteins	are	direct	inhibitors	of	E2A,	a	helix-loop-helix	protein,	which	activates	the	
pre-TCRα	 promoter44.	 The	 higher	 accumulation	 of	 Id3	 results	 in	 stronger	
inhibition	 of	 E2A,	 and	 thus	 expression	 of	 γδ	 T-cell	 hallmark	 genes.	 Conversely,	
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weaker	 signals	 through	 the	 Notch	 receptors	 and	 pre-TCR	 would	 result	 in	 more	
modest	accumulation	of	Id3,	and	hence	weaker	inhibition	of	E2A	leading	to	further	
development	along	the	αβ	lineage17,41.	By	analogy,	as	a	consequence	it	is	also	likely	
that	 the	 signals	 downstream	 of	 each	 TCR	 results	 in	 differential	 regulation	 of	
transcription	 factors	 that	 are	 essential	 for	 the	 functional	maturation	 of	 different	
effector	subsets41.	Thus,	 the	TCR	signal	strength	required	 for	 the	development	of	
multiple	 subsets	 of	 γδ	 T	 cells	 is	 likely	 heterogeneous.	 Consistent	 with	 this	














are	 the	 first	 to	 leave	 the	 foetal	 thymus,	 giving	 rise	 to	 skin-associated	 dendritic	
epidermal	T	cells	 (DETCs).	Thymocytes	bearing	a	Vγ6Jγ1Cγ1	TCR	at	E16-18	give	
rise	 to	 the	 γδ	 T	 cells	 in	 the	 tongue	 and	 reproductive	 tract,	 whereas	 peri-and	
postnatal	thymocytes	bearing	Vγ1Cγ1	and	Vγ4Cγ1	TCRs	give	rise	to	systemic	γδ	T	
cells	(that	predominate	in	lymph	nodes	and	spleen).		
Many	 of	 the	 studies	 elucidating	 the	 physiological	 roles	 of	 γδ	 T	 cells	 have	 been	
performed	in	murine	models,	where	the	identification	of	pro-inflammatory	subsets	
naturally	producing	either	IFN-γ	or	IL-17	was	a	major	recent	breakthrough49–51.		




producing	 γδ	 cells,	whereas	 their	 IL-17-expressing	 counterparts	 display	 a	 CD27-	
CCR6+	phenotype49–51.	Moreover,	the	two	subsets	show	distinct	Vγ	chain	usage	in	
their	 TCR	 repertoires,	with	 a	 bias	 towards	 Vγ1	 among	 IFN-γ-producing	 γδ	 cells,	
and	 an	 enrichment	 in	 Vγ4	 and	 Vγ6	 in	 IL-17-producing	 γδ	 cells52.	Moreover,	 the	
transcription	factors	Sox13	and	RORγt	(Rorc)	are	essential	for	IL-17	producing	γδ	
T-cells,	including	Vγ6+	and	some	Vγ4+	T	cells,	while	Eomes	and	Tbet	are	hallmarks	
of	 IFN-γ	 producing	 subtypes,	 such	 as	 Vγ5+	 dendritic	 epidermal	 T-cells41.	 The	





of	 nucleated	 cells)	 in	 peripheral	 blood	 but	 are	 abundant	 in	 tissues,	 especially	 in	
epithelial	layers46.	For	identification	purposes,	they	are	usually	sub-divided	based	









somatically	 rearrange	 their	 TCR	 genes	 to	 generate	 great	 diversity;	 and	 can	
selective	expand	particular	subpopulations	upon	infection.	But,	on	the	other	hand,	
γδ	cells	endow	the	T	cell	compartment	with	a	rapid,	innate-like	reaction	to	insults,	
which	 places	 them	 in	 the	 afferent	 phase	 of	 the	 immune	 response.	 γδ	 T	 cells	 are	
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responsible	 for	 “lymphoid	 stress	 surveillance”,	 i.e.,	 sensing	 and	 responding	
immediately	 to	 infections	 or	 non-microbial	 stress	 without	 the	 need	 of	 clonal	
expansion	or	de	novo	differentiation,	in	synchrony	with	prototypic	innate	immune	
responses60.	Critically,	this	implicates	γδ	T	cells	in	inflammation61,	autoimmunity62,	





In	humans,	 γδ	T	 cells	 have	 a	 small	 repertoire	of	V	 gene	 segments	 to	 select	 from	
when	undergoing	TCR	chain	rearrangement	in	comparison	with	those	available	for	
Vα	 (43–45	 (Ref.68))	 and	Vβ	 (40–48	 (Ref.69)).	Three	main	Vδ	gene	 segments,	Vδ1,	
Vδ2	and	Vδ3	(Table	1),	are	most	frequently	used	in	rearrangement	of	the	δ	chain;	
less	commonly	used	are	the	five	V	segments	that	have	both	Vδ	and	Vα	designation	




for	 rearrangement,	 the	 complementarity-determining	 regions	3δ	 (CDR3δ)	 allows	
the	incorporation	of	multiple	Dδ	segments	(in	forward	and	reverse	direction)	and	










































cell	 population	 in	 the	 gut	 epithelium75.	 The	Vδ1	T-cell	 population	 expands	 upon	
infections	with	bacteria	(Mycobacterium	tuberculosis,	Listeria	monocytogenes	and	
Borrelia	 burgdorferi)	 and	 virus	 (HIV	 and	 cytomegalovirus	 (CMV))76–78.	
Importantly,	γδ	tumor	infiltrating	lymphocytes	(TILs)	were	described	as	being	the	




ovarian	 and	melanoma82–84,	 recognize	 and	 kill	 both	 the	 autologous	 tumor	 and	 a	
broad	 range	 of	 related	 tumors,	 presumably	 via	 the	 recognition	 of	 shared	 stress-
related	 ligands,	 but	 do	 not	 kill	 nontransformed	 cells85.	 This,	 together	 with	 the	
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observation	 that	Vδ1	T	 cells	 infiltrate	and	 respond	 to	 solid	 tumors,	 supports	 the	
use	of	Vδ1	T	cells	as	a	promising	cancer	immunotherapeutic	approach72.		
Several	 studies	 attempted	 to	 improve	 Vδ1	 T	 cell	 efficacy	 to	 be	 used	 in	 cancer	
treatments.	 In	 the	 host	 lab,	 Correia	 and	 collaborators	 formulated	 an	 in	 vitro	
protocol	 that	 induces	 the	expression	of	natural	 cytotoxicity	 receptors	 (NCRs;	e.g.	
NKp30,	NKp44	and	NKp46),	on	Vδ1	T	cells	 isolated	from	peripheral	blood.	These	
de	 novo	 NCRs,	 which	 had	 been	 previously	 regarded	 as	 NK-specific	 markers,	
enhance	 tumor	 targeting	by	Vδ1	T	 cells86.	 	 Although	neither	Vδ1+	nor	Vδ2+	 cells	
express	NCRs	constitutively,	these	can	be	selectively	upregulated	in	Vδ1+	cells	by	
AKT-dependent	 signals	 provided	 synergistically	 by	 γc	 cytokines	 (IL-2	 or	 IL-15)	
and	 TCR	 stimulation86,87.	 However,	 the	 intracellular	 signaling	 mechanisms	
involved	 in	 γδ	 T	 cell	 activation	 and	 expansion	 are	 still	 poorly	 understood.	 The	
insufficient	γδ	T	cell	numbers	was	an	additional	limitation	to	the	use	of	Vδ1	T	cells	
in	 the	 clinic.	 This	 limitation	was	 recently	 overcome	by	 a	 robust	 protocol	 for	 the	
selective	 expansion	 and	 differentiation	 of	 cytotoxic	 Vδ1	 T	 cells88.	 These	 cells	
selectively	 target	 leukemic	 cells	 via	 the	 combined	 action	 of	 TCR	 and	 NCRs	 and	
production	of	IFN-γ	and	TNF-α,	in	vitro	and	in	vivo,	but	not	IL-1788,	which	has	been	
implicated	in	the	promotion	of	tumor	cell	growth72,89.		




cells	 are	 activated	 by	 stress-induced	 self-antigens	 that	 are	 oſten	 constitutively	
expressed	by	solid	tumors,	leukemias	and	lymphomas92.	In	particular,	Vδ1	T	cells	
recognize	 MIC-A/B93,94	 induced	 by	 oxidative	 stress95,	 and	 oſten	 upregulated	 on	
malignant	cells96.	The	MIC-A/B	recognition	by	NKG2D	receptor	on	Vδ1	(but	also	on	
Vδ2)	 T	 cells	 is	 critical	 for	 recognition	 and	 subsequent	 killing	 of	 several	 target	
cancers	 via	 perforin	 and	 granzymes92,97.	 Vδ1	 T	 cells	 have	 been	 reported	 to	
recognize	several	ligands	presented	by	different	members	of	the	MHC	superfamily	











Vδ2	 TCR	 chains,	 suggesting	 that	 some	 of	 the	 specificities	within	 this	 population	
may	be	 important	 in	 responding	 to	pathogenic	 challenges.	Vδ2	T	 cells	 are	 found	
only	 in	 humans	 and	 higher	 primates	 and	 constitute	 the	 best	 studied	 γδ	 T	 cell	
subset.		
Vδ2	 T	 cells	 are	 often	 sub-divided	 on	 the	 basis	 of	 surface	 expression	 of	 two	
receptors:	 CD45RA	 and	 CD27.	 However,	 CD27	 does	 not	 identify	 a	 human	 γδ	 T	
subset	comparable	to	the	CD27+	γδ	T	subset	in	mouse	(i.e.	pre-committed	to	robust	
IFN-γ	secretion)50.	CD27	is	a	member	of	the	TNF	receptor	family	with	known	co-
stimulatory	 activity	 that	 is	 expressed	 by	 a	 major	 proportion	 of	 human	 Vδ2	 T	
cells104.	CD27	and	CD45RA	identify	four	Vδ2	T	subsets:	(i)	‘Naive’	(Tnaive)	CD45RA+	
CD27+	Vγ9Vδ2+	 cells	 are	highly	proliferative,	do	not	 secrete	 IFN-γ,	 and	generally	
comprise	10–20%	of	those	in	peripheral	blood	(but	the	major	population	in	lymph	
nodes)105.	(ii)	Tnaive	cells	become	largely	CD45RA-	CD27+	(and	CD45RO+)	after	TCR	




CD45RO+)	 ‘Effector	Memory’	 (TEM)	 cells	 that	 lose	CCR7	and	CD62L,	 but	 acquired	
the	tissue-associated	chemokine	receptors	CCR2,	CCR5,	CCR6	and	CXCR3	(Ref.106).	
Although	with	low	capacity	for	proliferation,	TEM	cells	secrete	abundant	IFN-γ	and	
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tumor	 necrosis	 factor-α	 (TNF-α)	 and	 are	 present	 in	 higher	 percentages	 in	 blood	
and	 inflammatory	sites.	 (iv)	TCM	cells	also	appear	 to	generate	a	CD45RA+	(CD27-,	
CCR7-)	 effector	 memory	 (TEMRA)	 population	 when	 activated	 with	 IL-15	 (Ref.107),	
however	these	cells	are	virtually	absent	from	blood.	TEMRA	cells	express	abundant	
perforin,	 granulysin	and	display	 robust	 cytolytic	 activity	 (but	 little	production	of	
IFN-γ).	Additionally,	TEMRA	 cells	are	unresponsive	 to	 further	TCR	stimulation	and	
have	 little	 proliferative	 capacity,	 a	 phenotype	 consistent	 with	 a	 terminally	
differentiated	state108.	
Vδ2	T	cells	are	unique	 in	 their	 recognition	of	 low-molecular-weight	non-peptidic	
and	 phospho-containing	 compounds	 collectively	 called	 phosphoantigens	 (PAgs).	
Vδ2	T	cells	responds	robustly	to	isopentenyl	pyrophosphate	(IPP),	an	intermediate	
in	 the	 human	 mevalonate	 pathway	 and	 to	 (E)-4-hydroxy-3-methyl-but-2-enyl-
pyrophosphate	 (HMBPP),	 a	 microbial	 isoprenoid	 intermediate109.	 Importantly,	
several	microbial	 and	 plant	 PAgs	 produced	 through	 the	 deoxyxylulose	 pathway,	
such	 as	 HMBPP,	 show	 10,000-fold	 higher	 activity	 than	 those	 from	 mammalian	
PAgs54.	 Nanomolar	 concentrations	 of	 HMB-PP	 lead	 to	 rapid	 TCR-dependent	
activation	 of	 Vγ9Vδ2	 T	 cells,	 enabling	 them	 to	 respond	 to	 a	 diverse	 range	 of	
pathogens,	 including	 Mycobacterium	 tuberculosis110,111	 and	 Plasmodium	
falciparum112.	 Indeed,	 in	 vitro	 incubation	 of	 PBL	 with	 mycobacterial	 lysates	
induces	 an	 expansion	 of	 Vγ9Vδ2-expressing	 γδ	 T	 cells,	 and	 the	 stimulatory	
components	 are	 protease	 resistant	 and	 phosphatase	 sensitive54,113.	 Importantly,	
the	 recognition	 of	 PAgs	 is	 restricted	 mainly	 to	 higher	 primates,	 with	 mice	 and	
other	rodents	not	possessing	any	T	cell	subsets	that	respond	to	PAgs114.		
The	ability	to	respond	to	prenyl	pyrophosphates	has	been	used	to	redirect	Vδ2	T	
cells	 to	 tumors	 by	manipulating	 isoprenoid	metabolism	 in	 the	 cancer	 cells.	 Such	
manipulation	 can	 be	 achieved	 using	 aminobisphosphonates	 (e.g.	 zoledronate,	
pamidronate,	risedronate)	which	 inhibit	 farnesyl	pyrophosphate	synthase	(FPPS)	
in	 the	mevalonate	pathway	 leading	 to	 the	accumulation	of	prenyl	pyrophosphate	
substrates114–116.	 In	 addition,	 although	 some	 Vγ9Vδ2	 T	 cells	 respond	 poorly	 to	
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PAgs,	they	can	respond	robustly	to	naturally	occurring	primary	alkylamines,	such	












findings	 raised	a	 series	of	new	questions	associated	with	 the	occurrence	of	both	
stimulatory	 and	 inhibitory	 anti-BTN	mAbs	 that	 was	 better	 understood	 after	 the	
characterization	 of	 the	 3D	 structure	 of	 BTN3A1	 (Ref.122).	 Currently	 findings	
indicates	that	while	the	inhibitory	antibody	bounds	to	the	distal	part	of	the	V-like	
domain,	the	stimulatory	antibody	bounds	to	a	more	membrane	proximal	region	of	
the	 V-like	 domain,	 preventing	 or	 facilitating	 the	 BTN3	 homodimerization	
respectively123.	 However,	 the	 precise	 role	 of	 BTN3A	 molecules	 in	 PAg	 induced	
activation	 of	 Vγ9Vδ2	 T	 cells	 has	 been	 controversial	 and	 remains	 to	 be	 fully	
elucidated.	Different	molecular	mechanisms	have	been	proposed	in	order	to	clarify	
the	Vγ9Vδ2	T	cell	activation	process	by	BTN3A1.	While	Vavassori	et	al.119	suggest	
that	 BTN3A1	 as	 antigen	 presenting	 molecule	 triggers	 Vγ9Vδ2	 T	 cell	 activation,	
data	 from	 Sandstrom	 et	al.124	 and	Harly	 et	al.121	 support	 an	 inside-out	 signaling	
mechanism	 for	 BTN3A1,	 where	 phosphonatigens	 bind	 to	 its	 intracellular	 region	
and	in	which	model	immobilization	of	BTN3A1	at	the	cell	surface	may	contribute	
to	 an	 extracellular	 cue	 for	 recognition	 by	 Vγ9Vδ2	 TCRs.	 This	 could	 be	 through	
several	means	that	work	individually	or	in	concert	to	initiate	TCR	recognition:	(i)	
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(iii)	 involves	 an	 unknown	 accessory	 protein	 that	 is	 the	 true	 Vγ9Vδ2	 TCR	
ligand71,124–128.	
Several	approaches	have	been	developed	in	order	to	redirect	Vδ2	T	cells	to	target	
different	 tumors.	 Zheng	 et	 al.	 combined	 the	 extracellular	 domains	 of	 TCR	 from	
Vγ9Vδ2	TILs	 and	 conjugated	 them	with	Fc	domain	of	human	 IgG1	 (Ref.129).	This	
bispecific	 construct	 mediated	 the	 killing	 of	 a	 range	 of	 ovarian	 cancer	 cells	 via	
antibody-dependent	 cellular	 cytotoxicity	 (ADCC).	 ADCC	 can	 be	 mediated	 by	
binding	 of	 CD16	 (FccRIII)	 to	 the	 Fc	 region	 of	 IgGs.	 A	 similar	 approach	 involves	
transducing	 Vδ2	 T	 cells	 with	 chimeric	 antigen	 receptors	 (CARs)	 that	 recognizes	
conformational	epitopes	independently	of	their	TCR	(recently	reviewed	in	Maus	et	
al.130).	Recently,	Deniger	et	al.	have	transduced	polyclonal	γδ	T	cells	with	a	CD19-
specific	 CAR,	 demonstrating	 their	 efficacy	 in	 killing	 CD19+	 leukemia	 cells131.	
Additionally,	the	transduction	of	TCRαβ	into	γδ	T	cells132	or	the	transduction	of	a	
specific	 TCRγδ	 into	 αβ	 T	 cells133	 have	 been	 showed	 to	 efficiently	 target	 specific	
tumors114.	
Altogether	the	presence	an	accumulation	of	γδ	T	cells	in	areas	of	disease	relevance	
(tissues	 prone	 to	 cancers	 and/or	 infections)	 makes	 them	 an	 obvious	 target	 for	
immunotherapy.	 Understanding	 the	 antigens	 to	 which	 they	 respond,	 how	 they	










likely	 induced	 by	 stress	 signals	 and	 sensed	 by	 either	 T-cell	 or	 natural	 killer	
receptors.	Some	γδ	T	cell	populations	are	also	particularly	responsive	to	cytokines	
or	innate	toll-like	receptor	(TLR)	agonists47,54.	Following	proliferation	and	effector	
responses,	 the	 return	 to	 homeostasis	 is	 controlled	 by	 inhibitory	 receptors.	
Altogether,	 the	various	 layers	of	T	(TCR	and	costimulatory/inhibitory	receptors),	
NK,	 and	 cytokine	 receptor	 signals	 synergistically	 regulate	 the	 activation	 and	
differentiation	of	effector	γδ	T	cell	populations	(Figure	2).	
	




The	 TCRγδ	 complex	 is	 composed	 by	 the	 TCRγδ	 itself	 and	 various	 CD3	 chains	
following	 the	 stoichiometry:	 TCRγδCD3ε2γδζ2	 in	 humans,	 and	 TCRγδCD3ε2γ2ζ2	 in	























The	 TCR	 complex	 does	 not	 present	 intrinsic	 kinase	 activity	 but	 the	 intracellular	
signalling	 is	 initiated	 after	 phosphorylation	 of	 immunoreceptor	 tyrosine-based	
activation	 motifs	 (ITAMs)	 in	 the	 CD3	 cytoplasmic	 domains	 by	 the	 Src-family	
kinases	(SFKs)	Lck	and	Fyn137.	The	recruitment	of	these	SFKs	to	the	TCR	complex	
in	 γδ	 T	 cells	 remains	 obscure	 since	 these	 cells	 do	 not	 express	 the	 CD4	 or	 CD8	





phospholylation	 and	 activation	 of	 Zap70	 that	 facilitates	 phosphorylation	 of	 the	
scaffolding	 proteins	 SLP-76	 and	 LAT.	 This	 lead	 to	 the	 formation	 of	 a	
supramolecular	 signalosome	 that	 recruits	 the	 phospholipase	 PLCγ1	 resulting	 on	
propagation	of	downstream	signalling	events136.	Here	again,	γδ	T	cell	signalling	is	
different	 from	 αβ	 T	 cells,	 since	 mutations	 on	 the	 binding	 site	 of	 PLCγ1	 on	 LAT	
resulted	 in	 a	 severe	 block	 in	murine	 αβ	 thymocyte	 development	while	 γδ	 T	 cell	
numbers	 were	 only	 modestly	 reduced	 in	 the	 thymus,	 intestine	 and	 liver,	 and	
remained	 normal	 in	 the	 skin.	 Unexpectedly,	 a	 population	 of	 γδ	 T	 cells	 in	 the	
secondary	lymphoid	organs	in	these	mice	underwent	uncontrolled	expansion	and	
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intermediates	of	 isoprenoid	 synthesis	–	 “phosphoantigens’’	 or	 “phosphoagonists”	
(P-Ags)109,111,140.	 These	 P-Ags	 were	 shown	 to	 trigger	 bona	 fide	 Vγ9Vδ2	 TCR	
signalling	in	various	studies.	Cipriani	and	colleagues	showed	that	the	activation	of	
Vγ9Vδ2	T	cells	with	the	P-Ag	isopentenyl	pyrophosphate	(IPP),	induced	rapid	and	
persistent	 PKC-dependent	 phosphorylation	 of	 ERK1/2,	 p38	 MAPK,	 and	 JNK,	
resulting	in	NF-κB	and	AP-1	activation	as	well	as	the	release	of	CCL-3,	CCL-4,	IFN-γ	








and	 co-workers	 showed	 that	 T10/T22-specific	 γδ	 T	 cells	 required	 thymic	
expression	of	 their	TCR	 ligands	 to	differentiate	 into	 IFN-γ	producers,	 in	 contrast	
with	“ligand	naïve”	IL-17	producers49.	Consistent	with	this,	TCR-dependent	thymic	
selection	was	also	shown	to	set	the	functional	potential	of	DETC	progenitors	away	
from	 IL-17	production150.	 Furthermore,	 peripheral	 IL-17-producing	CD27-	 CCR6+	
γδ	 T	 cells	 were	 shown	 to	 expand	 and	 produce	 IL-17	 independently	 of	 TCR	
activation151.	 However,	 a	 subsequent	 study	 by	 Chien	 and	 collaborators	
demonstrated	that	a	subset	of	phycoerythrin	(PE)-specific	γδ	T	cells	produced	IL-
17	 specifically	 upon	 TCR	 ligation152.	 Moreover,	 a	 recent	 study	 by	 Hayday	 and	
colleagues	suggested	that	an	impairment	in	Zap70	signalling	(in	SKG	mice)	mostly	
affected	 the	 development	 of	 IL-17+	 rather	 than	 IFN-γ+	 γδ	 T	 cells153.	 The	 authors	
further	 proposed	 that	 “innate-like”	 γδ	 T	 cell	 populations,	 including	 IL-17	
producers	and	some	subsets	of	IFN-γ	producers,	receive	strong	TCR	signals	during	
thymic	 development	 to	 become	 hyporesponsive	 to	 TCR	 stimulation	 in	 the	
periphery153.	 Future	 research	 should	 thus	 clarify	 the	 developmental	 effects	 of	
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manipulating	 distinct	 TCRγδ	 signalling	 pathways	 and	 their	 downstream	
(transcriptional	 and	 post-transcriptional)	 mechanisms	 on	 discrete	 γδ	 T	 cell	
subsets.	
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2.2.1. Signal	2:	costimulatory	receptors	
A	 series	 of	 T	 cell	 costimulatory	 receptors	 are	 known	 to	 induce	 qualitative	 and	
quantitative	 changes	 that	 lower	 activation	 thresholds,	 prevent	 “anergy”	 and	
enhance	 T	 cell	 functions.	 Typical	 costimulatory	 receptors	 are	 type	 I	
transmembrane	 proteins	 that	 can	 be	 divided	 into	 two	 groups,	 based	 on	 their	
structural	 characteristics:	 Immunoglobulin	 (Ig)	 or	 Tumour	 Necrosis	 Factor	
Receptor	 (TNFR)	 superfamilies.	 Ig	 superfamily	 members	 have	 a	 variable	 Ig-like	
extracellular	domain	and	a	short	cytoplasmic	tail,	whereas	TNFR	family	members	
present	extracellular	domains	rich	in	six	cysteine	repeats	(which	form	disulphide	
bridges)	 and	 a	more	 complex	 cytoplasmic	 tail	 (reviewed	 in191).	 These	 two	main	
types	of	costimulatory	receptors	display	different	modes	of	intracellular	signalling:	
whereas	 the	 CD28	 family	members	 associate	 directly	 with	 protein	 kinases	 (like	
PI3K	 or	 ITK),	 TNFR	 superfamily	 coreceptors	 require	 the	 adaptor	 proteins	 TRAF	
(TNFR-associated	 factor),	 namely	 TRAF2	 and	 TRAF5,	 to	 link	 to	 downstream	
signalling	mediators	(Table	2).	Here,	based	on	their	specific	roles	in	γδ	T	cells,	we	
shall	 discuss	 CD28	 (of	 the	 Ig	 superfamily)	 and	 the	 TNFR	 superfamily	members,	
CD27,	CD30	and	CD137	(4-1BB).		
The	best	studied	costimulatory	receptor,	CD28,	has	historically	yielded	paradoxical	
results	on	γδ	T	cells158.	We	have	recently	 readdressed	 this	 issue	 for	both	human	
and	 mouse	 γδ	 T	 cells.	 We	 described	 that	 CD28	 is	 constitutively	 expressed	 on	
lymphoid	γδ	T	cells	and	promotes	survival	and	proliferation	via	 IL-2	production.	
CD28	 receptor	 agonists	 enhanced	 γδ	 T	 cell	 expansion,	 which	 was	 conversely	
inhibited	 by	 blocking	 antibodies	 against	 its	 B7	 ligands154.	 Importantly,	 CD28-
deficient	mice	displayed	lower	(relative	to	controls)	numbers	of	total	or	activated	
γδ	T	cells	upon	Plasmodium	berghei	infection,	and	failed	to	expand	both	their	IFN-
γ+	 and	 IL-17+	 subsets154.	 By	 contrast,	 Hayes	 and	 colleagues	 reported	 that	 both	
functional	 γδ	 T	 cell	 subsets	 differentiated	 and	 expanded	 normally	 in	 a	 Listeria	
model192.	It	would	be	interesting	to	determine	how	variable	is	the	dependence	on	
CD28	costimulation	for	γδ	T	cell	responses	to	distinct	infectious	agents.		
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In	naïve	mice,	while	CD28	is	not	required	for	the	development	of	either	IFN-γ+	or	
IL-17+	 γδ	 T	 cell	 subsets192,	 the	 TNFR	 superfamily	 member	 CD27	 is	 selectively	
implicated	 in	 the	generation	of	 IFN-γ+	γδ	T	cells50.	 In	 fact,	we	showed	 that	CD27	
expression	 segregates	 IFN-γ+	 (CD27+)	 and	 IL-17+	 (CD27-)	 γδ	 T	 cells.	 Most	
interestingly,	 these	 phenotypes	 are	 established	 in	 the	 thymus,	 and	 since	
embryonic	 stages.	 Based	 on	 the	 results	 from	 our149	 and	 Chien’s49	 teams,	 the	
development	 of	 IFN-γ-producing	 γδ	 T	 cells	 seemingly	 requires	 strong	 TCR	
signalling	and	CD27	costimulation	in	the	thymus.	
Beyond	 its	 role	 in	 thymic	 differentiation,	 CD27	 is	 critical	 for	 the	 expansion	 of	
peripheral	 IFN-γ-producing	 γδ	 T	 cells	 upon	 infection	 with	 herpes	 viruses	 or	
malaria	parasites	in	mice193.	We	showed	that,	in	the	context	of	TCR	stimulation	and	
upon	ligation	to	CD70,	CD27	signalling	activates	the	non-canonical	NF-κB	pathway	
and	 enhances	 the	 expression	 of	 anti-apoptotic	 and	 cell	 cycle-related	 genes,	 thus	
promoting	murine	γδ	T	cell	survival	and	proliferation193.		






of	 CD70-CD27	 signals	may	be	 beneficial	 in	 the	 context	 of	 γδ	T	 cell-based	 cancer	
immunotherapy.	
Upon	 activation,	 human	 γδ	 T	 cells	 can	 also	 express	 another	 TNFR	 superfamily	
member,	CD30	(Ref.195).	CD30	signalling,	which	potentiated	calcium	fluxes	induced	by	
TCR	 activation,	 also	 enhanced	 pro-inflammatory	 cytokine	 production162.	 Recently,	
Yoshikai	 and	 colleagues	 compared	 γδ	 T	 cell	 homeostasis	 and	 response	 to	 Listeria	
monocytogenes	 in	 CD30-sufficient	 versus	 deficient	 mice.	 They	 demonstrated	 a	
selective	depletion	of	IL-17-producing	Vγ6+	T	cells	 in	mucosal	tissues	 in	the	steady-
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state	and	upon	 infection196.	This	associated	with	reduced	bacterial	clearance,	which	




that	 4-1BB	 was	 expressed	 and	 functional	 on	 activated	 human	 γδ	 T	 cells,	 and	 its	
ligation	upon	cell	transfer	protected	NOD/	SCID	mice	against	Listeria	infection.	
Interestingly,	 activated	 Vγ9Vδ2	 T	 cells	 also	 express	 high	 levels	 of	 4-1BBL	
(CD137L)197,	which	besides	acting	as	a	ligand	for	4-1BB	on	T	and	NK	cells,	may	also	
participate	in	Vγ9Vδ2	T	cell	activation	due	to	its	known	reverse	signalling	ability198.	
This	 may	 in	 fact	 also	 apply	 to	 CD70	 (CD27-ligand),	 which	 is	 highly	 induced	 upon	










IL-7	 and	 IL-15	 are	 seemingly	 the	 key	 determinants	 of	 murine	 γδ	 T	 cell	
development200–202	 and	 homeostasis203.	 A	 recent	 study	 that	 depleted	 IL-7	
specifically	 from	 (Foxn1+)	 thymic	 epithelial	 cells	 showed	 that	 γδ	 T	 cells	 were	
significantly	 reduced	 in	 the	 adult	 thymus	 and	 in	 the	 gut,	 whereas	 they	 were	
completely	absent	in	the	foetal	thymus	and	epidermis201.	In	the	dermis,	it	was	also	
IL-7,	but	not	IL-15,	that	supported	the	development	and	survival	of	the	resident	γδ	








viral	 hepatitis	 infection	 in	 vivo206.	 Moreover,	 IL-7	 also	 seems	 to	 support	 the	
expansion	of	human	IL-17-producing	γδ	T	cells171.		
We	recently	assessed	the	functional	differentiation	of	human	γδ	thymocytes,	which	
are	 >80%	 of	 the	 Vδ1	 subtype.	 We	 observed	 that	 IL-15	 and	 IL-2,	 but	 not	 IL-7,	
induced	 the	 cytotoxic	 type	 1	 (IFN-γ-producing)	 programme	 in	 functionally	
immature	γδ	thymocytes169.	This	was	consistent	with	previous	data	on	peripheral	
γδ	 T	 cells	 isolated	 from	 cancer	 patients207.	 However,	 additional	 reports	 on	
peripheral	Vγ9Vδ2	T	 cell	 cultures	 showed	 that	 IL-15	or	 IL-2	 stimulation,	despite	
efficient	ERK	and	AKT	activation,	were	not	sufficient	to	induce	effector	responses;	
these	 required	 phosphoantigen-dependent	 TCR	 activation	 and	 downstream	
calcium	 mobilization170,208.	 Unexpectedly,	 in	 our	 cultures	 of	 γδ	 (mostly	 Vδ1)	
thymocytes,	TCR	stimulation	was	not	required	for	neither	ERK	activation	nor	T-bet	
and	Eomesodermin	induction	and	the	acquisition	of	effector	functions169.	
IL-2	 and	 IL-15	 play	 key	 roles	 in	 the	 peripheral	 expansion	 of	 Vγ9Vδ2	 T	 cells	 in	
response	 to	 microbial	 phosphoantigens	 or	 synthetic	 drugs	 like	
bisphosphonates170,209.	This	notwithstanding,	 it	 is	 important	 to	note,	 towards	 the	
therapeutic	 application	 of	 Vγ9Vδ2	 T	 cells,	 that	 optimal	 effector	 responses	
seemingly	 require	 the	 combination	 of	 these	 cytokines	 with	 TCR	 agonists.	 Thus,	
recent	 work	 from	 Chen	 and	 colleagues	 demonstrated	 that	 the	 differentiation	 of	
cytotoxic	type	1	Vγ9Vδ2	T	cells	capable	of	controlling	Mycobacterium	tuberculosis	
infection	in	macaques	required	a	phosphoantigen/	IL-2	combination210.		
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Effector	 γδ	 T	 cell	 differentiation	 is	 also	 greatly	 impacted	 by	 inflammatory	
cytokines,	 particularly	 IL-12	 and	 IL-18	 that	 typically	 promote	 IFN-γ	 production;	
and	IL-1β	and	IL-23	that	mostly	drive	IL-17	production.		
High	expression	of	IL-12Rβ	expression	on	activated	murine	γδ	T	cells	guarantees	a	
dominance	 of	 type	 1	 (IFN-γ+)	 over	 type	 2	 (IL-4+)	 effector	 fates	 211.	 Type	 1	
differentiation	 is	 also	 predominant	 in	 human	 γδ	 T	 cells,	 and	 can	 be	 further	
enhanced	 by	 IL-18	 (Ref.212,213)	 or	 IL-21	 (Ref214).	 The	 induction	 of	 a	 type	 17	
programme	 in	 human	 γδ	 T	 cells	 requires	 persistent	 stimulation	 with	 IL-23	 for	
neonatal	Vγ9Vδ2	T	cells215;	and	IL-23	and	IL-1β	in	the	presence	of	TGF-β	for	adult	
Vγ9Vδ2	 T	 cells216,217.	 In	 mice,	 IL-1β	 and	 IL-23	 are	 also	 the	 main	 drivers	 of	
abundant	 IL-17	production	by	peripheral	γδ	T	cells62,64,193,218–220,	although	recent	
data	surprisingly	suggest	that	IL-18	can	replace	IL-1β	in	combining	with	IL-23	to	














and	 ULBP(1-6)	 families	 in	 humans;	 and	 to	 H60,	 MULT1	 and	 various	 RAE1	
molecules	in	mice224.	NKG2D	ligands	are	induced	upon	cellular	stress,	for	example,	
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downstream	 of	 the	 DNA-damage	 response	 pathway	 in	 tumour	 cells225,226.	 The	
biological	 significance	 of	 this	 recognition	 system	 is	 underlined	 by	 the	 increased	
susceptibility	of	NKG2D-deficient	mice	to	tumour	development227.	
Intracellularly,	NKG2D	binds	to	DNAX-activating	protein	of	10	kDa	(DAP10),	which	
carries	 an	 YXNM	 motif	 that	 after	 tyrosine	 phosphorylation	 recruits	 PI3K	 or	 a	
Grb2–Vav1–SOS1	 signalling	 complex	 (Table	 2).	 This	 motif	 is	 similar	 to	 that	 in	
CD28,	 and	 thus,	 NKG2D/	DAP10	may	 provide	 T	 cells	with	 costimulatory	 signals	
that	 synergise	with	 the	 ITAM-based	 TCR/CD3	 complex173.	 However,	 unlike	 αβ	 T	
cells	 but	 similarly	 to	 NK	 cells,	 γδ	 T	 cells	 can	 express	 both	 DAP10	 and	 DAP12	
(Ref.174).	The	latter	contains	an	ITAM	motif,	which	after	tyrosine	phosphorylation	




NKG2D	 in	 human	 Vγ9Vδ2	 T	 cells	 was	 supported	 by	 additive	 effects	 on	 TCR-
mediated	 activation:	 an	 upregulation	 of	 cytokine	 production	 upon	MICA-NKG2D	
interactions229;	and	an	increase	in	intracellular	calcium	mobilization	and	cytotoxic	
activity144.	 However,	 other	 lines	 of	 evidence	 have	 suggested	 that	 NKG2D	 signals	
can	 activate	 γδ	 T	 cells	 in	 the	 absence	 of	 TCR	 engagement:	 NKG2D	 ligation	 can	




Another	 NKR	 implicated	 in	 tumor	 cell	 recognition	 by	 Vγ9Vδ2	 T	 cells	 is	 DNAX	
accessory	 molecule-1	 (DNAM-1).	 DNAM-1	 is	 an	 Ig-like	 family	 glycoprotein	
composed	 of	 a	 cytoplasmic	 domain	 containing	 three	 putative	 sites	 of	
phosphorylation	 by	 intracellular	 kinases.	 The	 phosphorylation	 of	 the	 Ser329	 by	
protein	 kinase	 C	 (PKC)	 was	 shown	 to	 be	 critical	 for	 the	 association	 between	
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DNAM-1	and	LFA-1	which	recruits	the	Fyn	Src	kinase	to	phosphorylate	the	Tyr322	
of	 DNAM-1,	 thus	 initiating	 downstream	 signalling	 leading	 to	 SLP-76	 and	 Vav1	
phosphorylation	 (Table	 2)233.	 Antibody-mediated	 DNAM-1	 blockade	 impaired	
Vγ9Vδ2	T	cell	cytotoxicity	and	IFN-γ	production	against	hepatocellular	carcinoma	
lines	expressing	Nectin-like-5182.	
Recently,	 we	 characterized	 a	 Vδ1+	 T	 cell	 population	 capable	 of	 targeting	






NKp44	 can	 signal	 via	 CD3ζ	 and	 DAP12,	 respectively177.	We	 further	 showed	 that	
NKp30	 and	NKp44	 are	 both	 functional	 in	NCR+	 Vδ1+	 T	 cells,	 and	 synergise	with	
NKG2D	to	target	lymphocytic	leukaemia	cells86.		
In	sum,	NKRs	seem	critical	for	tumour	recognition	and	deployment	of	the	cytotoxic	
program	 that	 is	 endowed	 by	 TCR/	 γc	 cytokine-dependent	 differentiation,	 thus	





negatively	 regulate	 the	 T	 cell	 response	 in	 order	 to	 return	 to	 the	 homeostatic	
baseline.	Inhibitory	receptors	like	PD-1	or	CTLA-4	are	known	to	be	critical	for	this	
contracting	phase	of	the	T	cell	response	and	have	become	major	clinical	targets	in	
cancer	 immunotherapy.	 Although	 γδ	 T	 cells	 rarely	 express	 CTLA-4,	 they	 can	
upregulate	PD-1	upon	activation,	while	they	constitutively	express	BTLA,	and	thus	
these	two	receptors	may	be	the	key	to	control	γδ	T	cell	responses.	
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Programmed	Death-1	(PD-1)	 is	absent	or	 low	expressed	on	circulating	Vγ9Vδ2	T	
cells	 but	 is	 rapidly	 induced	 upon	 activation234.	 The	 cytoplasmic	 tail	 of	 PD-1	
contains	 conserved	 immunoreceptor	 tyrosine-based	 inhibitory	motif	 (ITIM)	 and	
switch	 motif	 (ITSM),	 both	 of	 which	 are	 phosphorylated	 to	 recruit	 negative	
regulators	 that	 block	 Lck	 activity	 downstream	of	 the	TCR	 complex235.	Moreover,	
PD-1	 ligation	 can	 augment	 the	 activity	 of	 the	 protein	 phosphatase	 and	 tensin	
homolog	(PTEN),	a	cellular	phosphatase	that	inhibits	PI3K/AKT	signalling	and	thus	
leads	to	impaired	survival,	proliferation	and	IL-2	release236.	The	expression	of	the	
ligand	 PD-L1	 on	 tumour	 cells	 inhibited	 Vγ9Vδ2	 T	 cell	 cytotoxicity	 and	 IFN-γ	
production234.	 However,	 zoledronate-induced	 accumulation	 of	 P-Ags	 in	 tumour	
cells	 and	 consequent	Vγ9Vδ2	TCR	 activation	 seemed	 to	 overcome	 the	 inhibitory	






1)	 and	 SHP-2,	 which	 leads	 to	 attenuation	 of	 cellular	 activation	 and	 growth237.	
Recent	 data	 showed	 that	 BTLA	 engagement	 with	 HVEM	 reduced	 P-Ag/TCR-
mediated	 signalling	 and	 inhibited	 Vγ9Vδ2	 T	 cell	 proliferation,	 including	 in	
response	 to	 lymphoma	 cells188.	 Conversely,	 BTLA-HVEM	 blockade	 using	
monoclonal	 antibodies	 enhanced	 Vγ9Vδ2	 TCR	 signalling	 and	 may	 thus	 have	
therapeutic	potential	for	the	positive	manipulation	of	γδ	T	cells.	
A	 detailed	 study	 on	BTLA	 function	 in	murine	 γδ	 T	 cells	 has	 revealed	 a	 selective	
involvement	 in	 the	homeostasis	of	 the	 IL-17-producing	CD27-	γδ	T	cell	subset190.	
Although	these	cells	constitutively	express	low	levels	of	BTLA,	it	is	upregulated	by	
IL-7	 stimulation	 and	 thereby	 limits	 γδ	 T	 cell	 numbers.	 Consequently,	 BTLA-
deficient	 mice	 accumulated	 IL-17+	 CD27-	 γδ	 T	 cells	 and	 were	 more	 susceptible	












tumorigenic	 and	 ultimately	malignant238.	 The	 rapid	 advances	 in	 cancer	 research	
have	generated	a	rich	and	complex	body	of	knowledge.	These	advances	are	being	
translated	 into	 more	 selective	 and	 effective	 treatment	 of	 cancers	 and,	 although	
there	 are	 still	 considerable	 challenges,	 particularly	 with	 drug	 resistance	 and	
metastatic	 disease,	 many	 patients	 with	 otherwise	 lethal	 malignancies	 now	
experience	 protracted	 remissions	 or	 cure.	 One	 largely	 unheralded	 theme	 of	 this	
story	is	the	extent	to	which	new	biological	insights	and	novel	clinical	applications	
have	their	origins	with	leukaemia	and	related	blood	cell	cancers239.	Nevertheless,	
the	 deep	 characterization	 of	 cancer	 biology,	 including	 the	 cellular	 origin,	 the	
molecular	 changes	 and	 the	 clonal	 evolution	 of	 the	 cancer	 cell	 populations	 will	
originate	crucial	biological	insights	with	translational	therapeutic	potential239,240.		
The	 self-renewal	 and	 differentiation	 processes,	 which	 occur	 in	 hematopoiesis	
through	 life,	 can	 become	deregulated	 and	 result	 in	 leukemia.	 This	 hematological	
cancer	is	generally	characterized	by	an	accumulation	of	immature	blasts	that	fail	to	
differentiate	 into	 functional	 cells.	 Leukemia	 is	 a	 greek-derived	 word	 meaning	








Acute	 lymphoblastic	 leukemia	 (ALL)	 is	 the	 most	 common	 cancer	 in	 children,	
accounting	 for	 approximately	 25%	 of	 all	 the	 pediatric	 cancers242.	 Due	 to	 the	
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remarkable	advances	in	molecular	characterization	of	ALL	cells	and	new	therapies	
in	 clinical	 trials,	 the	 treatment	of	ALL	patients	dramatically	 improved	 in	 the	 last	
decades	and	the	overall	survival	rate	of	ALL	patients	is	about	85%242–244.	
The	majority	symptoms	and	signs	associated	with	ALL	at	diagnosis	derive	from	the	




mediastinal	 masses	 are	 manifestations	 that	 occur	 upon	 the	 progression	 of	 the	
disease.	 The	 involvement	 of	 the	 central	 nervous	 system	 (CNS)	 is	 also	 a	 common	
feature,	resulting	in	the	appearance	of	symptoms	like	headache,	nausea,	vomiting,	
lethargy	and	cranial	nerve	dysfunction.	The	diagnostic	of	ALL	is	achieved	when	the	
presence	 of	 these	 symptoms	 is	 associated	 with	 the	 molecular,	 cytogenetic	 and	
immunophenotypic	characterization	of	the	leukemic	blasts245.	
ALL	 is	 a	 very	 heterogeneous	 disease	 that	 presents	 several	 variations	 on	 cellular	
morphology,	 immunological	 markers	 and	 cytogenetic	 abnormalities.	 The	
malignant	ALL	cells	can	be	broadly	characterized	into	B-ALL	or	T-ALL	with	BM	or	
thymic	origin,	 respectively246,247	and	subsequently	divided	according	 to	 the	stage	
of	 differentiation.	 Uckun	 and	 collegues248	 defines	 three	 stages	 of	 T-ALL	
maturation:	 pro-thymocytes	 (CD7+	 only),	 immature	 thymocytes	 (CD7+,	 CD2+	
and/or	CD5+,	CD3-)	and	mature	thymocytes	(CD7+,	CD2+,	CD5+,	CD3+).	Additionally	
the	 European	 Group	 for	 Immunological	 Characterization	 of	 Leukemias	 (EGIL)249	
uses	 a	 further	marker,	 CD1	 and	 consider	 the	 following	 stages:	 pro-T-ALL	 (CD7+	
only),	pre-T-ALL	(CD7+,	CD1-,	CD2+	and/or	CD5	and/or	CD8+,	CD3-),	cortical	T-ALL	
(CD1+,	 independently	of	the	presence	of	other	markers)	and	mature	T-ALL	(CD1-,	








multistep	 pathogenesis	 involving	 proliferative	 advantage	 and	 differentiation	
impairment.	 It	 is	 currently	 accepted	 that	 T-cell	 leukemogenesis	 is	 a	 stepwise	
process	 that	 culminates	 in	 the	 acquisition	 of	 a	 fully	malignant	 phenotype.	 These	
events	 include	defects	 in	the	control	of	cell	cycle	machinery,	gene	mutations	that	
confer	 self-renewal	 capacity	 to	 thymic	 progenitors,	 deregulated	 expression	 of	
pivotal	transcription	factors	and	also	aberrant	activation	of	protein	kinases253–255.	
The	 genetic	 abnormalities	 in	 T-ALL	 can	 be	 categorized	 in	 mutually	 exclusive	
chromosome	 translocations	 that	 arrest	 T-cell	 development	 at	 a	 specific	
maturational	 stage	 and	 are	 associated	with	 a	 distinct	 gene-expression	 signature.	
Frequently,	these	translocations	are	combined	with	deletions	or	point	mutations	in	
genes	 that	 affect	 cell	 cycle	 or	 signaling	 pathways.	 The	 knowledge	 of	 these	
molecular	abnormalities	may	have	prognostic	significance	and	provide	targets	for	
novel	 therapies.	The	chimeric	oncogene	BCR-ABL1	results	 from	the	translocation	






where	 deregulated	 activity	 of	 RAG	 proteins	 appears	 to	 be	 responsible	 for	 the	
formation	 of	 chimeric	 proteins	 with	 aberrant	 expression,	 activity	 or	 functions.	
Notch1	was	first	discovered	as	a	partner	gene	in	the	t(7;9)(q34;q34)	chromosomal	
translocation258	 and	was	 later	 implicated	 in	 the	pathogenesis	of	up	 to	60%	of	T-
ALL	cases,	harboring	activating	mutations,	involving	negative	regulatory	domains	
responsible	 for	 the	 control	 of	 initiation	 and	 termination	 of	 Notch	 signaling259,260	
(Figure	3).	Mutations	in	the	FBXW7	gene	are	present	in	15%	of	T-ALL	cases,	and	
deregulate	 the	 proteasomal	 degradation	 of	 activated	 Notch1	 protein	 and	






and	 PI3K-AKT	 signaling263,264.	 In	 addition,	 Notch1	 directly	 activates	 c-Myc	 and	
these	two	molecules	together	activate	common	target	genes	required	for	growth	of	
leukemic	cells265,266.	 In	addition	to	Notch1	mutations,	T-ALLs	 frequently	acquired	
abnormal	 chromosomal	 translocations	 that	 result	 in	 aberrant	 expression	 of	
transcription	 factor	 oncogenes,	 such	 as	 TAL1,	 LMO1,	 LMO2,	 TLX1	 and	 TLX3	
(reviewed	in	Van	Vlierberghe	et	al.259).	
Figure	 3:	 Downstream	 signaling	 pathways	 and	 molecules	 initiated	 in	 Notch-
mediated	acute	T	cell	lymphoblastic	leukemia	(T-ALL).	
Arrows	 indicate	 positive	 interactions,	 and	 inhibition	 lines	 show	 negative	 regulatory	 interactions	
contributing	 to	 the	 development	 and/or	maintenance	 of	 T-ALL.	 Growth-promoting	molecules	 or	
pathways	 are	 in	 blue,	 whereas	 growth-inhibitory	 molecules	 are	 in	 red.	 (adapted	 from	 Koch	 et	
al.266).	
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Besides	 genetic	 lesions	 in	 transcription	 factors	 and	 chromatin	 regulators,	 genes	
encoding	 critical	 components	 of	 signaling	 pathways	 controlling	 the	 growth,	 pro-	
liferation	and	survival	of	T	cell	are	frequently	mutated	in	T-ALL.	The	IL-7R	signals	
through	 the	 JAK/STAT	 pathway	 and	 is	 strictly	 required	 to	 support	 the	 growth,	




been	 identified	 in	 approximately	10%	of	pediatric	T-ALL271,272	 although	 they	are	





Both	 altered	 forms	 of	 AKT	 with	 abnormal	 constitutively	 phosphorylation	
independently	of	external	growth	factors,	as	well	as	NF-κB,	a	downstream	target	of	
PI3K/AKT	 with	 constitutive	 activation,	 have	 been	 associated	 with	 T-ALL278,279.	
Interestingly,	 the	presence	of	 activating	mutations	of	PI3K	and/or	AKT	has	been	
poorly	 described	 in	 T-ALL	 patients.	 Thus,	 it	 has	 been	 suggested	 that	 PI3K/AKT	
pathway	 over-activation	 results	 from	 alterations	 in	 upstream	 mechanisms	 that	
remains	 to	 be	 fully	 understood254,279.	 PTEN,	 the	 main	 negative	 regulator	 of	 the	
PI3K/AKT	pathway,	is	frequently	inactivated	in	human	cancer	as	result	of	various	
genetic	lesions280,281.	These	alterations	result	in	decreased	or	absent	PTEN	protein	
expression	 and	 activity,	 with	 consequent	 hyperactivation	 of	 the	 PI3K/AKT	
pathway.	 Deletion	 mutations	 in	 PTEN	 occur	 in	 5%–10%	 of	 T-ALL	 cases,	 and	
overall	17%	of	T-ALL	cases	lack	PTEN	protein	expression259.	
Gutierrez	 and	 collaborators	 identified	 that	 PTEN	 deletion	 has	 more	 adverse	
therapeutic	 consequences	 than	 mutational	 disruptions	 that	 preserve	 the	












Protein	 kinase	 CK2	 (formerly	 casein	 kinase	 II)	 is	 a	 pleiotropic	 and	 ubiquitous	
enzyme	generally	 present	 in	 the	 cell	 as	 a	 tetramer	 consisting	 of	 two	 catalytic	 (α	
















than	 90%	 sequence	 identity	 over	 their	 N-terminal	 330	 amino	 acids,	 with	
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completely	unrelated	C-termini.	A	 third	 catalytic	 and	 less	 known	 isoform	of	CK2	
(α’’)	 was	 reported	 in	 human	 hepatocyte	 that	 is	 nearly	 identical	 to	 α	 but	 with	
diferente	32	amino	acids	at	the	end	of	the	protein287,294.	Both	CK2α’	and	CK2α’’	had	
no	 obvious	 catalytic	 differences,	 however	 some	 data	 suggest	 functional	
specialization	 mediated	 by	 specific	 binding	 partners295,296.	 CK2β	 presents	 close	
similarity	of	the	catalytic	subunits	but	it	does	not	share	extensive	identity	with	any	
other	 known	 protein285.	 The	 CK2β	 subunit	 interacts	 with	 CK2α	 subunits	 and	 is	
responsible	 for	 docking	 and/or	 recruitment	 of	 CK2	 substrates	 or	 potential	
regulators297.	 In	 this	 respect,	 potential	 CK2	 targets,	 such	 as	 Nopp140,	 p53,	 Fas-
associated	 factor-1	 (FAF-1),	 topoisomerase	 II	 and	 CD5,	 as	well	 as	 potential	 CK2	








Mammalian	 CK2,	 tetrameric	 CK2	 complexes	 contain	 identical	 (i.e.	 two	





CK2	 provides	 survival	 and	 proliferative	 advantage	 to	 tumor	 cells.	 CK2	 functions	
seem	to	encompass	most	of,	if	not	all,	the	‘hallmarks	of	cancer’238,286.	CK2	protects	
cell	 apoptosis	 through	 several	 mechanisms	 from	 the	 blockade	 of	 protein	
degradation,	 stimulation	 of	 antiapoptotic	 responses	 upon	 different	 stresses,	
enhancement	 of	 oncogenes’	 transformation	 properties	 and	 stabilization	 of	
oncokinases286.	

































a	 Apoptosis	 resistance	 of	 the	 multiple	 drug	 resistance	 (MDR)	 variants	 of	 these	 lines	 can	 be	
overcome	by	treatment	with	CK2	inhibitors.	b	Cell	death	induced	by	CK2	blockage	is	more	evident	





mantle	 cell	 lymphoma	 (MCL),	 diffuse	 large	 B-cell	 lymphoma	 (DLBCL),	 B-CLL,	 B-	
ALL	 and	 T-ALL	 (Table	 3)	 and	 has	 been	 widely	 associated	 with	 increased	
proliferation,	 angiogenesis,	 secretion	 of	 growth	 factors,	 invasiveness	 and	




more	 sensitive	 to	 CK2	 downregulation	 than	 normal	 counterparts286.	 Given	 the	
generalized	increased	activity	of	CK2	in	cancers,	the	central	role	of	CK2	in	multiple	
pathways	 that	 support	 the	 cancer	 phenotype	 and	 the	 evidence	 that	 CK2	 is	 an	
essential	 protein	 for	 cancer	 cell	 survival,	 the	 development	 of	 selective	 CK2	




Different	 studies	 indicate	 that	 CK2	 targeting	with	 selective	 inhibitors	 is	 feasible	
and	 highly	 effective	 in	 causing	 tumor	 cell	 death.	 Over	 the	 past	 two	 decades,	




phosphotransferring	 reaction	 and	 ii)	 the	 non-competitive	 ATP	 inhibitors	
(allosteric	inhibitors	or	substrate	competitors),	which	bind	to	structural	elements	
unrelated	with	 the	ATP-binding	 regions288.	 For	 instance,	 relatively	 small	 organic	
compounds	 such	 as	 TBB,	DRB,	DMAT,	 IQA,	 emodin,	 CX-4945,	 and	 the	 flavonoids	
apigenin,	 luteolin,	 and	 quercetin	 have	 been	 shown	 to	 target	 and	 block	 the	 ATP-
binding	 site	 of	 the	 CK2	 catalytic	 subunit308–315.	 Other	 examples	 are	 Pc,	 a	 cyclic	
peptide	 that	 antagonizes	 the	 interaction	between	CK2	 subunits316,	 and	 antisense	
oligonucleotides	that	target	transcription	of	the	CK2	alpha	gene,	thereby	inducing	
cell	 death	 and	 antitumoral	 activity317.	 CIGB-300	 is	 a	 new	 anti-CK2	 peptide	 that	
explores	 a	 novel	 concept	 to	 impair	 CK2	 activity:	 targeting	 its	 substrates,	 rather	
than	the	enzyme	per	se318.	
These	 CK2	 inhibitors	 have	 resulted	 in	 a	 number	 of	 successful	 proof	 of	 concepts	
exhibiting	antiapoptotic	effect	both	in	vitro	and	in	vivo	tumor	models.	Among	the	
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CK2	 experimental	 inhibitors,	 only	 the	 small	 molecule	 CX-4945	 and	 the	 cell-
permeable	peptide	CIGB-300	have	already	reached	the	clinical	stage.	
CX-4945	 (Silmitasertib)	 is	 an	 orally	 administered	 CK2	 inhibitor	 developed	 by	
Cylene	 Pharmaceuticals	 Inc.308,315.	 CX-4945	 has	 shown	 tumor	 growth	 inhibition	
effects	 of	 76–97%	 in	 breast,	 prostate,	 pancreatic,	 and	 glioblastoma	 tumors.	 CX-
4945	has	been	studied	in	different	human	cancer	and	is	currently	in	Phase	I	and	II	
clinical	 trials.	The	Phase	 I	 trial	addresses	 the	safety	and	tolerability	of	 increasing	
doses	 of	 CX-4945	 to	 determine	 the	 maximum	 tolerated	 dose	 (MTD).	 The	
subsequent	 Phase	 II	 trial	 is	 a	 randomized	 study	 of	 antitumor	 activity	 in	
cholangiocarcinoma	 patients	 treated	 with	 the	 standard-of-care	 protocol	 of	
gemcitabine	plus	cisplatin	 in	combination	with	CX-4945	(Ref.288).	 In	addition,	 the	
hematological	 and	 solid	 tumors,	 in	 which	 CK2	 has	 been	 described	 to	 be	




to	be	 tightly	regulated	 in	normal	cells,	but	hyperactive	 in	cellular	 transformation	
and	 cancer.	 In	 this	 work,	 CK2	 emerge	 as	 an	 attractive	 candidate	 to	 control	 the	
survival	of	both	normal	and	malignant	γδ	T	cells.	
	 	




γδ	 T	 cells	 play	 a	 key	 role	 in	 immunosurveillance.	 However,	 the	 molecular	








improve	 γδ	 T	 cell-associated	 immunotherapies.	 By	 elucidating	 the	 signaling	


































Human	 thymic	 specimens	 from	 newborn	 to	 15	 year-old	 children	were	 obtained	
during	 pediatric	 corrective	 cardiac	 surgery	 after	 parents’	 written	 informed	




Human	blood	 samples	were	 collected	 from	healthy	donors	 and	buffy	 coats	were	




bone	marrow)	were	obtained	after	 inform	content	of	 the	patient.	The	 study	was	
conducted	 in	 accordance	with	 the	Declaration	 of	Helsinki	 and	 approved	by	 local	
ethical	 committees	 from	 “Hôpital	 Necker	 Enfants-Malades”,	 Paris	 Descartes	
University	and	“Institut		national		de		recherche		médicale”	(Paris).	
All	 experimental	 procedures	 in	 mouse	 animal	 models	 were	 performed	 in	 strict	
accordance	 with	 the	 recommendations	 of	 the	 European	 Commission	 (Directive	
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Isolation	and	in	vitro	cell	culture		
Thymic	 T	 cells	 were	 collected	 after	 thymus	 tissue	 manual	 dispersion	 and	
separation	 by	 Histopaque-1077	 (Sigma-Aldrich)	 density	 gradient	 separation	 by	
centrifugation	 during	 30	 minutes	 at	 room	 temperature	 (RT).	 TCRγδ-positive	 T	
cells	 were	 isolated	 (to	 >97%	 purity)	 by	 magnetic	 positive	 selection;	 TCRαβ-
positive	T-cells	were	isolated	(to	>96%	purity)	by	magnetic	positive	selection	from	
the	 TCRγδ-negative	 fraction	 (Miltenyi	 Biotec).	 During	 magnetic	 cell	 sorting	 all	
procedures	were	performed	at	4ºC	following	the	manufacture’s	instructions.	Cells	
were	used	as	fresh	or,	when	indicted,	cells	were	cultured	at	37°C	with	5%	CO2	in	
complete	 RPMI-1640	 supplemented	 with	 10%	 FBS,	 1mM	 sodium	 pyruvate,	




22™)	 cell	 lines	were	 cultured	 in	 RPMI-1640	 supplemented	with	 10%	 FBS,	 1mM	
sodium	 pyruvate,	 10U/ml	 penicillin,	 10μg/ml	 streptomycin	 following	 the	
manufacture	instructions.	The	Hel	(DSMZ,	ACC	11)	cell	line	was	cultured	in	IMDM	




Bicistronic	 retroviral	 expression	 vectors	 (LZRS)	 containing	 the	 gene	 of	 interest	
were	 used.	 The	 used	 vectors	 contained	 the	 internal	 ribosomal	 entry	 site	 IRES	
followed	by	enhanced	green	fluorescence	protein	(eGFP),	(LZRS-IRES-eGFP)	empty	
vector	used	as	negative	control;	or	 the	gene	of	 interest,	expressing	myrPKB/AKT	
(constitutively	 activated	 AKT)	 and	 eGFP	 (LZRS-myrPKB/AKT-IRES-eGFP)	 as	
previously	described319.	Retrovirus	was	generated	by	transient	transfection	of	TAT	
cells	 co-transfected	 with	 helper	 vectors	 pCL-Eco	 and	 pCMV-VSV-G.	 Supernatant	
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viral	 particles	 were	 isolated	 by	 high-speed	 centrifugation	 and	 used	 to	 stable	
transfect	the	PEER	cell	line.	
To	increase	the	percentage	of	transduced	cells	for	the	following	experiments,	GFP+	




Anti-human	 monoclonal	 antibodies	 were	 used	 against:	 CD3	 (UCHT1),	 CD27	
(LG.7F9),	 CD4	 (RPA-T4),	 CD8	 (HIT8a),	 CD7	 (4H9),	 panTCRαβ	 (IP26)	 and	 IFNγ	
(4S.B3)	from	eBioscience;	CD28	(CD28.2),	CD8	(SK1),	CD45	(HI30),	Vδ2	(B6),	CD3	
(OKT3),	CD45RA	(HI100)	CD69	(FN50),	TNF-α	(MAb11),	CD107a	(H4A3)	Annexin-
V	 and	 7-AAD	 from	 Biolegend;	 panTCRγδ	 (5A6.E9)	 from	 ThermoFisher;	 Vδ1	
(REA173	 or	 TS8.2)	 from	Miltenyi	 Biotech;	 p-S129-AKT,	 p-S473-AKT,	 AKT,	 p-S9-
GSK3β,	 GSK3β,	 p-S380-PTEN,	 PTEN,	 p-S235/236-S6	 and	 S6,	 p-T202/Y204-
ERK1/2,	 ERK1,	 from	 Cell	 Signaling;	 p-Y694/699-STAT5	 from	 Merck/Millipore;	
Calnexin	 and	 GAPDH	 from	 Sicgen;	 7-AAD	 from	 Invitrogen	 and	 Bcl-2	 from	Dako.	









previously	 fixed	 and	 permeabilized	 using	 fixation/permeabilization	 and	
permeabilization	 buffers	 (both	 from	 eBioscience),	 following	 the	 manufacturer’s	
instructions.		




with	 cold	 PBS,	 and	 then	 resuspend	 in	 Annexin	 V	 Binding	 Buffer.	 The	 cells	were	
stained	 with	 fluorochrome-conjugated	 Annexin	 V	 during	 20	 min	 at	 room	
temperature	 in	 the	 dark.	 7-AAD	 was	 added	 to	 the	 cells	 just	 before	 the	 flow	
cytometry	analysis.	
For	cell	cycle	analysis,	cells	were	stained	 for	1h	at	37°C	with	30μL	of	7-AAD	(BD	
Pharmingen)	 resuspended	 in	 permeabilization	 buffer	 (eBioscience)	 and	 then	
washed	 tree	 times	 with	 RPMI	 and	 fluorescence	 intensity	 was	 immediately	
measured	by	flow	cytometry	analysis	in	linear	mode.	
CFSE-based	 proliferation	 assays	 (CellTrace	 CFSE	 kit,	 Invitrogen,	 final	
concentration	0.5mM)	were	performed	as	described50.		











CK2	 activity	 was	 measured	 in	 cell	 lysates	 (from	 equal	 cell	 numbers)	 using	 the	
Casein	 Kinase-2	 Assay	 kit	 (17-132)	 from	 Upstate	 Biotechnology,	 following	 the	
manufacturer’s	 instructions.	 Briefly,	 total	 protein	 lysate	 were	 incubated	 for	 10	
minutes	 at	 30°C	 in	 a	 reaction	 mixture	 containing:	 CK2α-specific	 peptide,	 [γ-
32P]ATP	 and	 PKA	 inhibitor	 cocktail.	 The	 radioactivity	 incorporated	 into	 the	
substrate	was	determined	in	P81	phosphocellulose	paper-squares	by	scintillation	
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counting	as	previously	reported321.	CK2	activity	 in	γδ+	and	αβ+	xenograft-derived	
blasts	 was	 measured	 on	 samples,	 which	 showed	 comparable	 percentages	 of	




Cell	 lysates	were	used	 for	 immunobloting	as	previously	described321.	Briefly,	 the	
cells	were	lysed,	at	4ºC,	 in	cold	lysis	buffer	(50	mM	Tris	[pH	7.6],	150	mM	EDTA,	
1%	 Nonidet	 P-40	 in	 PBS)	 enriched	 with	 protease	 and	 phosphatase	 inhibitor	
cocktails	(Roche).	The	total	proteins	were	quantified	using	a	Bradford	assay	(Bio-
Rad),	 following	 the	 manufacturer’s	 instructions.	 Equal	 amounts	 of	 total	 protein	
was	denatured	in	Laemmli	buffer	(Bio-Rad),	boiled	for	5	min	at	95ºC,	and	loaded	in	
a	10%	SDS-PAGE.	After	electrophoretic	separation,	 the	proteins	were	transferred	
to	 nitrocellulose	 blotting	 paper	 (Amersham	 Biosciences).	 The	 membranes	 were	
blocked	with	5%	BSA	and	0.5%	Tween	20	(Sigma-Aldrich)	in	PBS	and	probed	with	
the	 indicated	 primary	 Abs	 overnight	 at	 4ºC.	 After	 rinse,	 the	 membranes	 were	




Total	 RNA	 was	 extracted	 using	 the	 RNeasy	 Mini	 kit	 (Qiagen)	 according	 to	 the	
manufacturer’s	 instructions.	 Concentration	 and	 purity	 were	 determined	 by	
spectrophotometry	 analysis	 using	 the	 NanoDrop	 ND-1000	 spectrophotometer	
(Thermo	Scientific).	Total	RNA	was	reverse	transcribed	into	cDNA	using	a	M-MLV	
RT	 kit	 (Promega).	 Briefly,	 purified	 RNA	 samples	 and	 random	 primers	 were	
denatured	 by	 heat	 shock	 at	 70ºC	 during	 10	 minutes	 followed	 by	 reverse	
transcription	in	described	reaction	mix	with	dNTPs	and	enzyme	M-MLV	during	60	
minutes	 at	 42ºC.	 The	 enzyme	 was	 inactivated	 at	 90ºC	 during	 10	 minutes.	
Quantitative	real-time	PCR	and	analysis	was	performed	using	primers	from	Table	
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4	 on	 ViiA	 7	 Real-Time	 PCR	 system	 using	 the	 ViiA	 7	 software	 v1.2	 (Applied	
Biosystems;	 Life	 Technologies)	 using	 SYBR	 Green	 detection	 system	 (Applied	
Biosystems;	 Life	 Technologies).	GAPDH	 or	Beta-2-Microglobulin	 genes	were	 used	























TCRαβ	 or	 TCRγδ-positive	 T-ALL	 cells	 obtained	 from	 patient	 diagnostic	 were	
injected	into	8-12	weeks	old	NSG	(NOD-SCID	IL-2Rγnull)	mice	(1x106	cells/mouse,	
tail	 vein	 injections).	Mice	were	monitored	weekly	 by	 flow	 cytometry	 for	 human	
leukemic	 load	 (hCD7+,	 hCD45+	 cells)	 in	 peripheral	 blood.	 Mice	 were	 euthanized	
when	 terminally	 ill	 and	 blast	 cells	 from	bone	marrow	were	 collected.	 For	 the	 in	
vivo	 experiment	 of	 γδ	 T-ALL	 treatment,	 10-12-weeks-old	 NRGS	 (NOD-Rag1null	
IL2Rγnull)	mice	were	 injected	 subcutaneously	 in	 the	 right	 flank	with	2x106	PEER	
cells	resuspended	in	100µL	of	PBS.	At	day	20,	all	mice	presented	palpable	tumors	
(100-150mm3)	and	were	randomly	distributed	into	two	groups	(n≥3).	The	animals	




daily	 and	 weighed	 frequently.	 Tumors	 were	 measured	 every	 two	 days	 with	 a	
caliper	and	 tumor	volume	was	calculated	(volume	=	(length	x	width)2/2).	At	day	




Statistical	 significance	 of	 differences	 between	 indicated	 conditions	was	 assessed	
using	Student’s	t-test	with	Welch’s	correction	and	is	indicated	when	significant	as	*	
(P<.05);	 **	 (P<.01);	 ***	 (P<.001).	 All	 statistical	 analysis	 was	 performed	 using	
GraphPad	Prism	software.	
	

























All	 jawed	 and	 jawless	 vertebrates	 have	 evolved	 three	 lineages	 of	 lymphocytes	
based	 on	 somatic	 gene	 diversification	 of	 Ag	 receptors322.	Within	 the	 lymphocyte	
trilogy,	γδ	T	cells	clearly	remain	the	most	poorly	understood	lineage,	both	in	terms	
of	 Ag	 recognition	 and	 differentiation	 into	 effector	 cell	 subsets60.	 This	
notwithstanding,	 γδ	 T	 cells	 are	 already	 being	 targeted	 in	 cancer	
immunotherapy85,323	 based	 on	 multiple	 promising	 preclinical	 studies	 in	 both	
mice65,66,324,325	and	humans84,231,323,326.	
Human	 γδ	 PBLs	 are	 endowed	 with	 potent	 cytotoxicity	 against	
hematological86,231,323	 and	 epithelial84,327	 malignant	 cells.	 Moreover,	 γδ	 PBLs	 are	
highly	 polarized	 toward	 IFN-γ	 production	 since	 early	 life,	 as	 preterm	 babies	
harbor	significant	proportions	of	IFN-γ+	γδ	(but	not	αβ)	T	cells	in	the	blood328,	and	





cells329.	 γδ	 T	 cells	 thus	 constitute	 the	 first	 functional	 population	 of	 circulating	 T	
cells328.
	
Given	 an	 individual’s	 history	 of	 infections,	 circulating	 γδ	 PBLs	 can	 display	 very	
heterogeneous	phenotypes	ranging	from	naive	to	effector/memory	and	terminally	




Interestingly,	 we50	 and	 others150,331	 have	 shown	 that	 murine	 γδ	 T	 cells	 acquire	
their	 effector	 properties	 during	 thymic	 development,	 in	 a	 process	 regulated	 by	
TCRγδ	 (and	 coreceptor)	 signaling146.	 For	 example,	 IFN-γ–producing	 γδ	 T	 cells	
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require	TCR	and	CD27	signals	for	differentiation	in	the	mouse	thymus50,150,331.	This	
raises	 the	 question	 whether	 human	 γδ	 thymocytes	 can	 also	 complete	 their	
functional	differentiation	before	being	exported	to	the	periphery.	Although	thymic	
commitment	 to	 the	 γδ	 T	 cell	 lineage	 is	 controlled	 by	Notch	 signaling33,332,	much	
less	is	known	about	the	subsequent	steps	of	functional	differentiation	of	human	γδ	
T	 cells47,48,330.	 This	 will	 likely	 have	major	 implications	 for	 their	 manipulation	 in	
cancer	immunotherapy.	
Building	 on	 these	 considerations,	 in	 this	 study	 we	 have	 used	 pediatric	 thymic	
tissue	 to	 address	 the	 molecular	 mechanisms	 of	 human	 γδ	 T	 cell	 differentiation	
toward	 antitumor	 lymphocytes.	 Our	 results	 reveal	 an	 NK-like	 mode	 of	
differentiation	 that	 is	 de-	 pendent	 on	 IL-2/IL-15	 signals	 but	 surprisingly	 not	 on	
TCR	 activation.	 Interestingly,	 this	 process	 must	 take	 place	 in	 the	 periphery,	
because,	 unlike	 their	 murine	 counterparts,	 human	 γδ	 thymocytes	 are	 devoid	 of	
cytotoxic	 type	 1	 effector	 functions.	 Finally,	 our	 data	 disclose	 an	 MAPK/ERK-




1.1	 Human	 γδ	 thymocytes	 are	 devoid	 of	 cytotoxicity	 and	 IFN-γ	
production	
Inspired	by	the	recent	identification	of	fully	differentiated	effector	γδ	T	cell	subsets	
in	 the	 murine	 thymus48–50,150,	 we	 started	 this	 study	 by	 analyzing	 the	 surface	
phenotype	 and	 functional	 potential	 of	 γδ	 T	 cells	 isolated	 from	 human	 pediatric	
thymic	 samples.	 Based	 on	 the	 differentiation	 markers	 CD1a333,	 CD27,	 and	
CD45RA106,	 the	 vast	 majority	 of	 γδ	 thymocytes	 showed	 an	 immature	 and	 naive	
phenotype,	which	contrasted	with	the	dominant	effector/memory	phenotype106	of	
γδ	 PBLs	 (Figure	 5A).	 Also	 unlike	 these,	 γδ	 thymocytes	 produced	 negligible	
proinflammatory	cytokines,	particularly	IFN-γ	and	TNF-α	(Figure	5B).	Moreover,	
γδ	 thymocytes	 lacked	 cytolytic	 activity	 (Figure	 5C),	 namely	 against	 leukemia	
76 results 
	
target	 cells,	which	were	 promptly	 killed	 by	 their	 PBL	 counterparts	 (Figure	 5D).	
These	 data	 clearly	 demonstrate	 that,	 unlike	 murine	 γδ	 thymocytes48,50,150,331,	




Figure	 5:	 Human	 γδ	 thymocytes	 are	 devoid	 of	 IFN-γ	 production	 and	 cytotoxic	
functions.	
TCRγδ+CD3+	cells	were	isolated	from	pediatric	thymic	biopsies	(Thymus/T)	or	from	the	peripheral	
blood	 of	 healthy	 donors	 (Blood/B)	 and	 analyzed	 ex	 vivo	 by	 flow	 cytometry.	 Dead	 cells	 were	
excluded	from	the	analysis	using	LIVE/DEAD	Fixable	Dead	Cell	Stain	Kits	(Molecular	Probes).	(A)	
Surface	expression	of	CD27,	CD45RA,	and	CD1a.	(B	and	C)	Intracellular	staining	for	IFN-	γ	and	TNF-
α	 (B)	 or	 the	 degranulation	 marker	 CD107a	 (C)	 following	 4	 h	 of	 stimulation	 with	 PMA	 and	
ionomycin.	 (D)	Cytotoxic	activity	against	MOLT-4	 leukemia	cells.	Percentage	of	apoptotic	annexin	
V+	 within	 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one–	 succinimidyl	 ester	 (DDAO-SE+)	
(prelabeled)	tumor	cells	after	3	h	of	coincubation	with	γδ	T	cells	at	a	10:1	E:T	ratio.	Results	in	this	
figure	 are	 representative	 of	 3–12	 independent	 experiments;	 each	 dot	 represents	 an	 individual	
sample.	**p	,	0.005.		
	





investigate	 the	 molecular	 cues	 required	 for	 acquisition	 of	 antitumor	 effector	
properties.	 Focusing	 first	 on	 IFN-γ	 production,	we	 considered	 that	 naive	 CD4+	T	
cells	typically	require	TCR/CD3	and	CD28	ligation	in	the	presence	of	IL-2	and	IL-12	
for	differentiation	along	 the	 “T	helper	1”	pathway334.	Although	 such	a	 “Th1	mix”	
was	indeed	capable	of	generating	IFN-γ+	γδ	T	cells,	we	surprisingly	found	that	IL-2	
alone	was	also	sufficient	(Figure	6A,	upper	panel).	This	effect	was	potentiated	by	
IL-12,	 whereas	 TGF-β	 abrogated	 the	 process.	 Unexpectedly,	 the	 addition	 of	 TCR	





also	 promoted	 TNF-α	 expression	 (Figure	 6A,	 lower	 panel),	 upregulated	 the	
activation	 marker	 CD69	 (Figure	 6B),	 and	 drove	 thymocytes	 along	 the	
effector/memory	 differentiation	 pathway,	 toward	 a	 CD45RA+	 CD27–	 T	 effector	
memory	stage	(Figure	6C).	
Concerning	 γδ	 T	 cell	 cytotoxicity,	 IL-2	 and	 IL-15	 (but	 not	 IL-7)	 induced	 the	
expression	 of	 the	 degranulation	marker	 CD107a	 on	 γδ	 thymocytes	 (Figure	 6D)	
and	 endowed	 them	 with	 potent	 killing	 capacity	 against	 leukemia	 target	 cells	
(Figure	 6E).	 Of	 note,	 exogenous	 IL-2	 and	 IL-15	 also	 enhanced	 the	 effector	
functions	of	γδ	PBLs,	especially	 their	degranulation/cytotoxic	potential	 (data	not	
shown).	








Importantly,	 they	 also	 show	 that	 IL-2	 and	 IL-15	 signals	 are	 sufficient,	 in	 the	
absence	 of	TCR	 activation,	 to	 generate	 fully	 functional	 γδ	T	 cells	 from	 immature	
thymocytes.	
	
Figure	 6:	 IL-2	 and	 IL-15	 signals	 differentiate	 γδ	 thymocytes	 into	 cytotoxic	 type	 1	
effector	T	cells.	
MACS-purified	γδ	 thymocytes	were	cultured	 for	7	d	 in	 the	presence	of	10	ng/ml	of	 the	 indicated	
cytokines;	 anti-CD3	 mAb	 (1	 mg/ml)	 was	 added	 when	 noted,	 and	 as	 part	 of	 the	 Th1	 mix	 also	
contained	anti-CD28	mAb	(5	mg/	ml),	IL-2,	and	IL-12.	(A)	Intracellular	staining	for	IFN-γ	following	
4	h	of	stimulation	with	PMA	and	ionomycin.	(B)	Surface	expression	of	the	activation	marker	CD69.	
(C)	 Surface	 staining	 for	 CD27	 and	 CD45RA.	 (D)	 Intracellular	 staining	 for	 CD107a.	 (E)	 Cytotoxic	
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activity	 against	MOLT-4	 leukemia	 cells	 (as	 in	 FIGURE	 1D).	 (F)	 Correlations	 between	 fractions	 of	
cells	expressing	IFN-γ,	TNF-α,	or	CD107a.	Each	dot	represents	a	specific	culture	condition	from	the	
experiments	 in	 FIGURE	 (A)	 and	 (D).	 (G)	 Real-time	 PCR	 data	 for	 the	 expression	 of	 T-bet	 (Tbx21,	
upper	panel),	eomesodermin	(Eomes,	middle	panel),	and	perforin	(Pfn,	lower	panel),	normalized	to	
housekeeping	b2-microglobulin	(B2m),	on	γδ	thymocytes	either	freshly	isolated	or	cultured	for	7	d	






PBLs	 but	 more	 abundant	 in	 tissues)	 and	 Vδ2+	 cells	 (60–95%	 of	 γδ	 PBLs),	 both	
strongly	biased	toward	cytotoxic	type	1	functions323,335,	we	next	assessed	whether	
they	 followed	similar	rules	of	differentiation.	Consistent	with	the	 literature47,	 the	
thymic	 γδ	 repertoire	 was	 largely	 biased	 for	 Vδ1+	 thymocytes,	 with	 an	 average	




gating	 on	 the	 Vδ2+	 population	 were	 affected	 by	 an	 important	 intersample	
variation.	 We	 considered	 that	 this	 could	 be	 due	 to	 blood	 contamination	 or	
recirculation	(back	to	the	thymus)	of	mature	Vγ9Vδ2	cells,	which	are	much	more	
abundant	 in	 the	blood	 than	 in	 the	 thymus	 (3%	of	 total	γδ	 thymocytes).	To	over-	
come	 these	 problems,	 we	 purified	 CD1a+	 γδ	 T	 cells,	 which	 are	 exclusive	 to	 the	
thymus	(Figure	5A,	 lower	panel)	and	cultured	them	for	7	days	with	IL-7,	IL-2,	or	
IL-15.	We	 found	 that	both	Vδ1+	and	Vδ2+	 cells	 similarly	acquired	 type	1	effector	
properties	in	response	to	IL-2	and	IL-15,	but	not	IL-7	(Figure	7A).	
As	an	alternative	developmental	strategy,	we	differentiated	γδ	T	cells	from	sorted	
CD3-TCRγδ-CD4-CD8-	 thymic	 precursors	 cultured	 on	 OP9-DL1	 monolayers,	 as	
previously	 described336.	 In	 the	 presence	 of	 IL-7	 alone,	 Vδ1	 and	 Vδ2	 T	 cells	
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developed	normally	 (Figure	 7B)	 to	 a	 Vδ1/Vδ2	 ratio	 similar	 to	 that	 observed	 ex	
vivo	(data	not	shown).	We	therefore	think	this	is	an	elegant	model	to	characterize	
γδ	T	cell	differentiation	 from	very	early	developmental	 stages.	Most	 importantly,	
the	 further	 addition	 of	 IL-2	 was	 necessary	 to	 generate	 IFN-γ–	 (Figure	 7C)	 and	
TNF-α–	(Figure	7D)	producing	γδ	T	cells,	and	this	occurred	similarly	for	Vδ1	and	
Vδ2	T	cell	 subsets	 (Figure	 7C,	 7D).	These	data	demonstrate	 that	 IL-2	 (or	 IL-15)	
signals	 drive	 the	 functional	 differentiation	 of	 both	major	 subsets	 of	 human	 γδ	T	
cells.	
	
Figure	 7:	 Vδ1	 and	 Vδ2	 subsets	 of	 γδ	 T	 cells	 follow	 similar	 rules	 of	 functional	
differentiation.	
































To	 gain	 further	 mechanistic	 insight	 into	 the	 type	 1	 differentiation	 pathway	 of	
human	γδ	T	cells,	we	probed	 the	 three	major	signaling	pathways	downstream	of	
common	 γ-chain	 cytokine	 receptors	 and	 observed	 that	 IL-2	 stimulation	
hyperphosphorylated	ERK1/2	(MAPK	pathway),	STAT5	(JAK/STAT	pathway),	and	
AKT	(PI3K	pathway)	(Figure	8A).	To	determine	which	of	these	signaling	pathways	
was	 critical	 for	 functional	 differentiation	 of	 γδ	 T	 cells,	we	 analyzed	 the	 effect	 of	
specific	chemical	inhibitors	on	γδ	thymocyte	cultures.	When	added	at	the	start	of	
the	cultures,	all	of	these	drugs	interfered	with	γδ	T	cell	proliferation	and	prevented	
their	 functional	 differentiation	 (data	 not	 shown).	 Of	 note,	 although	 proliferation	
was	necessary	for	IFN-γ	induction,	this	specifically	required	IL-2	or	IL-15	signals,	
as	 IL-7	 failed	 to	 do	 so	 even	 after	 five	 cell	 divisions	 (Figure	 8B).	 To	 dissociate	
proliferation	 from	 differentiation,	 we	 added	 the	 inhibitors	 at	 day	 4	 of	 culture,	
when	 cells	 had	 already	undergone	 five	 rounds	of	 division	 (Figure	 8B).	Whereas	
blocking	 STAT5	 or	 PI3K/AKT	 had	 no	 detectable	 effect,	 the	MAPK/ERK	 inhibitor	




Interestingly,	 IL-2	 or	 IL-15	 signals	 also	 enhanced	 IL-2	 production	 by	 γδ	 T	 cells,	
thus	providing	an	autocrine	mechanism	to	sustain	their	functional	differentiation.	
The	 production	 of	 IL-2	 (as	 well	 as	 TNF-α)	 by	 γδ	 T	 cells	 was	 also	 completely	
abolished	 by	 the	 addition	 of	 UO126,	 but	 not	 LY294002	 or	 Ssi	 (data	 not	 shown).	
These	 data	 demonstrate	 that	 γδ	 T	 cell	 cytotoxic	 type	 1	 differentiation	 can	 be	
manipulated	by	drugs	specifically	targeting	the	MAPK/ERK	pathway339.	
Collectively,	our	results	identify	MAPK-mediated	IL-2/IL-15	signaling	as	the	major	




Figure	 8:	 The	MAPK/ERK	 signaling	 pathway	 is	 required	 for	 IL-2–mediated	 type	 1	
differentiation	of	human	γδ	T	cells.		










and	 STAT5a	 in	 cell	 lysates	 obtained	 at	 the	 indicated	 timepoints.	 C,	 control	 medium	 without	
cytokines.	The	numbers	above	the	blots	correspond	to	desitometric	analysis	of	the	corresponding	
bands.	(B)	Effect	of	chemical	inhibitors	on	the	production	of	IFN-γ	in	γδ	thymocyte	cultures.	At	day	















T-cell	 commitment	 is	 coupled	 to	 somatic	 T	 cell	 receptor	 (TCR)	 rearrangements,	
which	generates	thymocytes	bearing	either	an	αβ	or	a	γδ	TCR17.	The	expression	of	
a	 pre-TCR	 composed	 of	 TCRβ	 and	 the	 invariant	 pTα	 chain	 in	 αβ	 thymocyte	
progenitors	results	 in	a	massive	proliferative	burst	(“β-selection”)	which	dictates	
that	 αβ	 T	 cells	 largely	 outnumber	 their	 γδ	 counterparts.	 Likely	 a	 consequence,	
while	significant	progress	has	been	made	in	our	understanding	of	human	αβ	T-cell	
development,	 the	 molecular	 determinants	 of	 γδ	 thymocytes	 remain	 poorly	
characterized17.		
Most	of	what	we	know	about	thymic	γδ	T	cell	differentiation	comes	from	studies	
performed	 in	 mice,	 showing	 how	 various	 receptors	 (namely,	 TCRγδ,	 CD27	 and	
LTβR)	and	downstream	transcription	factors	(such	as	Id3,	Sox13,	TCF1	and	Lef1)	
control	 various	 maturation	 steps,	 from	 divergence	 from	 the	 αβ	 lineage	 to	 the	
acquisition	 of	 effector	 functions	 such	 as	 pro-inflammatory	 cytokine	
production29,43,50,340–342.	By	contrast,	much	less	is	known	about	human	thymic	γδ	T	




of	 all	 cases)	 form	 of	 T-ALL	 with	 distinctive	 clinical	 features343–345.	 Given	 that	
malignant	 γδ	 T	 cells	 have	 been	 very	 poorly	 studied	 and	 lack	 defined	molecular	
targets,	 we	 have	 here	 addressed	 the	 potential	 role	 of	 Casein	 Kinase	 2	 (CK2),	 a	
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signaling	 effector	 molecule	 previously	 implicated	 in	 chronic	 lymphocytic	
leukemia321,346,	 multiple	 myeloma347,	 B-ALL348,349,	 T-ALL283,350	 and	 other	
hematological	disorders	(reviewed	in351).	
CK2	 is	 a	 ubiquitous	 and	 constitutively	 activated	 serine-threonine	 protein	 kinase	
that	 regulates	multiple	pathways	 including	PI3K/AKT	and	WNT	signaling,	NF-κB	
transcription,	 and	 the	 DNA	 damage	 response351.	 CK2	 displays	 pro-survival	 and	
anti-apoptotic	 functions	 that	were	 described	 in	 several	 cancer	 cell	 types.	 CK2	 is	
frequently	 overexpressed	 or	 hyperactivated	 in	 both	 solid	 tumors	 and	 in	
hematological	 malignancies,	 thus	 making	 it	 a	 promising	 target	 for	 cancer	
treatment351.	 	 By	 contrast,	 the	 physiological	 function	 of	 CK2	 in	 non-transformed	
cells	 is	 less	 established.	 Recent	 studies	 in	 mice	 have	 demonstrated	 that	 CK2	
activity	is	necessary	for	peripheral	T	cell	activation	and	function:	interference	with	
CK2	signaling	impaired	CD4+	T	cell	activation	and	differentiation	into	Th2	or	Th17	
cells352,	 while	 the	 genetic	 deletion	 of	 CK2	 in	 CD4+	 Foxp3+	 regulatory	 T	 cells	
abolished	 their	 suppressive	 activity	 against	 allergy-promoting	 Th2	 cells353.	
However,	no	functional	role	has	yet	been	attributed	to	CK2	in	the	thymus.	
In	this	study	we	identified	a	novel	role	for	CK2	in	controlling	the	survival	of	normal	
γδ	 thymocytes	 and	 γδ	 T-ALL	 cells.	 We	 analyzed	 CK2	 activity	 in	 γδ	 versus	 αβ	
thymocytes	 and	 T-ALL	 cells,	 its	 regulation	 by	 cell-extrinsic	 signals,	 the	






obtained	 from	 pediatric	 thymic	 biopsies.	 We	 measured	 CK2	 activity	 using	 a	
substrate-specific	 kinase	 assay	 in	 freshly-isolated	 TCRγδ+	 or	 TCRαβ+	 cells,	 and	
unexpectedly	 found	 2-fold	 higher	 activity	 in	 γδ	 thymocytes	 relative	 to	 their	 αβ	
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counterparts	 (Figure	 9A).	 To	 address	 its	 physiological	 relevance,	 we	 treated	
thymocytes	 for	24	hours	with	a	highly	specific	ATP-competitive	 inhibitor	of	CK2,	
CX-4945288.	 Flow	 cytometry	 analysis	 of	Annexin	V/	7-AAD-stained	 cells	 revealed	
increased	apoptosis	of	γδ	compared	to	CD4+	and	CD8+	αβ	thymocytes	(Figure	9B).	
To	assess	the	longer-term	impact	of	CX-4945	treatment,	thymocytes	were	cultured	
in	 the	presence	of	TCR	plus	costimulation	 for	7	days.	γδ	 thymocytes	were	highly	
susceptible	to	apoptosis	upon	CK2	inhibition	in	a	dose	dependent-manner	(Figure	
9C).	 By	 contrast,	 as	 previously	 reported283,	 CD4+	 or	 CD8+	αβ	 thymocyte	 survival	




















































































We	 next	 asked	which	 signals	 regulated	 CK2	 activity	 in	 γδ	 thymocytes.	 Very	 few	
studies	have	documented	CK2	modulation	by	physiological	stimuli	in	T	cells352,354.	
When	we	stimulated	(for	6	hours)	isolated	thymocyte	subsets	via	the	TCR	complex	
using	 agonist	 anti-CD3ε	 antibodies,	 we	 observed	 ~3-fold	 enhancement	 of	 CK2	
activity	 selectively	 in	 γδ	 thymocytes	 (Figure	 10A).	We	also	 tested	 the	 impact	 of	
costimulation,	 particularly	 through	 CD27	which	we	 have	 shown	 to	 play	 a	major	
role	 in	 γδ	 T-cell	 development	 and	 expansion50,104,355.	 However,	 the	 addition	 of	
soluble	 recombinant	 CD27-ligand/	 CD70	 (sCD70)	 had	 no	 additive	 effect	 on	 CK2	
activity	 (Figure	 10A).	 Thus,	 our	 data	 suggest	 that	 CK2	 activity	 in	 healthy	 γδ	
thymocytes	is	modulated	primarily	by	TCR	signals.	
To	gain	insight	on	the	downstream	effects	of	CK2	signaling	and	its	inhibition	in	γδ	
thymocytes,	we	 focused	 on	 the	AKT	 signaling	 pathway,	which	 is	 involved	 in	 cell	
survival	and	proliferation	and	known	to	be	regulated	by	CK2	in	both	normal	and	
malignant	 αβ	 T	 lymphocytes186,283.	 We	 observed	 that	 TCR/	 CD27	 stimulation	
inhibited	 PTEN,	 as	 measured	 by	 the	 increase	 in	 its	 phosphorylated	 form,	 and	
potentiated	the	AKT	signaling	pathway	in	γδ	but	not	αβ	thymocytes,	as	shown	by	
the	 phosphorylation	 of	 AKT	 and	 its	 downstream	 targets	 GSK3β	 and	 S6	 (Figure	
2C).	 The	 GSK3β	 phosphorylation	 at	 S9	 offers	 an	 intracellular	 readout	 for	 AKT	
activity356.	These	effects	were	 completely	 reversed	by	CX-4945	 (Figure	 10C).	As	
functional	 outcomes	 of	 CK2	 inhibition,	 we	 observed	 decreased	 γδ	 thymocyte	
proliferation	 (Figure	 10D)	 and	 survival	 (Figure	 10E).	 Moreover,	 in	 agreement	
with	 the	 implication	 of	 AKT	 signaling	 downstream	 of	 CK2,	we	 found	 a	 similarly	
striking	 effect	 on	 γδ	 thymocyte	 survival	 upon	 treatment	 with	 the	 specific	 AKT	
inhibitor,	MK-2206357	(Figure	10E).	
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4945	 (CD3+CD27+CX);	 values	were	normalized	 to	unstimulated	 control	 (dashed	 line).	 (B)	mRNA	
(top)	and	protein	(bottom;	western	blot)	levels	of	CK2α	and	CK2α’	of	γδ	thymocytes	stimulated	as	
in	 (A).	 (C)	Western	blot	 analysis	 of	 (phospho)proteins	 implicated	 in	AKT	 signaling,	 in	 γδ	 and	αβ	
thymocytes	(1x106	cells	per	sample)	stimulated	as	in	(A).		(D)	Proliferation	(CFSE	dilution	assay)	of	
γδ	 thymocytes	 after	 7	 days	 in	 culture	with	 rhIL-2	 under	 the	 indicated	 conditions:	medium	 only	
(Ctrl);	 anti-CD3	 antibody	 stimulation	 (CD3);	 soluble	 CD27-ligand	 (CD27);	 their	 combination	
(CD3+CD27)	 and	 with	 5μM	 CX-4945	 (CD3+CD27+CX).	 (E)	 Survival	 (%	 of	 live	 cells)	 of	 γδ	
thymocytes	 after	 7	 days	 of	 stimulation	 (or	 not,	 Ctrl	 for	 control)	with	 anti-CD3	 antibodies	 (CD3),	
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We	next	 asked	how	CK2	activity	would	 impact	 on	γδ	T-ALL.	 First,	we	 compared	
CK2	 activity	 in	 normal	 γδ	 and	 αβ	 thymocytes	 versus	 γδ	 and	 αβ	 T-cell	 blasts	
obtained	 from	 T-ALL	 patients	 (and	 expanded	 in	 NSG	 mice,	 with	 similar	
engraftment,	 as	 detailed	 in	 the	 Methods	 section).	 As	 expected,	 αβ	 T-ALL	 cells	
displayed	higher	 levels	of	CK2	activity	 than	αβ	thymocytes	(Figure	 11).	Notably,	
we	detected	markedly	higher	CK2	activity	in	γδ	T-ALL	cells	as	compared	to	healthy	
thymocytes	 and	 αβ	 T-ALL	 blasts	 (Figure	 11).	 Moreover,	 the	 γδ	 T-ALL	 cell	 line	
PEER	reproduced	the	very	high	CK2	activity	observed	in	γδ	T-ALL	blasts	(Figure	
11),	making	it	a	good	model	for	further	biochemical	and	functional	CK2	tests	in	γδ	




In	vitro	CK2α	 activity	 (kinase	 assay;	 6.6x106	 cells	 per	 assay)	 in	 freshly-isolated	 γδ	 (n=4)	 and	 αβ	
(n=4)	thymocyte	samples;	γδ	(n=6)	and	αβ	(n=14)	T-cell	samples	obtained	from	T-ALL	patients	and	
expanded	 in	NSG	mice	(as	described	 in	 the	Methods);	and	the	γδ	T-ALL	cell	 line,	PEER	(n=4).	 (T-
test,	*p	<0.05,	***p	<0.001)	
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in	 γδ	 T-ALL	 cells	 (Figure	 12B),	 in	 contrast	with	 healthy	 γδ	 thymocytes	 (Figure	
10A).	Of	note,	PEER	cells	are	CD27+	Vδ1+	γδ	T-ALL	cells	(data	not	shown).	A	CD27-











or	 plus	 5μM	 CX-4945	 (CD3+CD27+CX).	 Data	 are	 representative	 of	 five	 independent	 experiments	
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cells	 treated	with	 CX-4945	 (5mM)	during	 the	 indicated	 times.	Western	 blot	 analysis	 of	 (E)	 Poly-
(ADP-ribose)	polymerase	(PARP)	and	cleaved	PARP	of	PEER	cells	treated	for	6h	as	in	(C);	and	(F)	
phospho-AKT	 (S129;	 and	 calnexin	 loading	 control)	 and	 (G)	 cell	 survival	 after	 48h	 of	 PEER	 cells	
transduced	with	a	bicistronic	retroviral	DNA	construct:	either	empty	vector	(LZRS)	expressing	only	
IRES	followed	by	eGFP	(LZRS-IRES-eGFP);	or	vector	co-expressing	myrPKB/AKT	and	eGFP	(LZRS-
myrPKB/AKT-IRES-eGFP)	 (AKThi);	 and	 treated	 with	 3μM	 CX-4945	 or	 vehicle.	 (H)	 Survival	
(percentage	 of	 live	 cells)	 of	 human	 γδ	 thymocytes	 or	 γδ	 T-ALL	 PEER	 cells	 following	 24h	 of	
incubation	with	CX-4945	(5μM),	TBB	(50μM),	Harmine	(10μM)	or	TG-003	(10μM)	analyzed	by	flow	
cytometry	using	Annexin-V/	7-AAD	staining.	Values	were	normalized	to	controls	(Ctrl),	 i.e.,	 in	the	
absence	of	 chemical	 inhibitors.	Each	dot	 represents	an	 independent	 sample.	 	 (T-test,	 *p	<0.05;	 **	
p<0.01).	
	
Functionally,	CK2	 inhibition	 led	 to	γδ	T-ALL	cell	 cycle	arrest	 at	G2/M	phase,	 cell	
apoptosis	 and	 decreased	 Bcl-2	 protein	 levels	 and	 increased	 cleavage	 of	 PARP	
(Poly-(ADP-ribose)	 polymerase)	 (Figure	 12D-E).	 To	 further	 examine	 the	
functional	impact	of	AKT	activation	downstream	from	CK2,	we	tried	to	rescue	this	
apoptotic	phenotype	by	 expressing	 a	myristoylated,	 constitutively	 active	 form	of	
AKT358.	 Cells	 expressing	 myristoylated	 AKT	 displayed	 high	 levels	 of	 AKT	
phosphorylation	 that	 were	 insensitive	 to	 CK2	 inhibition	 (Figure	 12F).	
Importantly,	 AKT	 hyperactivation	 partially	 rescued	 γδ	 T-ALL	 survival	 under	 CX-
4945	treatment	(Figure	12G).	On	the	other	hand,	CK2	activity	was	not	affected	by	
AKT	 hyperactivation	 (data	 not	 shown),	 collectively	 suggesting	 that	 AKT	
phosphorylation	 is	 downstream	 rather	 than	 upstream	of	 CK2,	 and	 that	 AKT	 is	 a	
key	mediator	of	CK2	functions.		
To	 verify	 that	 CX-4945	 effects	 were	 mediated	 by	 inhibition	 of	 CK2	 rather	 than	
other	 kinases,	 CLK2	 and	 DYRK1A,	 recently	 reported	 to	 be	 sensitive	 to	 CX-4945	
treatment359,360,	 we	 also	 tested	 another	 CK2	 inhibitor,	 4,5,6,7-
tetrabromobenzotriazole	(TBB);	TG-003,	which	specifically	targets	CLK2359,361;	and	
Harmine,	 which	 selectively	 inhibits	 DYRK1A362.	 Importantly,	 only	 the	 other	 CK2	












Upon	48	hours	hours	of	 in	vitro	 treatment	with	CX-4945,	we	observed	 increased	
cell	 apoptosis	 in	primary	γδ	T-ALL	 samples	 compared	 to	αβ	T-ALL	 cells	 (Figure	
13A).	We	performed	a	more	detailed	test	with	the	T-ALL	cell	lines,	at	various	time	
points	 of	 incubation	 with	 CX-4945,	 and	 found	 a	 profound	 and	 dose-dependent	
































































































Finally,	 the	 increased	 sensitivity	of	 γδ	T-ALL	 cells	 to	CX-4945	 treatment	 in	vitro,	
led	us	to	explore	its	therapeutic	potential	in	vivo.	For	this	purpose,	we	established	
a	 xenograft	 model	 of	 human	 γδ	 T-ALL	 by	 injecting	 2x106	 PEER	 cells	
subcutaneously	in	immune	deficient	NRGS	(NOD-Rag1null	IL2Rγnull)	mice.	After	the	
detection	 of	 palpable	 tumor,	 mice	 were	 equally	 distributed	 according	 to	 tumor	
burden	into	two	groups	to	receive	CX-4945	(orally,	twice	a	day)	or	vehicle	control.	
We	 observed	 a	 striking	 impact	 of	 CX-4945	 treatment	 on	 tumor	 growth	 (Figure	
14A).	Upon	sacrificing	the	mice	at	day	18	(an	ethical	requirement	for	the	control	
group),	we	scored	great	 reductions	 in	 the	CX-4945-treated	group	concerning	 the	
tumor	weight	(Figure	14B),	as	well	 its	dissemination	to	the	blood,	bone	marrow	
and	spleen	(Figures	14C-E).	Of	note,	 this	therapeutic	effect	was	dose-dependent,	
as	 it	was	only	observed	with	75	mg/kg	 (Figures	 14A-E)	but	not	with	25	mg/kg	
(data	not	shown)	of	CX-4945.	These	data	collectively	demonstrate	the	potential	of	
CK2	inhibition	for	treatment	of	γδ	T-ALL.	 	





(A)	 Tumor	 volume	 following	 injection	 of	 2x106	 PEER	 γδ	 T-ALL	 cells	 subcutaneously	 into	 NRGS	
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IV. DISCUSSION and CONCLUSIONS 
The	key	roles	played	by	γδ	T	cells	 in	 immunity	 to	 infection	and	 tumors	critically	
depend	 on	 their	 survival,	 activation	 and	 differentiation	 into	 effectors	 capable	 of	
secreting	cytokines	and	killing	infected	or	transformed	cells.	These	processes	are	
controlled,	 at	 the	 molecular	 level,	 by	 surface	 receptors	 that	 capture	 key	
extracellular	cues	and	convey	downstream	intracellular	signals	that	regulate	both	
lymphocyte	 physiology	 and	 pathology.	 In	 this	 PhD	 thesis	 we	 evaluated	 the	
contribution	 of	 cell	 receptor	 signaling	 pathways	 both	 in	 human	 γδ	 T	 cell	
differentiation	 and	 activation.	 We	 further	 assessed	 the	 role	 of	 those	 signaling	
pathways	 in	 γδ	 T	 cell	 malignancy,	 as	 they	 may	 constitute	 putative	 therapeutic	
targets.			
In	 the	 first	 section	 of	 this	 chapter	 we	 described	 the	 physiology	 and	 cytokine	
signatures	 of	 human	 γδ	 thymocytes	 as	 well	 as	 the	 molecular	 requirements	 to	
differentiate	these	cells	into	cytotoxic	against	tumors.	In	the	second	section	of	this	
chapter	we	described	 the	 signalling	pathways	 required	 for	 human	γδ	 thymocyte	
survival.	 In	 the	 end,	 we	 disclosed	 a	 hallmark	 protein	 involved	 in	 γδ	 T-ALL	










some	 critical	 processes	 involved	 in	 differentiation	 of	 these	 cells	 have	 been	
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elucidated,	 the	 signalling	 pathways	 and	molecular	 events	 involved	 in	 functional	
differentiation	following	γδ	T	cell	commitment	remain	to	be	fully	understood.		
In	mouse	models,	 γδ	 T	 cells	 can	 complete	 their	 functional	 differentiation	 in	 the	
thymus48–50,150	and	 it	 is	 currently	accepted	 that	TCR	signaling	shapes	 the	mature	
γδ	thymocyte	pool.	The	functional	differentiation	into	IFN-γ-	or	IL-17-producing	γδ	
T	 cells	 is	 tightly	 controlled	 both	 by	 thymic	 microenvironment	 factors	 and	
intracellular	 signalling	 pathways49,147.	 These	 include	 the	 ligands	 of	 TCRγδ	
expressed	 by	 thymic	 epithelial	 cells	 (TECs),	 downstream	 TCR	 signalling	
strength39,45,150	and	cytokines	such	as	TGF-β363	or	IL-7364.		
In	 contrast,	 the	 data	 presented	 here	 show	 that	 freshly	 isolated	 human	 γδ	
thymocytes	 (obtained	 from	 young	 children	 subjected	 to	 cardiac	 surgery)	 are	
functionally	 immature,	 unable	 to	 produce	 IFN-γ,	 TNF-α	 or	 IL-17.	 Moreover,	 we	
show	 that	 these	 cells	 do	 not	 present	 activation	markers	 nor	 cytotoxic	 functions	
against	 tumor	cells,	opposite	 to	what	 it	 is	observed	 in	circulating	γδ	PBLs.	Given	




1	 effectors),	 and	 in	 our	 study	we	 failed	 to	 identify	 any	 significant	 production	 of	
type	2	or	type	17	cytokines.	Particularly	IL-17,	which	is	constitutively	expressed	by	
a	subset	of	murine	γδ	T	cells48,330,	 is	rarely	expressed	(<1%)	in	human	γδ	T	cells	
from	 blood	 of	 healthy	 donors104,217,330.	 By	 contrast,	 IL-17-producing	 γδ	 T	 cells	
appear	to	accumulate	in	high	numbers	in	clinical	cases	of	severe	bacterial	or	viral	
infections23	and	autoimmune	disorders367–371.	More	recently,	IL-17-producing	γδ	T	
cells	 were	 reported	 to	 be	 the	 major	 player	 in	 protumoral	 inflammation	 in	
colorectal	 cancer	 where	 these	 γδ	 T	 cells	 acquired	 the	 ability	 to	 secrete	 IL-8,	
tumour	 necrosis	 factor	 (TNF)	 and	 granulocyte–macrophage	 colony-stimulating	
factor	 (GM-CSF),	 responsible	 for	 recruiting	 immunosuppressive	 MDSCs	 into	 the	
malignant	 microenvironment89.	 The	 mechanism	 whereby	 human	 γδ	 T	 cells	
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functionally	differentiate	into	IL-17	producers	remains	largely	unknown.	Previous	
studies	 in	 mouse	 models	 have	 demonstrated	 that	 IL-17A	 expression	 is	 mainly	
controlled	by	the	ubiquitously	expressed	transcription	factor	retinoic	acid-related	
orphan	 receptor	 (ROR)γ	 and	 its	 immune	 cell-specific	 isoform	 RORγt,	 with	
additional	 contributions	 from	 cytokines	 (including,	 IL-6,	 IL-21,	 IL-23	 and	TGF-β)	
and	 transcription	 factors	 such	 as	 STAT3,	 IFN-regulatory	 factor-4	 (IRF4),	 Runx	
transcription	 factor	 1	 and	 basic	 leucine	 zipper	 transcription	 factor	 ATF-like	
(BAFT)372–375.	Our	 laboratory	recently	showed	that	mouse	γδ	T	cells	are	strongly	
dependent	 on	 RORγt	 but	 surprisingly	 do	 not	 require	 accessory	 transcription	
factors	 like	 BATF	 for	 IL-17	 production376.	 Interestingly,	 in	 humans,	 Rauen	 et	 al.	
reported	 an	 RORγt	 isoform,	 denoted	 as	 RORγt-Δ(5-8),	 which	 suppresses	 IL-17A	
production	 through	 direct	 transcriptional	 repression	 at	 both	 the	 IL17A	 and	 the	






an	 ideal	 system	 to	 investigate	 the	molecular	 cues	 required	 for	 acquisition	of	 the	




The	 redundant	 functions	 of	 IL-2	 and	 IL-15	 can	 be	 explained	 by	 the	 structure	 of	
their	respective	receptors,	which	share	not	only	the	γc	chain	but	also	their	second	
signaling	 subunit,	 the	 IL-2Rβ.	 A	 third	 subunit,	 IL-2Rα	 or	 IL-15Rα,	 is	 cytokine	
specific	 and	 stabilizes	 binding	 but	 apparently	 lacks	 signaling	 activity.	 Structural	
comparisons	of	IL-2-IL2-Rα	and	IL-15-IL15-Rα	interactions	have	emphasized	their	





γδ	T	 cells.	 This	 is	 in	 stark	 contrast	with	 the	major	 role	described	 for	 IL-7	 in	 the	
functional	differentiation	of	human	NKT	cells380	and	IL-17-producing	γδ	T	cells364.	
These	lines	of	evidence	establish	an	interesting	cytokine	dichotomy	for	human	γδ	
T	cells:	whereas	 IL-7	promotes	 type	17	effector	 functions,	 IL-2	and	 IL-15	are	 the	
main	drivers	of	the	type	1	program.	Of	note,	since	IL-15	stimulation	induces	γδ	T	
cells	 to	 produce	 IL-2,	 this	 cytokine	 could	 also	 be	 the	 autocrine	 signal	 and	 direct	
mediator	of	the	type	1	program	downstream	of	IL-15	signals.	
Unexpectedly,	 TCR	 activation	 was	 not	 required	 for	 the	 cytotoxic	 type	 1		
differentiation	of	human	γδ	thymocytes.	Recent	work	from	Hayday	and	colleagues	
on	 murine	 γδ	 T	 cells	 suggests	 that	 innate-like	 γδ	 T	 cell	 subsets	 may	 lack	 TCR	
responsiveness	 in	 the	 periphery	 following	 strong	 TCR	 signaling	 during	 thymic	
development153.	 In	 the	 same	 line	 of	 thought,	 this	 data	 supports	 the	 model	 of	






step	 model	 proposed	 by	 Hsieh	 and	 Farrar	 for	 murine	 Foxp3+	 regulatory	 T	 cell	
(Treg)	development381,382.	 Importantly,	whereas	 for	Treg	this	 two-step	process	 is	
completed	 in	 the	 thymus,	 human	 γδ	 T	 cell	 functional	 differentiation	 seemingly	
involves	a	second	step	that	takes	place	in	the	periphery.	Physiologically,	this	likely	
depends	on	the	provision	of	IL-2	by	activated	T	cells	(either	γδ	T	cells	themselves	
or	 their	αβ	 counterparts);	 or	 IL-15	by	myeloid	 and	 epithelial	 cells.	 Concerning	 a	
potential	autocrine	IL-2	 loop	based	on	γδ	T	cells,	we	have	previously	shown	that	
IL-2	production	requires	TCR	activation	in	the	presence	of	CD28	costimulation383.	
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Therefore,	 CD80/	 CD86	 expression	 by	 APCs,	 including	 dendritic	 cells	 but	 also	
Vγ9Vδ2	T	cells,	are	likely	additional	players	in	the	functional	differentiation	of	γδ	T	
cells.	 For	 therapeutic	 purposes	 in	 cancer	 immunotherapy,	 our	 results	 strongly	
suggest	that	the	provision	of	exogenous	IL-2	or	IL-15	may	be	critical,	not	only	for	




targeting	 the	 MAPK/	 ERK	 pathway339.	 In	 this	 context,	 dual-specificity	
phosphatases	(DUSPs)	seem	particularly	promising	targets	for	modulating	MAPK-















In	 order	 to	 further	 elucidate	 the	 process	 of	 normal/	 healthy	 γδ	 T	 cell	
differentiation	 and	 activation	 as	well	 as	 γδ	T	 cell	 tumorigenesis	 it	 is	 essential	 to	
understand	 how	multiple	 extracellular	 signals	 are	 integrated	within	 the	 cell	 and	
how	 we	 can	 instructively	 manipulate	 them	 towards	 improvement	 of	 in	




The	 protein	 kinase	 CK2	 is	 a	 ubiquitous	 serine/threonine,	 acidophilic	 protein	
kinase	 implicated	 in	 several	 functions	 including	 cell	 growth	 and	 proliferation.	
Since	 CK2	 is	 a	 potent	 suppressor	 of	 apoptosis	 and	 supports	 cell	 survival,	 its	
upregulation	is	a	hallmark	acquired	by	many	cancer	cells.		
However,	 the	 CK2	 functions,	 in	 healthy	 human	 cells,	 remain	 unclear.	 In	 mouse	
models,	 CK2	 is	 known	 to	 be	 a	 key	 factor	 in	 embryonic	 development	 and	 CK2α	
knockout	 are	 lethal	 by	 embryonic	 day	 11	 (E11)	 and	 have	 apparent	 gross	
morphological	 cardiac	 and	 neural	 tube	 defects386–389.	 	 The	 mouse	 embryos	
knockout	for	CK2β	die	at	E6.5;	for	unknown	reasons390	and	the	knockout	embryos	
for	 CK2α’	 result	 in	 infertile	 male	 mice,	 with	 defective	 spermatozoa	
morphogenesis391,392.	CK2	transcripts	and	proteins	are	differentially	expressed	 in	
animal	 models,	 however	 CK2	 subunits	 are	 expressed	 at	 higher	 levels	 in	 both	
neuroepithelial	 and	 epithelial	 cells,	 connective	 tissue,	 skeletal	 muscle,	 cartilage,	
brain	and	testis	compared	to	other	cell	 types,	evidences	 that	support	 the	diverse	
functions	and	distribution	of	this	kinase392.	
Recent	 studies	 in	 mice	 have	 shown	 that	 epithelial	 cells	 and	 peripheral	 T	 cells	
depend	on	CK2	for	their	survival	and	function.	CK2	is	required	for	the	survival	of	




classified	 as	 an	 oncogene	 and	 the	mechanism	 of	 its	 regulation	 remained	 poorly	
described354.	 CK2	 presents	 constitutive	 kinase	 activity	 and	 until	 now,	 no	 actual	
CK2	 gain-of-function	 mutations	 have	 ever	 been	 found	 nor	 associated	 with	
cancer306.	 The	 increased	 CK2	 activity	 is	 typically	 associated	 with	 cell	
transformation	 in	 several	 hematological	 and	 solid	 tumors307	 but	 none	
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thymocytes	 (that	 are	 mainly	 of	 the	 Vδ1+	 subset)	 and	 a	 strikingly	 increased	
sensitivity	to	CK2	inhibition	compared	to	their	αβ	T	cell	counterparts,	either	CD4+	
or	CD8+	T	cells.	The	reasons	that	may	justify	the	increased	CK2	activity	at	steady	
state	 in	 γδ	 T	 cells	 remains	 to	 be	 elucidated.	 Similarly	 to	 what	 was	 previously	
described	in	different	cell	types307,394,	we	did	not	find	any	relationship	to	the	gene	
expression	 or	 protein	 levels	 of	 any	 CK2	 subunit	 that	 may	 justify	 the	 increased	
enzymatic	 activity.	On	 the	other	hand,	we	may	 speculate	 that	 the	different	basal	
levels	of	CK2	activity	in	γδ	versus	αβ	thymocytes	are	due	to	stronger	TCR	signals	
received	during	their	development.	It	is	well	established	that	strong	TCR	signaling	
favors	 γδ	 over	 αβ	 T-cell	 lineage	 commitment17,36,37,39,	 and	 further	 impacts	
subsequent	 γδ	 thymocyte	 development45.	 In	 this	 line	 of	 reasoning,	 the	 high	 CK2	





promotes	 CK2	 downstream	 signaling	 and	 IFN-γ	 and	 IL-17	 production	 in	 CD4+	 T	
cells	in	mouse	models304,352,395.	The	same	authors	showed	that	mice	that	express	a	
CD5	 protein	 containing	 a	 microdeletion	 with	 selective	 inability	 to	 interact	 with	
CK2	(CD5ΔCK2BD);	and	that	CD5-/-,	mice	presented	diminished	levels	of	IFN-γ+	IL-
17+	double	producers	T	cells	in	the	central	nervous	system	and	were	resistant	or	
less	 severely	 affected	 to	 EAE,	 respectively396.	 More	 recently,	 Boussiotis	 and	
colleagues	 identified	 PD-1	 as	 a	 new	 receptor	 with	 the	 ability	 to	 modulate	 CK2	
activity	 186.	 The	 authors	 showed	 that	 TCR	 plus	 CD28	 stimulation	 increased	 CK2	
protein	 levels	and	kinase	activity,	whereas	PD-1	suppressed	CK2	and	resulted	 in	
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impaired	 phosphorylation	 of	 PTEN	 and	 inhibition	 of	 AKT	 signaling	 pathway	 in	
human	 CD4+	 PBLs,	 while	 not	 affecting	 cell	 survival.	 In	 contrast,	 we	 described	
increased	 (~2.5	 fold)	 CK2	 activity	 in	 γδ	 thymocytes	 following	 TCR	 stimulation	
resulting	 in	 increased	 AKT-dependent	 cell	 survival.	 Similarly	 to	 what	 we	
previously	 described	 in	 peripheral	 Vγ9Vδ2	 T	 cells,	 CD27	 represents	 a	 key	
costimulatory	 factor	 that,	 together	 with	 TCR/CD3,	 promotes	 AKT	 signaling,	 cell	
survival	and	proliferation	of	γδ	thymocytes.	We	also	observed	increased	levels	of	
CD27	 at	 the	 cell	 surface	 following	 TCR	 activation	 that	 may	 serve	 as	 a	 positive	




Various	 costimulatory	 receptor	 domains	 have	 been	 tested	 in	 chimeric	 antigen	
receptor	(CAR)	in	primary	human	T	cells	that	give	us	insightful	information	about	
their	costimulatory	 functions.	These	constructs	 includes	CD28,	41BB,	 ICOS,	OX40	





T	 cell	 therapy,	 the	 CD27+	 tumor	 antigen-specific	 T	 cells	 persist	 long-term	 in	
patients	responding	to	therapy	and	are	remarkably	stable	in	contrast	to	CD27-	or	
CD28+	 CAR	 T	 cells399.	 Collectively,	 together	 with	 TCR,	 CD27	 is	 a	 costimulatory	
receptor	involved	in	CK2-AKT-mediated	survival.		
AKT	 phosphorylates	 the	 serine/threonine	 kinase	 glycogen	 synthase	 kinase-3β	
(GSK3β)	 at	 N-terminal	 regulatory	 serine	 residue	 (S9)	 inhibiting	 its	 activity	 and	
promotes	downstream	D-type	cyclins	expression	(data	not	showed)	that	supports	
cell	 cycle	 progression356,400–403.	 Following	 TCR/CD27	 activation	 we	 verified	 an	








complex	 2	 (mTORC2),	 respectively406.	 While	 mTORC1	 activates	 40S	 ribosomal	
protein	 S6	 kinase	 (S6K)	 and	 subsequently	 phosphorylates	 S6,	 mTORC2	 can	
phosphorylate	 AKT,	 at	 Ser473	 residue,	 accounting	 for	 a	 feedback	 loop	
mechanism404–407.	 In	 order	 to	 further	 evaluate	 the	 involvement	 of	 CK2	 in	






been	 recognized	 as	 an	 important	 post-translational	 modification	 regulating	
cellular	 processes.	 Emphasizing	 the	 importance	 of	 this	 modification	 is	 the	
existence	of	518	distinct	protein	kinases	in	the	genome,	and	the	estimate	that	one	
third	of	cellular	proteins	are	phosphorylated,	often	at	several	distinct	sites.	Proper	
regulation	of	 phosphorylation	 events	 is	 crucial	 to	 the	proper	 function	of	 cellular	




In	 this	 thesis,	 we	 describe	 that	 protein	 kinase	 CK2	 functions	 are	 increased	 in	
healthy	γδ	thymocytes,	compared	to	αβ	T	cell	counterparts.	Increased	CK2	activity	
is	 usually	 an	 acquired	 feature	 of	 malignant	 cells.	 Consistent	 with	 our	 prior	
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observations	 that	 TCRαβ+	 primary	 T-ALL	 cells	 display	 higher	 levels	 of	 CK2	




αβ	 T	 cell	 lineages	 extends	 from	 healthy	 thymocytes	 to	 transformed	 T-ALL	 cells.	
Thus,	primary	γδ	T-ALL	cells	 from	human	patients	displayed	>2-fold	higher	CK2	
activity	 compared	 to	 αβ	 T-ALL	 counterparts.	 Since	 we	 previously	 showed	 that	
endogenous	CK2	activity	correlates	with	increased	susceptibility	to	apoptosis	upon	
CK2	 inhibition283,321,350,	 this	 differential	 activity	 likely	 explains	 the	 higher	
sensitivity	of	γδ	T-ALL	cells	observed	in	this	study.	Of	note,	all	γδ	T-ALL	samples	
analyzed,	 as	 well	 as	 the	 PEER	 cell	 line,	 are	 of	 the	 Vδ1+	 subset,	 similarly	 to	 the	
majority	 of	 γδ	 T	 cells	 in	 the	 thymus;	 this	 is	 therefore	 consistent	 with	 γδ	 T-ALL	
initiating	in	the	thymus.			
Albeit	rare,	γδ	T-ALL	accounts	for	up	to	10%	of	T-ALL	cases,	which	is	significantly	
higher	 than	 the	 proportion	 (1%)	 of	 γδ	 thymocytes	 in	 the	 healthy	 thymus.	 This	




The	 ability	 of	 CK2	 to	 impact	 on	 AKT	 signaling	 was	 previously	 reported	 in	 T-
ALL283,321,350.	Here	we	showed,	 for	the	 first	 time,	 that	a	CK2-AKT	link	exists	 in	γδ	
thymocytes	and	γδ	T-ALL	cells.	More	importantly,	our	studies	demonstrated		that	
AKT	 is	 essential	 for	 CK2-mediated	 effects:	 i)	 chemical	 AKT	 inhibition	 (with	MK-
2206)	 mimicked	 CK2	 inhibition	 (with	 CX-4945);	 ii)	 the	 latter	 extinguished	 AKT	
signaling	 (AKT	 phosphorylation	 and	 downstream	 effects);	 and	 iii)	 ectopic	
expression	of	 a	 constitutively	 active	 form	of	AKT	partially	 rescued	 the	 apoptosis	
due	 to	CK2	 inhibition.	These	 results	 suggest	 that,	 although	AKT	activation	 is	 not	
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sufficient	 to	 fully	mimic	 CK2	 activity,	 it	 is	 absolutely	 required	 for	 CK2-mediated	
effects	 in	 γδ	 T	 cells.	 Activated	 AKT	 promotes	 cell	 survival	 through	 direct	
phosphorylation	 of	 anti-apoptotic	 molecules,	 or	 indirectly	 through	 the	
transcriptional	activation	of	anti-apoptotic	genes	and	increased	metabolic	capacity	
as	 previously	 discussed409,410.	 In	 addition	 to	DiMaria	 and	 colleagues’	 data	 shows	
that	the	maximal	AKT	activation	requires	phosphorylation	at	Ser129	by	CK2	both	
in	 vitro	 and	 in	 vivo411,412,	 we	 described	 that	 the	 inhibition	 of	 CK2	 activity	 in	 γδ	
thymocytes	 or	 γδ	 T-ALL	 cells	 abrogated	 the	 AKT/	 GSK3β	 and	 AKT/	 mTOR	
signaling	 pathway	 and	 had	 a	 major	 impact	 on	 cell	 survival	 and	 proliferation	
independently	of	mitogen-activated	protein	kinases/	extracellular	signal-regulated	
kinases	 (MAPK/	ERK)	(data	not	shown).	 Interestingly,	 the	strong	dependence	on	
AKT	may	be	specific	for	human	γδ	T-cells,	since	AKT-deficient	mice	were	reported	






both	 in	 tumor	 primary	 site	 and	 in	 blood,	 bone	 marrow	 and	 spleen	 metastasis.	
Overall,	 our	 observation	 of	 the	 high	 sensitivity	 γδ	 T-ALL	 cells	 to	 CK2	 inhibition	
(with	CX-4945)	in	vitro	and	in	vivo	clearly	supports	its	use	as	a	putative	therapy	for	
γδ	T-ALL.	Importantly,	CX-4945	is	safety	approved	in	humans	and	it	is	currently	in	
phase	 II	 clinical	 trials	 in	 patients	 with	 multiple	 myeloma	 or	 advanced	 solid	
cancers288.	
It	 appears	 that	 elevated	 levels	 of	 CK2	 activity	 alone	 are	 not	 indicative	 of	
deregulation	 since	 it	 is	 intrinsically	 present	 in	 certain	 cell	 types	 as	we	 describe	
here	in	healthy	γδ	thymocytes	compared	to	αβ	thymocytes.	However,	stable	levels	
of	 CK2	 appear	 to	 be	 critical	 to	 cell	 homeostasis.	 Indeed,	we	 show	 that	 γδ	T-ALL	
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present	 elevated	CK2	kinase	 activity	 and	 that	deregulation	of	CK2	 is	 likely	 to	be	
related	 to	 the	severity	of	disease	and	can	even	be	used	as	a	prognostic	 indicator	




several	 signaling	 pathways	 in	 γδ	 T-ALL,	 CX-4945	 treatment	 may	 be	 a	 valuable	
therapeutic	 approach	 that	 could	 replace	 the	 current	 therapies	 that	 target	
downstream	 pathways,	 including	 inhibitors	 of	 PI3K418,	 AKT419,420,	mTOR421,	 dual	
PI3K-mTOR	inhibitors422,	and	BCL2	inhibitors261,423,424.	
Finally,	 our	 study	 has	 implications,	 not	 only	 for	 hematology,	 but	 also	 for	 cancer	
immunotherapy,	since	γδ	T	cells	are	known	to	play	important	roles	in	anti-tumor	
responses72.	The	success	of	 their	 clinical	application,	particularly	 in	adoptive	cell	
therapy,	 will	 strongly	 depend	 on	 the	 capacity	 to	 survive	 ex	 vivo	 TCR-mediated	
activation	and	in	vivo	establishment	and	expansion.	Thus,	we	believe	that	a	better	
knowledge	of	the	molecular	determinants	of	γδ	T-cell	survival,	as	described	in	this	
thesis,	 for	 CK2,	 will	 be	 critical	 to	 optimize	 their	 performance	 in	 cancer	
immunotherapy.		
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V. FUTURE PERSPECTIVES 
	
The	 laboratories	 involved	 in	this	thesis,	 the	Silva-Santos	and	Barata	groups,	have	
performed	various	studies	with	hematological	tumors	that	provided	seminal	data	
on	 (i)	altered	mechanisms	acquired	by	malignant	T	cells	during	 tumor	 initiation,	
progression	 and	 response	 to	 treatment;	 and	 (ii)	 the	 potential	 of	 using	 γδ	 T	
lymphocytes	to	target	aggressive	leukemias.	
Mechanistically,	the	Barata	lab	dissected	the	major	signaling	pathways	responsible	
for	 leukemia	 development.	 IL-7	 mediates	 abnormal	 PI3K/AKT/mTOR	 signaling	
pathway	 as	 result	 of	 mutations,	 post-translation	 modifications,	 cell-intrinsic	
aberrations	 or	 microenvironmental	 factors	 that	 support	 irregular	 cell	 survival,	
proliferation	and	tumor	development	and	progression.	The	characterization	of	the	
signaling	pathways	involved	in	T-ALL	allows	us	to	identify	new	molecular	targets	





On	 the	other	hand,	 the	Silva-Santos	group	established	a	major	role	 for	activating	
NKRs	 in	 tumor	cell	 recognition	by	human	γδ	T	cells.	This	was	observed	 for	both	
Vγ9Vδ2+	and	Vδ1+	T-cell	subsets,	in	which	NKG2D	and	NCRs	(NKp30	and	NKp44)	
mediated	leukemia	cell	recognition.	We	hope	to	build	on	this	knowledge	to	devise	
more	 effective	 cancer	 immunotherapies,	 which	 will	 overcome	 the	 limitations	 of	
previous	γδ	T	cell-based	clinical	trials;	that	is	the	underlying	principle	of	the	novel	
Vδ1+	T	cell	(DOT)	technology	developed	in	our	 lab.	DOT	cells	employ	NKp30	and	
NKp44,	 besides	 the	 signature	 TCR,	 to	 recognize	 tumor	 cells	 (Figure	 15).	 These	
NCRs	 are	 a	 primate	 acquisition,	 as	 they	 are	 not	 expressed	 in	 mice,	 and	 even	
selectively	among	non-human	primates	(macaques	lack	NKp44,	for	instance).	The	
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two	 NCRs	 are	 located	 in	 distinct	 human	 chromosomes	 and	 share	 no	 homology.	
They	 are	 therefore	 two	 complementary	molecular	 tools	 to	 induce	 cytotoxicity	 in	
lymphocytes,	which	DOT	cells	employ	effectively	 to	 target	 tumor	cells.	Of	note,	a	
very	 attractive	 property	 of	 Vδ1+	 T	 cells	 (and	 γδ	 T	 cells	 as	 a	 whole)	 aiming	 at	











with	 HER2	 as	 TAA	 2.	 BTN3A1:	 butyrophilin-3A1,	 an	 isoform	 of	 CD277;	 MICA:	 MHC	 class	 I	
polypeptide-related	sequence	A;	ULBPs:	UL	Binding	Proteins;	DNAM-1:	DNAX	accessory	molecule-1	
(CD226)	(From	Silva-Santos	et	al.	Nat	Rev	Immunol	2015,	15:	683-91).	




tumor	 cell	 surface	 to	 engage	 the	 TCR	 and	 the	NCRs	 (on	DOT	 cells).	 Our	 current	
conceptualization	 postulates	 that	 they	 will	 be	 stress/	 transformation-induced	
molecules,	absent	(or	very	 low)	 in	healthy	cells	but	strongly	upregulated	 in	 their	
malignant	counterparts.	That	 is	 the	case	 for	B7-H6,	 the	known	ligand	for	NKp30.	
B7-H6	transcripts	have	not	been	detected	in	most	normal	adult	tissues,	consistent	




will	 be	 important	 to	 establish	 how	much	 tumors	 downregulate	 their	 expression	









potently	activated	by	TCRγδ	and	costimulatory	 ligands	 in	the	presence	of	 IL-2	or	
IL-15.	This	endows	 them	with	potent	 cytolytic	 (and	cytokine-secreting)	 function,	
but	requires	a	subsequent	phase	of	target	identification,	namely	for	discrimination	
between	 tumor	 and	 healthy	 cells.	 We	 propose	 this	 is	 mainly	 determined	 by	
activating	NKRs	that	bind	stress-inducible	proteins	that	selectively	accumulate	on	
the	 surface	of	 tumor	 cells.	The	NKRs	 can	either	be	 constitutively	 expressed	 (like	
NKG2D)	or	induced	upon	activation	(like	NCRs).	We	believe	the	integration	of	γδ	T	
cell	activation	with	tumor	cell	recognition,	as	we	demonstrated	for	DOT	cells,	will	




T	 cells	 as	 the	number	1	most	 favorable	 immune	prognostic	 population	 in	 tumor	
biopsies	derived	from	25	types	of	cancer79.	
	
As	 we	 continue	 our	 quest	 to	 manipulate	 γδ	 T	 cells	 for	 cancer	 immunotherapy,	
various	 major	 questions	 remain	 unanswered.	 For	 instance,	 it	 will	 be	 very	
important	 to	decipher	 the	 full	 repertoire	of	 tumor	antigens	 involved	 in	 γδ	T	 cell	
recognition,	 including	 the	 ligands	 of	 TCRs	 or	 NKRs,	 and	 to	 find	 additional	
determinants	 of	 tumor	 cell	 killing.	 γδ	 T	 cells	 express	 a	 very	 diverse	 panel	 of	
inhibitory	 and	 activating	 receptors	 that	 directly	 impact	 on	 their	 activation	 state	
and	 function.	 However,	 we	 still	 lack	 a	 dynamic	 picture	 of	 the	 receptors	 elicited	
along	 tumor-induced	 γδ	 T	 cell	 activation,	 and	 a	 deep	 understanding	 of	 the	
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The contributions of gd T-cells to immunity to infection or tumors critically depend on
their activation and differentiation into effectors capable of secreting cytokines and killing
infected or transformed cells.These processes are molecularly controlled by surface recep-
tors that capture key extracellular cues and convey downstream intracellular signals that
regulate gd T-cell physiology. The understanding of how environmental signals are inte-
grated by gd T-cells is critical for their manipulation in clinical settings. Here, we discuss
how different classes of surface receptors impact on human and murine gd T-cell differen-
tiation, activation, and expansion. In particular, we review the role of five receptor types:
the T-cell receptor (TCR), costimulatory receptors, cytokine receptors, NK receptors, and
inhibitory receptors. Some of the key players are the costimulatory receptors CD27 and
CD28, which differentially impact on pro-inflammatory subsets of gd T-cells; the cytokine
receptors IL-2R, IL-7R, and IL-15R, which drive functional differentiation and expansion of
gd T-cells; the NK receptor NKG2D and its contribution to gd T-cell cytotoxicity; and the
inhibitory receptors PD-1 and BTLA that control gd T-cell homeostasis. We discuss these
and other receptors in the context of a five-step model of receptor signaling in gd T-cell
differentiation and activation, and discuss its implications for the manipulation of gd T-cells
in immunotherapy.
Keywords: gdT-cells,T-cell receptor,T-cell costimulation, cytokines, natural killer receptors
INTRODUCTION
gd cells endow the T-cell compartment with a rapid, innate-
like reaction to insults, which places them in the afferent phase
of the immune response. Namely, gd T-cells are responsible for
“lymphoid stress surveillance,” i.e., sensing and responding imme-
diately to infections or non-microbial stress without the need of
clonal expansion or de novo differentiation, in synchrony with pro-
totypic innate immune responses (1). Critically, this implicates gd
T-cells in inflammation (2), autoimmunity (3), infectious diseases
(4, 5), and tumor surveillance (6–8).
Many of the studies elucidating the physiological roles of gd
T-cells have been performed in murine models, where a major
breakthrough has been the identification of pro-inflammatory
subsets naturally producing either IFNg or IL-17 (9–11). More-
over, these studies have been greatly facilitated by the identification
of cell surface markers that segregate the two functional gd T-
cell subsets: CD27, CD122, and NK1.1 mark IFNg-producing gd
cells,whereas their IL-17-expressing counterparts display a CD27 
CCR6+ phenotype (9–11). Moreover, the two subsets show dis-
tinct Vg chain usage in their TCR repertoires, with a bias toward
Vg1 among IFNg-producing gd cells, and an enrichment in Vg4
and Vg6 in IL-17-producing gd cells (12).
In humans, gd T-cells are primarily identified by their
Vd chain usage, with Vd1+ cells predominating in the thy-
mus and in peripheral tissues, while Vd2+ cells (mostly
co-expressing a Vg9 chain) constitute the majority of blood-
circulating gd T-cells. Both human gd T-cell subsets are highly
prone to secrete IFNg, but IL-17 can be induced in highly
inflammatory conditions triggered by infections (13) or tumors
(14, 15).
In both murine and human gd T-cells, functional responses
are initiated upon recognition of antigens that are likely induced
by stress signals and sensed by either T-cell or natural killer
receptors. Some gd T-cell populations are also particularly respon-
sive to cytokines or innate toll-like receptor (TLR) agonists (16,
17). Following proliferation and effector responses, the return
to homeostasis is controlled by inhibitory receptors. Here, we
discuss the various layers of contributions of T (TCR and cos-
timulatory/inhibitory receptors), NK, and cytokine receptors to
the activation and differentiation of effector gd T-cell populations
in mice and humans.
SIGNAL 1: T-CELL RECEPTOR
The gdTCR complex is composed by the gdTCR itself and var-
ious CD3 chains following the stoichiometry: TCRgdCD3+2gdz2
in humans and TCRgdCD3+2g2z2 in mice (18). The assembly of
a gdTCR complex in thymic progenitors has immediate conse-
quences for gd T-cell development. The “strong” signals stemming
from the gdTCR (when compared to the “weaker” pre-TCR sig-
naling) drive gd/ab common precursors into the gd lineage (19,
20). These“stronger”gdTCR signals associate with increased phos-
phorylation of ERK1/2, abundant calcium release and induction
of early growth response (Egr) transcription factors (21, 22).
The TCR complex does not present intrinsic kinase activity
but the intracellular signaling is initiated after phosphorylation of
immunoreceptor tyrosine-based activation motifs (ITAMs) in the
www.frontiersin.org January 2015 | Volume 6 | Article 15 | 1




























































Ribeiro et al. Receptor signaling in gd T-cells
CD3 cytoplasmic domains by the Src-family kinases (SFKs) Lck
and Fyn (23). The recruitment of these SFKs to the TCR complex
in gd T-cells remains obscure since these cells do not express the
CD4 or CD8 co-receptors, which have been shown, in ab T-cells,
to be responsible for recruiting SFKs upon abTCR ligation (23).
Nonetheless, the importance of SFKs in gd T-cells is underscored
by the substantial phosphorylation of ERK upon inhibition of Csk,
a potent inhibitor of SFKs (24).
SFK-mediated phosphorylation of the ITAMs on CD3 chains
allows the recruitment, phospholylation, and activation of Zap70
that facilitates phosphorylation of the scaffolding proteins SLP-
76 and LAT. This lead to the formation of a supramolecular
signalosome that recruits the phospholipase PLCg1, resulting in
propagation of downstream signaling events (22). Here again, gd
T-cell signaling is different from ab T-cells, since mutations on
the binding site of PLCg1 on LAT resulted in a severe block in
murine ab thymocyte development while gd T-cell numbers were
only modestly reduced in the thymus, intestine, and liver, and
remained normal in the skin. Unexpectedly, a population of gd
T-cells in the secondary lymphoid organs in these mice under-
went uncontrolled expansion and caused autoimmune pathology,
suggesting distinct functions for LAT/PLCg1-mediated signaling
in subpopulations of gd T-cells (21, 25).
In humans, the major gd T-cell subset in the peripheral blood,
Vg9Vd2 T-cells, are uniquely and specifically reactive to self- and
foreign non-peptidic phosphorylated intermediates of isoprenoid
synthesis – “phosphoantigens” or “phosphoagonists” (P-Ags) (26–
28). These P-Ags were shown to trigger bona fide Vg9Vd2 TCR sig-
naling in various studies. Cipriani and colleagues showed that the
activation of Vg9Vd2 T-cells with the P-Ag isopentenyl pyrophos-
phate (IPP), induced rapid and persistent PKC-dependent phos-
phorylation of ERK1/2, p38 MAPK, and JNK, resulting in NF-kB
and AP-1 activation as well as the release of MIP-1a, MIP-1b,
IFN-g, and TNF-a (29). Moreover, P-Ag stimulation and CD3-
crosslinking produced identical phosphorylation of the signaling
proteins Zap70, PI3K, LAT, ERK1/2, and p38 MAPK (30, 31); and
induced highly sustained calcium signaling in Vg9Vd2 T-cells (32).
Importantly, activation by P-Ags is the basis of current cancer
immunotherapy strategies involving Vg9Vd2 T-cells (33).
Recent work has produced some puzzling results on the role
of the gdTCR in the development of effector subsets of murine
gd T-cells (34–36), namely, CD27+ CD122+ gd T-cells producing
IFN-g or CD27  CCR6+ gd T-cells making IL-17 (9, 10). First,
Chien and co-workers showed that T10/T22-specific gd T-cells
required thymic expression of their TCR ligand to differentiate
into IFN-g producers, in contrast with “ligand naïve” IL-17 pro-
ducers (9). Consistent with this, TCR-dependent thymic selection
was also shown to set the functional potential of dendritic epi-
dermal T-cells (DETC) progenitors away from IL-17 production
(37). Furthermore,peripheral IL-17-producing CD27  CCR6+ gd
T-cells were shown to expand and produce IL-17 independently
of TCR activation (38). However, a subsequent study by Chien
and collaborators demonstrated that a subset of phycoerythrin
(PE)-specific gd T-cells produced IL-17 specifically upon TCR lig-
ation (39). Moreover, a recent study by Hayday and colleagues
suggested that an impairment in Zap70 signaling (in SKG mice)
mostly affected the development of IL-17+ rather than IFN-g+
gd T-cells (40). The authors further proposed that “innate-like”
gd T-cell populations, including IL-17 producers and some sub-
sets of IFN-g producers, receive strong TCR signals during thymic
development to become hyporesponsive to TCR stimulation in the
periphery (40). Future research should aim to resolve the appar-
ent contradictions of the available data, namely, by clarifying the
requirement on TCR ligand engagement, as well as the develop-
mental effects of manipulating distinct gdTCR signaling pathways
and their downstream (transcriptional and post-transcriptional)
mechanisms on gd T-cell subsets.
SIGNAL 2: COSTIMULATORY RECEPTORS
A series of T-cell costimulatory receptors are known to induce
qualitative and quantitative changes that lower activation thresh-
olds, prevent “anergy” and enhance T-cell functions. Typical cos-
timulatory receptors are type I transmembrane proteins that can
be divided into two groups, based on their structural charac-
teristics: immunoglobulin (Ig) or tumor necrosis factor receptor
(TNFR) superfamilies. Ig superfamily members have a variable
Ig-like extracellular domain and a short cytoplasmic tail, whereas
TNFR family members present extracellular domains rich in six
cysteine repeats (which form disulfide bridges) and a more com-
plex cytoplasmic tail [reviewed in Ref. (41)]. These two main types
of costimulatory receptors display different modes of intracellu-
lar signaling: whereas the CD28 family members associate directly
with protein kinases (like PI3K or ITK), TNFR superfamily co-
receptors require the adaptor proteins TRAF (TNFR-associated
factor), namely TRAF2 and TRAF5, to link to downstream sig-
naling mediators (Table 1). Here, based on their specific roles
in gd T-cells, we shall discuss CD28 (of the Ig superfamily)
and the TNFR superfamily members, CD27, CD30, and CD137
(4-1BB).
The best studied costimulatory receptor, CD28, has historically
yielded paradoxical results on gd T-cells (46). We have recently
readdressed this issue for both human and mouse gd T-cells. We
described that CD28 is constitutively expressed on lymphoid gd T-
cells and promotes survival and proliferation via IL-2 production.
CD28 receptor agonists enhanced gd T-cell expansion, which was
conversely inhibited by blocking antibodies against its B7 ligands
(42). Importantly, CD28-deficient mice displayed lower (relative
to controls) numbers of total or activated gd T-cells upon Plasmod-
ium berghei infection, and failed to expand both their IFN-g+ and
IL-17+ subsets (42). In contrast, Hayes and colleagues reported
that both functional gd T-cell subsets differentiated and expanded
normally in a Listeria model (80). It would be interesting to deter-
mine how variable is the dependence on CD28 costimulation for
gd T-cell responses to distinct infectious agents.
In naïve mice, while CD28 is not required for the development
of either IFN-g+ or IL-17+ gd T-cell subsets (80), the TNFR super-
family member CD27 is selectively implicated in the generation of
IFN-g+ gd T-cells (10). In fact, we showed that CD27 expres-
sion segregates IFN-g+ (CD27+) and IL-17+ (CD27 ) gd T-cells.
Most interestingly, these phenotypes are established in the thymus,
and since embryonic stages. Based on the results from our (10) and
Chien’s (9) teams, the development of IFN-g-producing gd T-cells
seemingly requires strong TCR signaling and CD27 costimulation
in the thymus.
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Table 1 | Co-receptors of gdT-cells – extracellular ligands and intracellular signaling pathways.





























































CD3z cAMP/PKA CC chemokines: CCL3,
CCL4, CCL5
(64–67)


















BTLA HVEM SHP-1 Zap70/ERK IL-17, TNF, IL-2 (77–79)
SHP-2
Beyond its role in thymic differentiation, CD27 is critical for the
expansion of peripheral IFN-g-producing gd T-cells upon infec-
tion with herpes viruses or malaria parasites in mice (81). We
showed that, in the context of TCR stimulation and upon liga-
tion to CD70, CD27 signaling activates the non-canonical NF-kB
pathway and enhances the expression of anti-apoptotic and cell
cycle-related genes, thus promoting murine gd T-cell survival and
proliferation (81).
We have also addressed the impact of CD27 costimulation
on the activation of human gd T-cells. Administration of solu-
ble recombinant CD70 enhanced, whereas anti-CD27 (or anti-
CD70) antibodies reduced, Vg9Vd2 T-cell expansion in vitro (82).
Moreover, CD27 signals induced calcium fluxes and upregulated
the expression of Cyclin D2 and the anti-apoptotic gene Bcl2a1.
Given the typical IFN-g secretion and cytotoxicity of activated
Vg9Vd2 T-cells (30), our work suggests that the modulation
of CD70–CD27 signals may be beneficial in the context of gd
T-cell-based cancer immunotherapy.
Upon activation, human gd T-cells can also express another
TNFR superfamily member, CD30 (83). CD30 signaling, which
potentiated calcium fluxes induced by TCR activation, also
enhanced pro-inflammatory cytokine production (50). Recently,
Yoshikai and colleagues compared gd T-cell homeostasis and
response to Listeria monocytogenes in CD30-sufficient versus
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deficient mice. They demonstrated a selective depletion of IL-17-
producing Vg6+ T-cells in mucosal tissues in the steady-state and
upon infection (84). This associated with reduced bacterial clear-
ance, which could be rescued, alongside the IL-17+ Vg6+ T-cell
pool, by agonistic anti-CD30 antibody administration. In contrast,
Lee et al. reported that agonistic anti-CD137 (4-1BB) antibodies
promoted the expansion of IFN-g+ Vg1+ T-cells, which protected
(in an IFN-g-dependent manner) also from Listeria infection (52).
This study also showed that 4-1BB was expressed and functional
on activated human gd T-cells, and its ligation upon cell transfer
protected NOD/SCID mice against Listeria infection.
Interestingly, activated Vg9Vd2 T-cells also express high levels
of 4-1BBL (CD137L) (85), which besides acting as a ligand for
4-1BB on T and NK-cells, may also participate in Vg9Vd2 T-cell
activation due to its known reverse signaling ability (86). This
may, in fact, also apply to CD70 (CD27-ligand), which is highly
induced upon phosphoantigen-mediated stimulation of Vg9Vd2
T-cells (82, 87). These possibilities deserve further investigation.
SIGNAL 3: CYTOKINE RECEPTORS
Interleukins are key determinants of T-cell survival, proliferation,
and differentiation. IL-7, IL-15, and IL-2 are essential for lym-
phocyte development and homeostasis; upon inflammation, other
cytokines, namely, IL-1b, IL-12, IL-18, IL-21, and IL-23, take a
central role in determining T-cell functions. Here, we review the
main contributions of homeostatic and inflammatory cytokines
specifically to gd T-cell physiology.
IL-7 and IL-15 are seemingly the key determinants of murine gd
T-cell development (88–90) and homeostasis (91). A recent study
that depleted IL-7 specifically from (Foxn1+) thymic epithelial
cells showed that gd T-cells were significantly reduced in the adult
thymus and in the gut, whereas they were completely absent in the
fetal thymus and epidermis (89). In the dermis, it was also IL-7, but
not IL-15, that supported the development and survival of the res-
ident gd T-cell population (92). Conversely, in the gut, IL-15 seems
to play the primordial role in sustaining the local intraepithelial
gd T-cell compartment (93).
Unexpectedly, IL-7 was recently reported to promote the
selective expansion of murine IL-17-producing gd T-cells (59).
STAT3-dependent IL-7 signals allowed CD27  gd T-cells to resist
activation-induced cell death (AICD) and undergo proliferative
responses to TCR agonists. Such an IL-7/IL-17 axis was also
reported to be required for the gd T-cell response to viral hepatitis
infection in vivo (94). Moreover, IL-7 also seems to support the
expansion of human IL-17-producing gd T-cells (59).
We recently assessed the functional differentiation of human
gd thymocytes, which are >80% of the Vd1 subtype. We observed
that IL-15 and IL-2, but not IL-7, induced the cytotoxic type 1
(IFN-g-producing) program in functionally immature gd thymo-
cytes (55). This was consistent with previous data on peripheral
gd T-cells isolated from cancer patients (95). However, additional
reports on peripheral Vg9Vd2 T-cell cultures showed that IL-15
or IL-2 stimulation, despite efficient ERK and AKT activation,
were not sufficient to induce effector responses; these required
phosphoantigen-dependent TCR activation and downstream cal-
cium mobilization (56, 96). Unexpectedly, in our cultures of gd
(mostly Vd1) thymocytes, TCR stimulation was not required for
neither ERK activation nor T-bet and eomesodermin induction
and the acquisition of effector functions (55).
IL-2 and IL-15 play key roles in the peripheral expansion of
Vg9Vd2 T-cells in response to microbial phosphoantigens or syn-
thetic drugs like bisphosphonates (56, 97). This notwithstanding,
it is important to note, toward the therapeutic application of
Vg9Vd2 T-cells, that optimal effector responses seemingly require
the combination of these cytokines with TCR agonists. Thus,
recent work from Chen and colleagues demonstrated that the dif-
ferentiation of cytotoxic type 1 Vg9Vd2 T-cells capable of control-
ling Mycobacterium tuberculosis infection in macaques required a
phosphoantigen/IL-2 combination (98).
Effector gd T-cell differentiation is also greatly impacted by
inflammatory cytokines, particularly IL-12 and IL-18 that typi-
cally promote IFN-g production; and IL-1b and IL-23 that mostly
drive IL-17 production.
High expression of IL-12Rb expression on activated murine gd
T-cells guarantees a dominance of type 1 (IFN-g+) over type 2
(IL-4+) effector fates (99). Type 1 differentiation is also predom-
inant in human gd T-cells, and can be further enhanced by IL-18
(100, 101) or IL-21 (102). The induction of a type 17 program in
human gd T-cells requires persistent stimulation with IL-23 for
neonatal Vg9Vd2 T-cells (15); and IL-23 and IL-1b in the pres-
ence of TGF-b for adult Vg9Vd2 T-cells (13, 103). In mice, IL-1b
and IL-23 are also the main drivers of abundant IL-17 produc-
tion by peripheral gd T-cells (3, 5, 81, 104–106), although recent
data surprisingly suggest that IL-18 can replace IL-1b in combin-
ing with IL-23 to induce IL-17 expression (107). In contrast, IL-1b
upstream of IL-1R seems essential for GM-CSF production by gd
T-cells (108).
Finally, IL-21 was recently suggested to endow human Vg9Vd2
T-cells with B-cell helper activity associated with a T follicular
helper cell-like phenotype (60, 109), which may impact on the
generation of high affinity antibodies against microbial infections.
SIGNAL 4: NATURAL KILLER RECEPTORS
An important key characteristic that allows the recognition of
transformed cells by gd T-cells is the expression of a wide set of
germline-encoded receptors that were initially described in NK-
cells and hence are collectively known as NK receptors (NKRs),
including natural cytotoxicity receptors (NCRs).
The C-type lectin-like NK receptor group 2 member D
(NKG2D) is the best studied NKR in gd T-cells. NKG2D binds
extracellularly to multiple ligands of the MIC(A–B) and ULBP
(1–6) families in humans; and to H60, MULT1, and various RAE1
molecules in mice (110). NKG2D ligands are induced upon cellu-
lar stress, for example, downstream of the DNA-damage response
pathway in tumor cells (111, 112). The biological significance of
this recognition system is underlined by the increased susceptibil-
ity of NKG2D-deficient mice to tumor development (113).
Intracellularly, NKG2D binds to DNAX-activating protein of
10 kDa (DAP10), which carries an YXNM motif that after tyrosine
phosphorylation recruits PI3K or a Grb2–Vav1–SOS1 signaling
complex (Table 1). This motif is similar to that in CD28, and
thus, NKG2D/DAP10 may provide T-cells with costimulatory sig-
nals that synergize with the ITAM-based TCR/CD3 complex (61).
However, unlike ab T-cells but similarly to NK-cells, gd T-cells can
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express both DAP10 and DAP12 (62). The latter contains an ITAM
motif, which after tyrosine phosphorylation recruits and activates
Syk and ZAP70. Interestingly, only murine but not human NKG2D
is able to associate with DAP12 (in addition to DAP10).
The controversy on a primary stimulatory versus costimulatory
role of NKG2D in gd T-cells has been discussed elsewhere (46,114).
Briefly, the costimulatory function of NKG2D in human Vg9Vd2
T-cells was supported by additive effects on TCR-mediated activa-
tion: an upregulation of cytokine production upon MICA-NKG2D
interactions (115); and an increase in intracellular calcium mobi-
lization and cytotoxic activity (32). However, other lines of evi-
dence have suggested that NKG2D signals can activate gd T-cells in
the absence of TCR engagement: NKG2D ligation can upregulate
CD69 expression in Vg9Vd2 T-cells to similar extent as TCR stim-
ulation (116); NKG2D but not TCR blockade can inhibit Vg9Vd2
T-cell cytotoxicity against various hematological tumors (117);
and murine DETC can target tumors upon recognition of NKG2D
ligands (6, 118).
Another NKR implicated in tumor cell recognition by Vg9Vd2
T-cells is DNAX accessory molecule-1 (DNAM-1). DNAM-1 is
an Ig-like family glycoprotein composed of a cytoplasmic domain
containing three putative sites of phosphorylation by intracellu-
lar kinases. The phosphorylation of the Ser329 by protein kinase
C (PKC) was shown to be critical for the association between
DNAM-1 and LFA-1, which recruits the Fyn Src kinase to phos-
phorylate the Tyr322 of DNAM-1, thus initiating downstream
signaling leading to SLP-76 and Vav1 phosphorylation (Table 1)
(119). Antibody-mediated DNAM-1 blockade impaired Vg9Vd2
T-cell cytotoxicity and IFN-g production against hepatocellular
carcinoma lines expressing Nectin-like-5 (71).
Recently, we characterized a Vd1+ T-cell population capable of
targeting hematological tumors resistant to fully activated Vg9Vd2
T-cells (120). Unexpectedly, the enhanced killer function resulted
from induced NCR expression, namely NKp30 and NKp44, which
had been previously regarded as NK-specific markers. Although
neither Vd1+ nor Vd2+ cells express NCRs constitutively, these can
be upregulated selectively in Vd1+ cells by PI3K/AKT-dependent
signals provided by gc cytokines (IL-2 or IL-15) and TCR stimu-
lation. Once expressed on the cell surface, NKp30 and NKp44 can
signal via CD3z and DAP12, respectively (64). We further showed
that NKp30 and NKp44 are both functional in NCR+ Vd1+ T-
cells and synergize with NKG2D to target lymphocytic leukemia
cells (120).
In sum, NKRs seem critical for tumor recognition and
deployment of the cytotoxic program that is endowed by
TCR/gc cytokine-dependent differentiation, thus defining dis-
tinct mechanisms to be integrated in gd T-cell-mediated cancer
immunotherapy.
SIGNAL 5: INHIBITORY RECEPTORS
Beyond efficient activation and deployment of effector functions,
it is necessary to negatively regulate the T-cell response in order to
return to the homeostatic baseline. Inhibitory receptors like PD-1
or CTLA-4 are known to be critical for this contracting phase of the
T-cell response and have become major clinical targets in cancer
immunotherapy. Although gd T-cells rarely express CTLA-4, they
can upregulate PD-1 upon activation, while they constitutively
express BTLA, and thus these two receptors may be the key to
control gd T-cell responses.
Programed death-1 (PD-1) is absent or low expressed on circu-
lating Vg9Vd2 T-cells but is rapidly induced upon activation (121).
The cytoplasmic tail of PD-1 contains conserved immunoreceptor
tyrosine-based inhibitory motif (ITIM) and switch motif (ITSM),
both of which are phosphorylated to recruit negative regulators
that block Lck activity downstream of the TCR complex (122).
Moreover, PD-1 ligation can augment the activity of the protein
phosphatase and tensin homolog (PTEN), a cellular phosphatase
that inhibits PI3K/AKT signaling and thus leads to impaired sur-
vival, proliferation, and IL-2 release (123). The expression of the
ligand PD-L1 on tumor cells inhibited Vg9Vd2 T-cell cytotoxic-
ity and IFN-g production (121). However, zoledronate-induced
accumulation of P-Ags in tumor cells and consequent Vg9Vd2
TCR activation seemed to overcome the inhibitory effect of PD-
1/PD-L1 interactions. More research is required to understand
the full extent to what PD-1 may control gd T-cell functions and
homeostasis.
B- and T-lymphocyte attenuator (BTLA) is another inhibitory
receptor, member of the CD28 family and structurally related to
PD-1 and CTLA-4. Binding to its ligand, herpesvirus entry medi-
ator (HVEM), induces phosphorylation of the ITIM domain and
association with SH2 domain-containing protein tyrosine phos-
phatase 1 (SHP-1) and SHP-2, which leads to attenuation of cel-
lular activation and growth (124). Recent data showed that BTLA
engagement with HVEM reduced P-Ag/TCR-mediated signaling
and inhibited Vg9Vd2 T-cell proliferation, including in response
to lymphoma cells (77). Conversely, BTLA-HVEM blockade using
monoclonal antibodies enhanced Vg9Vd2 TCR signaling and may
thus have therapeutic potential for the positive manipulation of
gd T-cells.
A detailed study on BTLA function in murine gd T-cells has
revealed a selective involvement in the homeostasis of the IL-
17-producing CD27  gd T-cell subset (78). Although these cells
constitutively express low levels of BTLA, it is upregulated by IL-7
stimulation and thereby limits gd T-cell numbers. Consequently,
BTLA-deficient mice accumulated IL-17+ CD27  gd T-cells and
were more susceptible (than wild-type controls) to dermatitis,
which could be reversed by agonist BTLA antibodies. Thus, BTLA
may be an important target for controlling pathogenic gd T-cells
in inflammatory and autoimmune diseases.
CONCLUDING REMARKS
A multitude of surface receptors has been shown to participate
in gd T-cell differentiation and activation. However, some cru-
cial aspects remain to be elucidated, such as the identity of most
gdTCR ligands. Most importantly, we must improve the transfer
of past and current basic research into future protocols for gd T-
cell-based immunotherapy. In this context, some key questions are:
how to balance gdTCR activation with“exhaustion”due to chronic
stimulation? What can be achieved by manipulating the NK-like
activation mode of gd T-cells? Which costimulatory receptors
should be modulated, and at what stages, to boost the desired gd
T-cell responses? Which combinations of cytokines enable the best
effector gd T-cells for each therapeutic application? Which recep-
tors are most useful to tune down or switch off pathogenic effector
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gd T-cells? The answers to these questions must be obtained in
appropriate in vivo pre-clinical models and hopefully next in the
clinic.
For now, we would like to propose that the five types of recep-
tor signals reviewed here define five distinct layers of regulation
of gd T-cell differentiation, activation, and function. The gdTCR
is critical for the initial stages of differentiation and for prolifera-
tive responses; both processes further require cytokine signals that
promote cell survival, proliferation, and terminal effector func-
tion. Costimulatory and inhibitory receptors control the extent of
gd T-cell expansion, with interesting biases toward specific effec-
tor subsets. Finally, NK receptors play a decisive role in tumor cell
targeting by gd T-cells. Thus, we believe that the recognition of
“stressed self” can be mediated by the gdTCR but also chiefly by
NK receptors like NKG2D. As such, the characterization of both
type of ligands on tumors may be critical to design protocols, select
and monitor patients, and increase the chances of efficacious gd
T-cell-based cancer immunotherapies.
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Human gd Thymocytes Are Functionally Immature and
Differentiate into Cytotoxic Type 1 Effector T Cells upon
IL-2/IL-15 Signaling
Julie C. Ribot, Sérgio T. Ribeiro, Daniel V. Correia, Ana E. Sousa, and Bruno Silva-Santos
Cytotoxicity and IFN-g production by human gd T cells underlie their potent antitumor functions. However, it remains unclear
where and how human gd T cells acquire these key effector properties. Given the recent disclosure of a major contribution of the
thymus to murine gd T cell functional differentiation, in this study we have analyzed a series of human pediatric thymuses. We
found that ex vivo–isolated gd thymocytes produced negligible IFN-g and lacked cytolytic activity against leukemia cells. How-
ever, these properties were selectively acquired upon stimulation with IL-2 or IL-15, but not IL-4 or IL-7. Unexpectedly, TCR
activation was dispensable for these stages of functional differentiation. The effects of IL-2/IL-15 depended on MAPK/ERK
signaling and induced de novo expression of the transcription factors T-bet and eomesodermin, as well as the cytolytic enzyme
perforin, required for the cytotoxic type 1 program. These findings have implications for the manipulation of gd T cells in cancer
immunotherapy. The Journal of Immunology, 2014, 192: 000–000.
A ll jawed and jawless vertebrates have evolved three lin-eages of lymphocytes based on somatic gene diversifi-cation of Ag receptors (1). Within the lymphocyte trilogy,
gd T cells clearly remain the most poorly understood lineage, both in
terms of Ag recognition and differentiation into effector cell subsets
(2). This notwithstanding, gd T cells are already being targeted in
cancer immunotherapy (3, 4) based on multiple promising preclinical
studies in both mice (5–8) and humans (3, 9–11).
Human gd PBLs are endowed with potent cytotoxicity against
hematological (3, 9, 10) and epithelial (11, 12) malignant cells.
Moreover, gd PBLs are highly polarized toward IFN-g production
since early life, as preterm babies harbor significant proportions of
IFN-g+ gd (but not ab) T cells in the blood (13), and CMV in-
fection in utero promotes the differentiation of IFN-g+ and perforin+
gd T cells (14). gd T cells thus constitute the first functional pop-
ulation of circulating T cells (13).
Given an individual’s history of infections, circulating gd PBLs
can display very heterogeneous phenotypes ranging from naive to
effector/memory and terminally differentiated effector cells (15). It is
therefore difficult to inquire where and how human gd T cells acquire
their effector functions. In healthy individuals, these are tightly linked
to IFN-g production, as alternative functional states, such as IL-17 or
IL-22 secretion, are very rare (16–18).
Interestingly, we (19) and others (20, 21) have shown that mu-
rine gd T cells acquire their effector properties during thymic
development, in a process regulated by TCRgd (and coreceptor)
signaling (22). For example, IFN-g–producing gd T cells require
TCR and CD27 signals for differentiation in the mouse thymus
(19–21). This raises the question whether human gd thymocytes
can also complete their functional differentiation before being
exported to the periphery. Although thymic commitment to the
gd T cell lineage is controlled by Notch signaling (23, 24), much
less is known about the subsequent steps of functional differ-
entiation of human gd T cells (16, 25, 26). This will likely have
major implications for their manipulation in cancer immuno-
therapy.
Building on these considerations, in this study we have used
pediatric thymic tissue to address the molecular mechanisms of
human gd T cell differentiation toward antitumor lymphocytes.
Our results reveal an NK-like mode of differentiation that is de-
pendent on IL-2/IL-15 signals but surprisingly not on TCR acti-
vation. Interestingly, this process must take place in the periphery,
because, unlike their murine counterparts, human gd thymocytes
are devoid of cytotoxic type 1 effector functions. Finally, our data
disclose an MAPK/ERK-mediated differentiation pathway that may
constitute an important target for future modulation of gd T cell
activity in the clinic.
Materials and Methods
Ethics
Thymic specimens were routinely obtained during pediatric corrective
cardiac surgery, after parent’s written informed consent. The study was
approved by the Ethics Board of the Faculdade de Medicina da Uni-
versidade de Lisboa.
Lymphocyte preparations
Thymic samples (from newborn to 9-y-old children) were processed by
tissue dispersion and Histopaque-1077 (Sigma-Aldrich) density gradient.
Peripheral blood was collected from anonymous healthy volunteers, diluted
with 1 volume of PBS (Invitrogen Life Technologies), and separated on a
Histopaque-1077 density gradient. gd T cells were isolated (to.95% purity)
by magnetic cell sorting by positive selection (Miltenyi Biotec). Alternatively,
CD1a+ gd T cells or CD32CD42CD82TCRgd2 thymic progenitors were
electronically sorted on a FACSAria cell sorter (BD Biosciences).
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Isolated gd T cells were cultured at 106 cells/ml at 37˚C, 5% CO2 in round-
bottom 96-well plates with RPMI 1640 and 2 mM L-glutamine (Invitrogen
Life Technologies) supplemented with 10% FBS (Invitrogen Life Tech-
nologies), 1 mM sodium pyruvate (Invitrogen Life Technologies), and 50
mg/ml penicillin and streptomycin (Invitrogen Life Technologies). Indi-
cated cytokines were added when mentioned (all from PreproTech, 10 ng/ml).
To study the effects of chemical inhibitors of signal transduction, the MEK
inhibitor UO126, the PI3K inhibitor LY294002, and the STAT5 inhib-
itor Ssi (all from Calbiochem) were added at 20 mM after 4 d in culture.
CD32CD42CD82TCRgd2 thymic progenitors were seeded at 2 3 105
cells/well into 48-well tissue culture plates (BD Biosciences) containing
a subconfluent monolayer of OP9-DL1 cells. Cocultures were performed in
culture medium consisting of DMEM (Invitrogen Life Technologies) sup-
plemented with 20% FCS, 100 IU/ml streptomycin, penicillin, and L-glu-
tamine (Invitrogen Life Technologies) in the presence of 10 ng/ml IL-7
(PreproTech). Where mentioned, IL-2 (10 ng/ml; PreproTech) was added.
Every 4–5 d, cells were harvested by forceful pipetting and transferred to
a fresh confluent monolayer of OP9-DL1 cells.
In vitro tumor-killing assays
The MOLT-4 leukemia cell line was stained with CellTrace Far Red
7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one–succinimidyl ester
(1 mM; Molecular Probes/Invitrogen) and each batch of 3 3 104 tumor
cells was incubated with 3 3 105 gd T cells in RPMI 1640 for 3 h in a
round-bottom plate with 96 wells. Cells were stained with annexin V–FITC
(BD Biosciences) and analyzed by FACS.
Flow cytometry (FACS) analysis
Surface and intracellular stainings were performed as previously described
(19). Cells were labeled with the following fluorescent mAbs: anti–TCRgd-
FITC (SA6.E9) from Invitrogen; anti–Vd1-FITC (TS8.2) from Thermo Scien-
tific; anti–Vd2-PE (B6), anti–CD3-PerCP-Cy5.5 (UCHT1), anti–CD69-PE-Cy7
(FN50), anti–TNF-a-PE-Cy7 (MAb11), anti–CD107a-Pacific Blue (H4A3),
and anti–CD45RA-allophycocyanin (HI100) from BioLegend; and anti–
CD8a-PE (HIT8a), anti–IL-2-PE (MQ1-17H12), anti–CD27-PE-Cy7 (LG.7F9),
anti–IFN-g-allophycocyanin (4S.B3), anti–CD4-eFluor 450 (RPA-T4), and
anti–CD1a-eFluor 450 (HI49) from eBioscience. Cell proliferation was
measured by following a standard CFSE staining protocol (19) (CellTrace
CFSE cell proliferation kit from Invitrogen; final concentration, 0.5 mM),
whereas apoptosis was assessed by annexin V–FITC (BD Pharmingen)
staining. Cells were analyzed on a FACSFortessa (BD Biosciences) and using
FlowJo software (Tree Star).
Immunoblotting
Cells were lysed in lysis buffer (50 mM Tris [pH 7.6], 150 mM EDTA,
1% Nonidet P-40 in PBS) enriched with a protease inhibitor mixture
(Roche) and a phosphatase inhibitor mixture (Roche). The total proteins
were quantified using a Bradford assay (Bio-Rad), following the manu-
facturer’s instructions. For following analysis, 30 mg total protein was
denatured in Laemmli buffer (Bio-Rad), boiled for 5 min, and loaded
in a 10% SDS-PAGE. After electrophoretic separation, the proteins
were transferred to nitrocellulose blotting paper (Amersham Biosciences).
The membranes were blocked with 5% BSA and 0.5% Tween 20
(Sigma-Aldrich) in PBS and probed with the following primary Abs:
p-ERK1/2 (Thr202/Try204), ERK1, p-AKT (Ser473) (Cell Signaling
Technology), p-STAT5 (Tyr694/699) (Merck/Millipore), STAT5a (Santa
Cruz Biotechnology), and connexin (Sicgen). These were detected
by the appropriate HRP-conjugated secondary Abs and developed by
chemiluminescence.
Real-time quantitative PCR
Total RNAwas extracted using the RNeasy Mini Kit (Qiagen) according to
the manufacturer’s protocol. Concentration and purity were determined by
spectrophotometry, and integrity was confirmed using an Agilent 2100
bioanalyzer with an RNA 6000 Nano assay (Agilent Technologies). Total
RNA was reverse-transcribed into cDNA using random hexamers and Super-
Script II first-strand synthesis reagents (Invitrogen). Real-time quantitative
PCR was performed on an ABI Prism 7500 Fast sequence detection system
using SYBR Green detection system (both from Applied Biosystems). For
each transcript, quantification was done using the calibration curve method.
The following primers were used: B2m, forward, 59-CTATCCAGCGT-
ACTCCAAAGATTC-39, reverse, 59-CTTGCTGAAAGACAAGTCTGA-
ATG-39; Tbx21, forward, 59-CACCTGTTGTGGTCCAAGTTT-39, reverse,
59-AACATCCTGTAGTGGCTGGTG-39; Pfn, forward, 59-GCAATGTG-
CATGTGTCTGTG-39, reverse, 59-GGGAGTGTGTACCACATGGA-39.
Statistical analysis
Differences between populations were assessed using the Student t test and
are indicated in the figures when significant.
FIGURE 1. Human gd thymocytes are devoid of IFN-g production and
cytotoxic functions. TCRgd+CD3+ cells were isolated from pediatric thymic
biopsies (Thymus/T) or from the peripheral blood of healthy donors (Blood/B)
and analyzed ex vivo by flow cytometry. Dead cells were excluded from
the analysis using LIVE/DEAD Fixable Dead Cell Stain Kits (Molecular
Probes). (A) Surface expression of CD27, CD45RA, and CD1a. (B and C)
Intracellular staining for IFN-g and TNF-a (B) or the degranulation marker
CD107a (C) following 4 h of stimulation with PMA and ionomycin. (D)
Cytotoxic activity against MOLT-4 leukemia cells. Percentage of apoptotic
annexin V+ within 7-hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one–
succinimidyl ester (DDAO-SE+) (prelabeled) tumor cells after 3 h of coin-
cubation with gd T cells at a 10:1 E:T ratio. Results in this figure are
representative of 3–12 independent experiments; each dot represents an
individual sample. **p , 0.005.
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Human gd thymocytes are devoid of cytotoxicity and IFN-g
production
Inspired by the recent identification of fully differentiated effector
gd T cell subsets in the murine thymus (19–21, 26), we started this
study by analyzing the surface phenotype and functional potential
of gd T cells isolated from human pediatric thymic samples. Based
on the differentiation markers CD1a (27), CD27, and CD45RA (15),
the vast majority of gd thymocytes showed an immature and naive
phenotype, which contrasted with the dominant effector/memory
phenotype (15) of gd PBLs (Fig. 1A). Also unlike these, gd thymo-
cytes produced negligible proinflammatory cytokines, particularly
IFN-g and TNF-a (Fig. 1B). Moreover, gd thymocytes lacked
cytolytic activity (Fig. 1C), namely against leukemia target cells,
which were promptly killed by their PBL counterparts (Fig. 1D).
These data clearly demonstrate that, unlike murine gd thymocytes
(19–21, 26), human gd T cells do not complete their functional
differentiation in the thymus, and they thus lack the cytotoxic type
1 characteristics of gd PBLs.
IL-2 and IL-15 signals drive human gd cytotoxic type 1 cell
differentiation
The functional immaturity of human gd thymocytes made them an
ideal system to investigate the molecular cues required for ac-
quisition of antitumor effector properties. Focusing first on IFN-g
FIGURE 2. IL-2 and IL-15 signals differentiate gd thymocytes into cytotoxic type 1 effector T cells. MACS-purified gd thymocytes were cultured for 7 d in the
presence of 10 ng/ml of the indicated cytokines; anti-CD3 mAb (1 mg/ml) was added when noted, and as part of the Th1 mix also contained anti-CD28 mAb (5 mg/
ml), IL-2, and IL-12. (A) Intracellular staining for IFN-g following 4 h of stimulation with PMA and ionomycin. (B) Surface expression of the activation marker
CD69. (C) Surface staining for CD27 and CD45RA. (D) Intracellular staining for CD107a. (E) Cytotoxic activity against MOLT-4 leukemia cells (as in Fig. 1D). (F)
Correlations between fractions of cells expressing IFN-g, TNF-a, or CD107a. Each dot represents a specific culture condition from the experiments in Fig. (A) and
(D). (G) Real-time PCR data for the expression of T-bet (Tbx21, upper panel), eomesodermin (Eomes, middle panel), and perforin (Pfn, lower panel), normalized to
housekeeping b2-microglobulin (B2m), on gd thymocytes either freshly isolated or cultured for 7 d with the indicated cytokines. Results in this figure are rep-
resentative of 3–18 independent experiments; each dot represents an individual sample. *p , 0.05, **p , 0.005.
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production, we considered that naive CD4+ T cells typically require
TCR/CD3 and CD28 ligation in the presence of IL-2 and IL-12 for
differentiation along the “T helper 1” pathway (28). Although such
a “Th1 mix” was indeed capable of generating IFN-g+ gd T cells,
we surprisingly found that IL-2 alone was also sufficient (Fig. 2A,
upper panel). This effect was potentiated by IL-12, whereas TGF-b
abrogated the process. Unexpectedly, the addition of TCR stim-
ulation via anti-CD3 mAb did not enhance, but rather reduced, the
IL-2–mediated differentiation of human IFN-g+ gd T cells (Fig. 2A,
upper panel).
We next tested a large panel of individual cytokines and ob-
served that besides IL-2, only IL-15 (but notably not IL-4 or IL-7)
was able to induce IFN-g production in gd thymocyte cultures
(Fig. 2A, middle panel). Both IL-2 and IL-15 treatments also pro-
moted TNF-a expression (Fig. 2A, lower panel), upregulated the
activation marker CD69 (Fig. 2B), and drove thymocytes along
the effector/memory differentiation pathway, toward a CD45RA+
CD27– T effector memory stage (Fig. 2C).
Concerning gd T cell cytotoxicity, IL-2 and IL-15 (but not IL-7)
induced the expression of the degranulation marker CD107a on gd
thymocytes (Fig. 2D) and endowed them with potent killing ca-
pacity against leukemia target cells (Fig. 2E). Of note, exogenous
IL-2 and IL-15 also enhanced the effector functions of gd PBLs,
especially their degranulation/cytotoxic potential (Supplemental
Fig. 1).
The acquisition of IFN-g/TNF-a production and cytolytic ca-
pacity by gd thymocytes were positively correlated, suggesting
a common pathway of cytotoxic type 1 differentiation (Fig. 2F).
Moreover, IL-2/IL-15 signals induced de novo expression of the
type 1 master transcription factors T-bet and eomesodermin, as well
as the cytolytic molecule perforin (Fig. 2G). These data firmly
demonstrate that IL-2 and IL-15 are key functional differentiation
factors for human gd T cells. Importantly, they also show that IL-2
and IL-15 signals are sufficient, in the absence of TCR activation,
to generate fully functional gd T cells from immature thymocytes.
Vd1 and Vd2 T cell subsets follow similar rules of functional
differentiation
Given that human gd T cells comprise two major subsets, Vd1+
cells (5–30% of gd PBLs but more abundant in tissues) and Vd2+
cells (60–95% of gd PBLs), both strongly biased toward cytotoxic
type 1 functions (3, 29), we next assessed whether they followed
similar rules of differentiation. Consistent with the literature (25),
the thymic gd repertoire was largely biased for Vd1+ thymocytes,
FIGURE 3. Vd1 and Vd2 subsets of gd T cells follow similar rules of functional differentiation. (A) CD1a+ gd thymocytes were FACS sorted and cultured
for 7 d with the indicated cytokines (at 10 ng/ml). Cells were restimulated for 4 h with PMA and ionomycin and stained for TCRVd1, TCRVd2, and intracellular
IFN-g and TNF-a. Histograms depict percentages of IFN-g+ cells (upper panels) or TNF-a+ cells (lower panels) within pregated Vd1+ or Vd2+ cells. (B and D)
CD32CD42CD82TCRgd2 thymic progenitors were FACS sorted and cultured on OP9-DL1 monolayers in the presence of IL-7 with or without IL-2. At indicated
time points, cells were harvested and stained for surface CD3, TCRVd1, TCRVd2 (B), and intracellular IFN-g (C) and TNF-a (D). Graphs represent percentages
of IFN-g + cells (C) or TNF-a+ cells (D) within pregated Vd1+ or Vd2+ cells. Dead cells were excluded from the analysis using LIVE/DEAD Fixable Dead Cell
Stain Kits. Data are representative of six to eight independent experiments with similar results; each dot represents an individual sample.
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with an average Vd1/Vd2 ratio of 25, which was maintained
in vitro upon IL-7, IL-2, or IL-15 treatment (Supplemental Fig.
2A). In all thymic samples analyzed, Vd1+ T cells behaved as
expected: they were functionally immature ex vivo and differen-
tiated into type 1 effectors in response to IL-2 or IL-15 stimuli
(Supplemental Fig. 2B). However, the results obtained by gating
on the Vd2+ population were affected by an important intersample
variation (Supplemental Fig. 2B). We considered that this could be
due to blood contamination or recirculation (back to the thymus)
of mature Vg9Vd2 cells, which are much more abundant in the
blood than in the thymus (,3% of total gd thymocytes). To over-
come these problems, we purified CD1a+ gd T cells, which are
exclusive to the thymus (Fig. 1A, lower panel) and cultured them
for 7 d with IL-7, IL-2, or IL-15. We found that both Vd1+ and Vd2+
cells similarly acquired type 1 effector properties in response to IL-2
and IL-15, but not IL-7 (Fig. 3A).
As an alternative developmental strategy, we differentiated gd
T cells from sorted CD32TCRgd2CD42CD82 thymic precursors
cultured on OP9-DL1 monolayers, as previously described (24). In
the presence of IL-7 alone, Vd1 and Vd2 T cells developed normally
(Fig. 3B) to a Vd1/Vd2 ratio similar to that observed ex vivo
(Supplemental Fig. 2A). We therefore think this is an elegant model
to characterize gd T cell differentiation from very early devel-
opmental stages. Most importantly, the further addition of IL-2
was necessary to generate IFN-g– (Fig. 3C) and TNF-a– (Fig. 3D)
producing gd T cells, and this occurred similarly for Vd1 and Vd2
T cell subsets (Fig. 3C, 3D). These data demonstrate that IL-2 (or
IL-15) signals drive the functional differentiation of both major
subsets of human gd T cells.
IL-2/IL-15 signals induce gd type 1 cell differentiation via the
MAPK/ERK pathway
To gain further mechanistic insight into the type 1 differentiation
pathway of human gd T cells, we probed the three major signaling
pathways downstream of common g-chain cytokine receptors and
observed that IL-2 stimulation hyperphosphorylated ERK1/2
(MAPK pathway), STAT5 (JAK/STAT pathway), and AKT (PI3K
pathway) (Fig. 4A). To determine which of these signaling pathways
was critical for functional differentiation of gd T cells, we an-
alyzed the effect of specific chemical inhibitors on gd thymocyte
cultures. When added at the start of the cultures, all of these
drugs interfered with gd T cell proliferation and prevented their
functional differentiation (Supplemental Fig. 3A). Of note, al-
though proliferation was necessary for IFN-g induction, this
specifically required IL-2 or IL-15 signals, as IL-7 failed to do so
even after five cell divisions (Fig. 4B). To dissociate proliferation
from differentiation, we added the inhibitors at day 4 of culture,
when cells had already undergone five rounds of division (Fig.
4B). Whereas blocking STAT5 or PI3K/AKT had no detectable
effect, the MAPK/ERK inhibitor UO126 (30, 31) completely
abrogated the differentiation of IFN-g+ or TNF-a+ gd T cells
(under IL-2 or IL-15 treatment) (Fig. 4B, Supplemental Fig. 3B).
Interestingly, IL-2 or IL-15 signals also enhanced IL-2 pro-
duction by gd T cells, thus providing an autocrine mechanism to
sustain their functional differentiation (Supplemental Fig. 3B).
The production of IL-2 (as well as TNF-a) by gd T cells was also
completely abolished by the addition of UO126, but not LY294002
or Ssi (Supplemental Fig. 3B). These data demonstrate that gd
T cell cytotoxic type 1 differentiation can be manipulated by drugs
specifically targeting the MAPK/ERK pathway (32).
Collectively, our results identify MAPK-mediated IL-2/IL-15
signaling as the major functional differentiation pathway of human
gd T cells toward antitumor (cytotoxic type 1) effector lymphocytes.
Discussion
Seminal studies in murine models have shown that gd T cells can
complete their functional differentiation in the thymus (19–21,
26). In contrast, the data presented in the present study show that
human gd thymocytes (obtained from young children subjected to
cardiac surgery) are functionally immature. Given that circulating
gd PBLs display type 1 effector properties (13, 18) and express
memory markers (15), human gd T cells must thus complete their
differentiation in the periphery, as reported for ab T cells (33, 34).
In healthy individuals, gd PBLs are strongly biased toward
IFN-g production (type 1 effectors), and throughout our study we
failed to identify any significant production of type 2 or type 17
FIGURE 4. The MAPK/ERK signaling pathway is required for IL-2–mediated type 1 differentiation of human gd T cells. MACS-purified gd thymocytes were
cultured in the presence of 10 ng/ml IL-2, IL-7, or IL-15. (A) Western blot analysis of p-ERK1/2 (Thr202/Try204), ERK1, p-AKT (Ser473), p-STAT5 (Tyr694/699), and
STAT5a in cell lysates obtained at the indicated timepoints. C, control medium without cytokines. The numbers above the blots correspond to desitometric analysis
of the corresponding bands. (B) Effect of chemical inhibitors on the production of IFN-g in gd thymocyte cultures. At day 4 (after five cell divisions, based on CFSE
dilution), specific inhibitors of STAT5 (Ssi), PI3K (LY294002), or MEK phosphorylation (UO126) were added (20 mM each), and at day 7 cells were
restimulated for 4 h with PMA and ionomycin and stained intracellularly for IFN-g. Dead cells were excluded from the analysis using LIVE/DEAD Fixable
Dead Cell Stain Kits. Data are representative of three to five independent experiments with similar results.
The Journal of Immunology 5
 at U











162 additional f i les 
	
	
cytokines. Namely, IL-17, which is constitutively expressed by
a subset of murine gd T cells (19, 26), is rarely expressed in hu-
man gd T cells from healthy donors (16–18). In contrast, IL-17–
producing gd T cells seem to accumulate to high numbers in
clinical cases of bacterial meningitis, and their rules of differen-
tiation have been previously dissected (17, 35).
In our study, the naive and immature phenotype of human gd
thymocytes provided an ideal system to investigate the molecular
cues required for acquisition of type 1 effector properties. Our work
demonstrated that IL-2 or IL-15 signals are sufficient to drive the
differentiation of human gd T cells into IFN-g/TNF-a producers
also endowed with potent cytotoxicity against tumor targets.
The redundant functions of IL-2 and IL-15 can be explained by
the structure of their respective receptors, which share not only the
common g-chain but also their second signaling subunit, IL-2Rb.
A third subunit, IL-2Ra or IL-15Ra, is cytokine specific and
stabilizes binding but apparently lacks signaling activity. Struc-
tural comparisons of IL-2/IL2-Ra and IL-15/IL15-Ra interactions
have emphasized their similarities (36, 37), and it has been re-
cently demonstrated that they induce similar downstream tran-
scriptional effects (38).
On the other hand, IL-7 clearly failed to trigger differentiation of
cytotoxic type 1 gd T cells. This is in stark contrast with the major
role described for IL-7 in the functional differentiation of human
NKT cells (39) and IL-17–producing gd T cells (40). These lines of
evidence establish an interesting cytokine dichotomy for human gd
T cells: whereas IL-7 promotes type 17 effector functions, IL-2 and
IL-15 are the main drivers of the type 1 program. Of note, because
IL-15 stimulation induces gd T cells to produce IL-2 (Supplemental
Fig. 3B), this cytokine could also be the direct (autocrine) mediator
of the type 1 program downstream of IL-15 signals.
Unexpectedly, TCR activation was not required for the func-
tional differentiation of human gd thymocytes. Recent work from
Hayday and colleagues (41) on murine gd T cells suggests that
innate-like gd T cell subsets may lack TCR responsiveness in the
periphery following strong TCR signaling during thymic devel-
opment. Naturally, we cannot assess whether human gd thymo-
cytes (the starting point of our in vitro experiments) have already
received TCR signals in vivo. Were this to be the case, IL-2 and
IL-15 would act as terminal differentiation factors in cells that had
been previously selected via their TCR. This is also reminiscent of
the two-step model proposed by Lio and Hsieh (42) and Farrar and
colleagues (43) for murine Foxp3+ regulatory T cell development.
Importantly, whereas for regulatory T cells this two-step process is
completed in the thymus, human gd T cell functional differenti-
ation seemingly involves a second step that takes place in the
periphery. Physiologically, this likely depends on the provision of
IL-2 by activated T cells (either gd T cells themselves or their ab
counterparts) or IL-15 by myeloid and epithelial cells. Concerning
a potential autocrine IL-2 loop based on gd T cells, we have
previously shown that IL-2 production requires TCR activation in
the presence of CD28 costimulation (44). Therefore, CD80/CD86,
as expressed by APCs, including dendritic cells but also Vg9Vd2
T cells, are likely additional players in the functional differentiation
of gd T cells. For therapeutic purposes (in cancer immunother-
apy), our results strongly suggest that the provision of exogenous
IL-2 or IL-15 may be critical, not only for gd PBL activation and
expansion, but also particularly for extensive differentiation of
antitumor effectors from recent thymic emigrants and circulating
naive gd T cells.
Downstream of IL-2/IL-15 receptors, our data provide the im-
portant insight that gd T cell cytotoxic type 1 differentiation can
be manipulated by drugs specifically targeting the MAPK/ERK
pathway (32). In this context, dual-specificity phosphatases seem
particularly promising targets for modulating MAPK-dependent
immune processes (32).
In conclusion, our results detach human gd T cells from para-
digms of T cell differentiation: their differentiation program is not
completed in the thymus, unlike murine gd T cells (19, 20, 26),
and it does not require TCR/co-receptor activation in the periph-
ery, in contrast with naive CD4+ T cells (28). Instead, IL-2/IL-15
signals are sufficient for functional differentiation of human gd
T cells, which clearly aligns them with NK cells (45) and some
naive CD8+ T cell populations (46). Thus, the three main cyto-
toxic type 1 lymphocyte subsets share a common, IL-2/IL-15–
dependent differentiation program with key implications in cancer
immunotherapy.
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Rysselberge, N. Twité, M. Goldman, A. Marchant, and F. Willems. 2010. Human
cytomegalovirus elicits fetal gd T cell responses in utero. J. Exp. Med. 207: 807–821.
15. Dieli, F., F. Poccia, M. Lipp, G. Sireci, N. Caccamo, C. Di Sano, and A. Salerno.
2003. Differentiation of effector/memory Vd2 T cells and migratory routes in
lymph nodes or inflammatory sites. J. Exp. Med. 198: 391–397.
16. Caccamo, N., M. Todaro, G. Sireci, S. Meraviglia, G. Stassi, and F. Dieli. 2013.
Mechanisms underlying lineage commitment and plasticity of human gd T cells.
Cell. Mol. Immunol. 10: 30–34.
6 IL-2/IL-15–MEDIATED gd T CELL FUNCTIONAL DIFFERENTIATION
 at U
















17. Ness-Schwickerath, K. J., C. Jin, and C. T. Morita. 2010. Cytokine requirements
for the differentiation and expansion of IL-17A- and IL-22-producing human
Vg2Vd2 T cells. J. Immunol. 184: 7268–7280.
18. DeBarros, A., M. Chaves-Ferreira, F. d’Orey, J. C. Ribot, and B. Silva-Santos.
2011. CD70-CD27 interactions provide survival and proliferative signals that
regulate T cell receptor-driven activation of human gd peripheral blood
lymphocytes. Eur. J. Immunol. 41: 195–201.
19. Ribot, J. C., A. deBarros, D. J. Pang, J. F. Neves, V. Peperzak, S. J. Roberts,
M. Girardi, J. Borst, A. C. Hayday, D. J. Pennington, and B. Silva-Santos. 2009.
CD27 is a thymic determinant of the balance between interferon-g- and inter-
leukin 17-producing gd T cell subsets. Nat. Immunol. 10: 427–436.
20. Jensen, K. D., X. Su, S. Shin, L. Li, S. Youssef, S. Yamasaki, L. Steinman,
T. Saito, R. M. Locksley, M. M. Davis, et al. 2008. Thymic selection determines
gd T cell effector fate: antigen-naive cells make interleukin-17 and antigen-
experienced cells make interferon g. Immunity 29: 90–100.
21. Turchinovich, G., and A. C. Hayday. 2011. Skint-1 identifies a common mo-
lecular mechanism for the development of interferon-g-secreting versus
interleukin-17-secreting gd T cells. Immunity 35: 59–68.
22. Turchinovich, G., and D. J. Pennington. 2011. T cell receptor signalling in gd
cell development: strength isn’t everything. Trends Immunol. 32: 567–573.
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Casein kinase 2 controls the survival of normal thymic and
leukemic γδ T cells via promotion of AKT signaling
ST Ribeiro1, M Tesio2,3, JC Ribot1,3, E Macintyre2, JT Barata1 and B Silva-Santos1
The thymus is the major site for normal and leukemic T-cell development. The dissection of the molecular determinants of T-cell
survival and differentiation is paramount for the manipulation of healthy or transformed T cells in cancer (immuno)therapy. Casein
kinase 2 (CK2) is a serine/threonine protein kinase whose anti-apoptotic functions have been described in various hematological
and solid tumors. Here we disclose an unanticipated role of CK2 in healthy human thymocytes that is selective to the γδ T-cell
lineage. γδ thymocytes display higher (and T-cell receptor inducible) CK2 activity than their αβ counterparts, and are strikingly
sensitive to death upon CK2 inhibition. Mechanistically, we show that CK2 regulates the pro-survival AKT signaling pathway in γδ
thymocytes and, importantly, also in γδ T-cell acute lymphoblastic leukemia (T-ALL) cells. When compared with healthy thymocytes
or leukemic αβ T cells, γδ T-ALL cells show upregulated CK2 activity, potentiated by CD27 costimulation, and enhanced apoptosis
upon CK2 blockade using the chemical inhibitor CX-4945. Critically, this results in inhibition of tumor growth in a xenograft model
of human γδ T-ALL. These data identify CK2 as a novel survival determinant of both healthy and leukemic γδ T cells, and may thus
greatly impact their therapeutic manipulation.
Leukemia advance online publication, 16 December 2016; doi:10.1038/leu.2016.363
INTRODUCTION
T cells develop in the thymus. The dissection of the cell-intrinsic
and -extrinsic signals that regulate thymocyte survival, prolifera-
tion and differentiation is critical to understand their potential for
transformation and to devise new therapies for T-cell acute
lymphoblastic leukemia (T-ALL).
T-cell commitment is coupled to somatic T-cell receptor (TCR)
rearrangements, generating thymocytes bearing either an αβ or a
γδ TCR.1 The expression of a pre-TCR composed of TCRβ and
the invariant pTα chain in αβ thymocyte progenitors results
in a massive proliferative burst (‘β-selection’) that dictates that
αβ T cells largely outnumber their γδ counterparts. Likely a
consequence, although significant progress has been made
in our understanding of human αβ T-cell development,
the molecular determinants of γδ thymocytes remain poorly
characterized.1
Most of what we know about thymic γδ T-cell differentiation
comes from studies performed in mice, showing how various
receptors (namely, TCRγδ, CD27 and LTβR) and downstream
transcription factors (such as Id3, Sox13, TCF1 and Lef1) control
various maturation steps, from divergence from the αβ lineage to
the acquisition of effector functions such as pro-inflammatory
cytokine production.2–7 In contrast, much less is known about
human thymic γδ T-cell differentiation. Notwithstanding, we
recently showed that interleukin (IL-2) or IL-15 differentiate
human γδ thymocytes into cytotoxic type 1 effector T cells,
rendering them highly efficacious against leukemic cells in vitro
and in vivo.8,9
γδ thymocytes can themselves transform into leukemic cells,
causing a rare (o10% of all cases) form of T-ALL with distinctive
clinical features.10–12 Given that malignant γδ T cells have been
very poorly studied and lack defined molecular targets, we have
here addressed the potential role of casein kinase 2 (CK2), a
signaling effector molecule previously implicated in chronic
lymphocytic leukemia,13,14 multiple myeloma,15 B-ALL,16,17
T-ALL18,19 and other hematological disorders (reviewed in Piazza
et al.20).
CK2 is a ubiquitous and constitutively activated serine/
threonine protein kinase that regulates multiple pathways
including phosphatidylinositol 3-kinase/AKT and WNT signaling,
nuclear factor-κB transcription and the DNA damage response.20
CK2 displays pro-survival and anti-apoptotic functions that were
described in several cancer cell types. CK2 is frequently over-
expressed or hyperactivated in both solid tumors and hematolo-
gical malignancies, thus making it a promising target for cancer
treatment.20 In contrast, the physiological function of CK2 in
nontransformed cells is less established. Recent studies in mice
have demonstrated that CK2 activity is necessary for peripheral
T-cell activation and function: interference with CK2 signaling
impaired CD4+ T-cell activation and differentiation into T helper
type 2 (Th2) or Th17 cells,21, whereas the genetic deletion of CK2
in CD4+ Foxp3+ regulatory T cells abolished their suppressive
activity against allergy-promoting Th2 cells.22 However, no
functional role has yet been attributed to CK2 in the human
thymus.
In this study we identified a novel role for CK2 in controlling the
survival of normal γδ thymocytes and γδ T-ALL cells. We analyzed
CK2 activity in γδ versus αβ thymocytes and T-ALL cells, its
regulation by cell-extrinsic signals, the downstream signaling
mechanisms and the effect of its inhibition in vitro and in vivo in a
xenograft model of γδ T-ALL.
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Thymic specimens (from newborn to 15-year-old children) were obtained
during pediatric corrective cardiac surgery after parents’ written informed
consent. The study was approved by the Ethics Board of Faculdade de
Medicina da Universidade de Lisboa. Primary T-ALL blasts derived from
diagnostic samples (peripheral blood or bone marrow), obtained
after informed content and amplified upon xenografting into NSG
(NOD.Cg-Prkdc(scid)Il2rg(tm1Wjll)/SzJ) mice.
Isolation, cell culture and viral transduction
Thymic T cells were collected after thymus tissue dispersion and separation
by Histopaque-1077 (Sigma-Aldrich, St Louis, MO, USA) density gradient
separation. TCRγδ-positive T cells were isolated (to 497% purity) by
magnetic positive selection; TCRαβ-positive T cells were isolated (to 496%
purity) by magnetic positive selection from the TCRγδ-negative fraction
(Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were used as fresh or,
when indicted, cells were cultured at 37 °C with 5% CO2 in complete
RPMI-1640 as previously described23 on indicated conditions. For long-
term in vitro cell culture of thymocytes (7 days), recombinant human IL-2
was added to the medium. The PEER T-ALL (DSMZ-German Collection of
Microorganisms and Cell Cultures, Braunschweig, Germany) and MOLT-4T-
ALL (ATCC CRL-1582) were cultured in 90% RPMI-1640+10% fetal bovine
serum following the manufacturer’s instructions. When indicated, PEER cell
line was transduced using a bicistronic retroviral DNA construct, either
empty vector (LZRS) expressing only IRES followed by eGFP (LZRS-IRES-
eGFP) or vector co-expressing myrPKB/AKT (constitutively activated AKT)
and eGFP (LZRS-myrPKB/AKT-IRES-eGFP) as previously described.24 To
increase the percentage of transduced cells for the following experiments,
GFP+ cells were sorted (≈100% purity) using a FACSAria high-speed cell
sorter (BD Biosciences, San Jose, CA, USA).
Chemicals and antibodies
Anti-human monoclonal antibodies were used against: CD3 (UCHT1), CD27
(LG.7F9), CD4 (RPA-T4), CD7 (4H9) and panαβTCR (IP26) from eBioscience
(San Diego, CA, USA); CD28 (CD28.2), CD8 (SK1), CD45 (HI30), Vδ2 (B6), CD3
(OKT3), CD45RA (HI100), Annexin-V and 7-aminoactinomycin D (7-AAD)
from Biolegend (San Diego, CA, USA); panγδTCR (5A6.E9) from Thermo-
Fisher (Rockford, IL, USA); Vδ1 (REA173) from Miltenyi Biotech; p-S129-AKT,
AKT, p-S9-GSK3β, GSK3β, p-S380-PTEN, PTEN, p-S235/236-S6 and S6 from
Cell Signaling (Danvers, MA, USA); Calnexin and GAPDH from Sicgen
(Cantanhede, Portugal); 7-AAD from Invitrogen (Carlsbad, CA, USA) and
B-cell lymphoma 2 (Bcl-2) from Dako (Glostrup, Denmark). Recombinant
human sCD27 ligand and recombinant human IL-2 were purchased
from Peprotech (Rocky Hill, NJ, USA); CX-4945 (Silmitasertib) from
Adooq Bioscience (Irvine, CA, USA) and Biorbyt (Cambridge, UK); TBB from
Sigma-Aldrich; TG-003 and Harmine from Focus Biomolecules (Plymouth
Meeting, PA, USA).
Flow cytometry, cell viability, cell cycle and proliferation analysis
Cells were stained for the indicated cell surface markers, and intracellular
staining was performed using fixation/permeabilization and permeabiliza-
tion buffers (both from eBioscience), following the manufacturer’s
instructions. Cell apoptosis was analyzed by flow cytometry using
Annexin-V/7-AAD staining as previously reported.25 For cell cycle analysis,
cells were stained for 1 h at 37 °C with 30 μl of 7-AAD (BD Pharmingen, San
Diego, CA, USA) in permeabilization buffer (eBioscience). CFSE-based
proliferation assays (CellTrace CFSE kit, Invitrogen, final concentration
0.5 mM) were performed as previously described.4 Samples were acquired
using LSRFortessa or Accuri C6 (both from BD Biosciences). Data were
analyzed using FlowJo software (TreeStar, Ashland, OR, USA).
CK2 kinase activity assay
CK2 activity was measured in cell lysates (from equal cell numbers) using
the casein kinase-2 assay kit (17-132) from Upstate Biotechnology (Lake
Placid, NY, USA), following the manufacturer’s instructions. Briefly, total
protein lysates were incubated for 10 min at 30 °C in a reaction mixture
containing: CK2α-specific peptide, [γ-32 P]ATP and protein kinase A
inhibitor cocktail. The radioactivity incorporated into the substrate was
determined in P81 phosphocellulose paper-squares by scintillation counting
as previously reported.14 CK2 activity in γδ+ and αβ+ xenograft-derived
blasts was measured on samples that showed comparable percentages of
human engraftment (defined by fluorescence-activated cell sorting
analysis based on the expression of CD45 and CD7 antigens).
Western blot analysis
Cell lysates were used for immunobloting as previously described.14 Briefly,
the cells were lysed, at 4 °C, in cold lysis buffer (50 mM Tris (pH 7.6), 150 mM
EDTA, 1% Nonidet P-40 in phosphate-buffered saline) enriched with
protease and phosphatase inhibitor cocktails (Roche, Burgess Hill, UK). The
total proteins were quantified using a Bradford assay (Bio-Rad, Hercules,
CA, USA), following the manufacturer’s instructions. Equal amounts of total
protein was denatured in Laemmli buffer (Bio-Rad), boiled for 5 min at
95 °C and loaded in a 10% SDS–polyacrylamide gel electrophoresis. After
electrophoretic separation, the proteins were transferred to nitrocellulose
blotting paper (Amersham Biosciences, Little Chalfont, UK). The mem-
branes were blocked with 5% bovine serum albumin and 0.5% Tween-20
(Sigma-Aldrich) in phosphate-buffered saline and probed with the
indicated primary antibodies overnight. After rinse, the membranes were
probed using appropriate horseradish peroxidase-conjugated secondary
antibodies and developed by chemiluminescence using the ChemiDoc XRS
+ imaging system (Bio-Rad).
In vivo mouse experiments
All experimental procedures were performed in strict accordance with the
recommendations of the European Commission (Directive 2010/63/UE),
French National Committee (87/848) and Portuguese authorities (Decreto-
Lei 113/2013) for the care and use of laboratory animals. TCRαβ- or TCRγδ-
positive T-ALL cells obtained from patient diagnostic were injected into
8–12-week-old NSG mice (1× 106 cells/mouse, tail vein injections). Mice
were monitored weekly by flow cytometry for human leukemic load
(hCD7+, hCD45+ cells) in peripheral blood. Mice were killed when
terminally ill and blast cells from bone marrow were collected. For the
in vivo experiment of γδ T-ALL treatment, 10–12-week-old NRGS mice were
injected subcutaneously in the right flank with 2× 106 PEER cells
resuspended in 100 μl of phosphate-buffered saline. At day 20, all mice
presented palpable tumors (100–150 mm3) and were randomly distributed
into two groups (n⩾ 3). The animals were treated with CX-4945 (75 mg/kg),
by oral gavage twice daily (b.i.d.) or vehicle control (25 mM sodium
bisphosphate buffer) as previously described.26 Mice were monitored daily
and weighed frequently. Tumors were measured every 2 days with a
caliper and tumor volume was calculated (volume= (length×width)2/2).
At day 13, after starting the treatment, all mice were killed (an ethical
requirement for the control group, when tumor reached 2000 mm3).
Statistical analysis
Statistical significance of differences between indicated conditions was
assessed using Student’s t-test with Welch’s correction and is indicated
when significant as *Po0.05; **Po0.01; **Po0.001. All statistical analyses
were performed using GraphPad Prism software (San Diego, CA, USA).
RESULTS
Human γδ thymocytes have enhanced CK2 activity and are highly
sensitive to its inhibition
This study initiated with the analysis of CK2 activity in normal
thymocyte subsets obtained from pediatric thymic biopsies. We
measured CK2 activity using a substrate-specific kinase assay in
freshly isolated TCRγδ+ or TCRαβ+ cells, and unexpectedly found
twofold higher activity in γδ thymocytes relative to their αβ
counterparts (Figure 1a). To address its physiological relevance, we
treated thymocytes for 24 h with a highly specific ATP-competitive
inhibitor of CK2, CX-4945.27 Flow cytometry analysis of Annexin-V/
7-AAD-stained cells revealed increased apoptosis of γδ compared
with CD4+ and CD8+ αβ thymocytes (Figure 1b). To assess the
longer-term impact of CX-4945 treatment, thymocytes were
cultured in the presence of TCR plus costimulation for 7 days.
The γδ thymocytes were highly susceptible to apoptosis upon CK2
inhibition in a dose dependent-manner (Figure 1c). In contrast, as
previously reported,18 CD4+ or CD8+ αβ thymocyte survival was
not significantly affected following CK2 inhibition (Figure 1c).
CK2 controls γδ thymocyte and T-ALL cell survival
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These data revealed that healthy γδ thymocytes are exquisitely
dependent on their high basal CK2 activity for survival, and thus
extremely sensitive to chemical inhibition using CX-4945. To verify
that these effects were mediated by inhibition of CK2 rather
than other kinases, CLK2 and DYRK1A, recently reported to be
sensitive to CX-4945 treatment,28,29 we also tested another CK2
inhibitor, 4,5,6,7-tetrabromobenzotriazole (TBB); TG-003 that
specifically targets CLK2;28,30 and Harmine that selectively inhibits
DYRK1A.31 Importantly, only the other CK2 inhibitor, TBB,
reproduced the effects of CX-4945, whereas TG-003 and Harmine
failed to affect γδ thymocyte survival (Supplementary Figure S1).
These results strongly suggest that the physiological target of
CX-4945 in γδ thymocytes is CK2.
CK2 activity in γδ thymocytes is modulated by TCR stimulation and
promotes AKT signaling
We next asked which signals regulated CK2 activity in γδ
thymocytes. Very few studies have documented CK2 modulation
by physiological stimuli in T cells.21,32 When we stimulated (for 6 h)
isolated thymocyte subsets via the TCR complex using agonist
anti-CD3ε antibodies, we observed an approximately threefold
enhancement of CK2 activity selectively in γδ thymocytes
(Figure 2a). We also tested the impact of costimulation, particularly
through CD27 that we have shown to play a major role in γδ T-cell
development and expansion.4,33,34 However, the addition of
soluble recombinant CD27-ligand/CD70 (sCD70) had no additive
effect on CK2 activity (Figure 2a). Thus, our data suggest that CK2
activity in healthy γδ thymocytes is modulated primarily by TCR
signals.
To gain insight into the downstream effects of CK2 signaling
and its inhibition in γδ thymocytes, we focused on the AKT
signaling pathway that is involved in cell survival and prolifera-
tion and known to be regulated by CK2 in both normal and
malignant αβ T lymphocytes.18,35 We observed that TCR/CD27
stimulation inhibited PTEN (phosphatase and tensin homolog),
as measured by the increase in its phosphorylated form, and
potentiated the AKT signaling pathway in γδ but not αβ
thymocytes, as shown by the phosphorylation of AKT and its
downstream targets glycogen synthase kinase-3β (GSK3β) and
S6 (Figure 2b and Supplementary Table S1). These effects were
completely reversed by CX-4945 (Figure 2b). As functional
outcomes of CK2 inhibition, we observed decreased γδ
thymocyte proliferation (Figure 2c) and survival (Figure 2d).
Moreover, in agreement with the implication of AKT signaling
downstream of CK2, we found a similarly striking effect on γδ
thymocyte survival upon treatment with the specific AKT
inhibitor, MK-2206 (ref. 36) (Figure 2d).
CD27-dependent upregulation of CK2 activity and downstream
AKT signaling in γδ T-ALL
We next asked how CK2 activity would affect γδ T-ALL. First, we
compared CK2 activity in normal γδ and αβ thymocytes versus γδ
and αβ T-cell blasts obtained from T-ALL patients (and expanded
in NSG mice, with similar engraftment, as detailed in the Materials
and methods section). As expected, αβ T-ALL cells displayed
higher levels of CK2 activity than αβ thymocytes (Figure 3).
Notably, we detected markedly higher CK2 activity in γδ T-ALL
cells as compared with healthy thymocytes and αβ T-ALL blasts
(Figure 3). Moreover, the γδ T-ALL cell line PEER reproduced the
very high CK2 activity observed in γδ T-ALL blasts (Figure 3),
making it a good model for further biochemical and functional
CK2 tests in γδ T-ALL.
The CK2 inhibitor, CX-4945, suppressed CK2 activity in γδ
T-ALL cells in a dose-dependent manner (Figure 4a). As with
healthy γδ thymocytes, the effects of CX-4945 were only
reproduced by another CK2 inhibitor, TBB, but not by TG-003
or Harmine that selectively target CLK2 and DYRK1A, respec-
tively (Supplementary Figure S1). Thus, in γδ T-ALL cells also,
CX-4945 exerts its effects by suppressing CK2 activity. On the
other hand, CK2 activity was enhanced upon activation, with
CD27 costimulation having a synergistic contribution in γδ
T-ALL cells (Figure 4b), in contrast with γδ thymocytes
(Figure 2a). Of note, PEER cells are CD27+ Vδ1+ γδ T-ALL cells
(Supplementary Figure S2). A CD27-dependent effect was also
observed on AKT signaling (Figure 4c), and was completely
abrogated upon CX-4945 treatment, also in a dose-dependent
manner (Supplementary Figure S3).
Functionally, CK2 inhibition led to γδ T-ALL cell cycle arrest at
G2/M phase, cell apoptosis and decreased Bcl-2 protein levels
(Figure 4d). To further examine the functional impact of AKT
activation downstream from CK2, we tried to rescue this
apoptotic phenotype by expressing a myristoylated, constitu-
tively active form of AKT.37 Cells expressing myristoylated AKT
displayed high levels of AKT phosphorylation that were
insensitive to CK2 inhibition (Figure 4e). Importantly, AKT
hyperactivation partially rescued γδ T-ALL survival under
CX-4945 treatment (Figure 4f). On the other hand, CK2 activity
was not affected by AKT hyperactivation (Supplementary

































































Figure 1. Human γδ thymocytes have enhanced CK2 activity and are highly sensitive to CX-4945. (a) In vitro CK2α activity (kinase assay) in
freshly isolated human thymic γδ and αβ T-cells (2× 106 cells per assay). CPM, counts per min. (b) Survival (% of live cells) of human thymic γδ,
CD4+ and CD8+ T cells following 24 h of incubation with 5 μM of the CK2 inhibitor, CX-4945, analyzed by flow cytometry using Annexin-V/7-
AAD staining. (c) Survival (% of live cells) of human thymic γδ, CD4+ and CD8+ T cells to different concentrations of CX-4945 (or vehicle),
analyzed by Annexin-V/7-AAD staining following 7 days in culture with recombinant human IL-2 (rhIL-2) plus CD3+CD27 or CD3+CD28
stimulation of sorted thymic γδ or αβ T cells, respectively. Data in this figure are representative of at least three independent experiments;
**Po0.01, ***Po0.001 (T-test).
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downstream rather than upstream of CK2, and that AKT is a key
mediator of CK2 functions.
γδ T-ALL cells are highly sensitive to CK2 inhibition in vitro and
in vivo
To further evaluate the functional impact of CK2 inhibition on γδ
T-ALL survival, we compared the effect of CX-4945 treatment on
primary γδ versus αβ T-ALL cells, as well as representative cell
lines, PEER and MOLT-4, respectively.
Upon 48 h of in vitro treatment with CX-4945, we observed
increased cell apoptosis in primary γδ T-ALL samples compared with
αβ T-ALL cells (Figure 5a). We performed a more detailed test with
the T-ALL cell lines, at various time points of incubation with CX-4945,
and found a profound and dose-dependent effect on PEER (γδ T-ALL)
that were significantly more susceptible to apoptosis that MOLT-4
(αβ T-ALL) cells (Figure 5b). These data suggest that γδ T-ALL cells,
like healthy γδ thymocytes (Figures 1b and c), are considerably more
sensitive to CK2 inhibition than αβ T-ALL cells.
Finally, the increased sensitivity of γδ T-ALL cells to CX-4945
treatment in vitro led us to explore its therapeutic potential in vivo.
For this purpose, we established a xenograft model of human
γδ T-ALL by injecting 2× 106 PEER cells subcutaneously in
immune-deficient NRGS (NOD-Rag1null IL2Rgammanull) mice. After
the detection of palpable tumor, mice were equally distributed
0 1 105 2 105 3 105 4 105
 T-ALL (cell line)
 T-ALL (patient samples)
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Figure 3. γδ T-ALL cells display higher CK2 activity than αβ
counterparts. In vitro CK2α activity (kinase assay; 6.6× 106 cells per
assay) in freshly isolated γδ (n= 4) and αβ (n= 4) thymocyte samples;
γδ (n= 6) and αβ (n= 14) T-cell samples obtained from T-ALL
patients and expanded in NSG mice (as described in the Materials
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Figure 2. CK2 activity in γδ thymocytes is modulated by TCR stimulation and activates AKT signaling. (a) In vitro CK2α activity in sorted γδ and
αβ thymocytes (2× 106 cells per sample) after 6 h of stimulation with anti-CD3 antibodies (CD3), plus soluble CD27-ligand (CD3+CD27) or plus
5 μM CX-4945 (CD3+CD27+CX); values were normalized to unstimulated control (dashed line). (b) Western blot analysis of (phospho)proteins
implicated in AKT signaling, in γδ and αβ thymocytes (1× 106 cells per sample) stimulated as in (a). (c) Proliferation (CFSE dilution assay) of γδ
thymocytes after 7 days in culture with recombinant human IL-2 (rhIL-2) under the indicated conditions: medium only (Ctrl); anti-CD3
antibody stimulation (CD3); soluble CD27-ligand (CD27); their combination (CD3+CD27); and with 5 μM CX-4945 (CD3+CD27+CX). (d) Survival
(% of live cells) of γδ thymocytes after 7 days of stimulation (or not, Ctrl for control) with anti-CD3 antibodies (CD3), plus soluble CD27-ligand
(CD3+CD27), plus 5 μM of CX-4945 or 10 μM of MK-2206. Data in this figure are representative of at least three independent experiments;
*Po0.05, ***Po0.001 (T-test).
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according to tumor burden into two groups to receive CX-4945
(orally, twice a day) or vehicle control. We observed a striking
impact of CX-4945 treatment on tumor growth (Figure 6a).
Upon killing the mice at day 18 (an ethical requirement for the
control group), we scored great reductions in the CX-4945-
treated group concerning the tumor weight (Figure 6b), as
well its dissemination to the blood, bone marrow and spleen
(Figures 6c–e). Of note, this therapeutic effect was dose
dependent, as it was only observed with 75mg/kg (Figures 6a–e)
but not with 25 mg/kg (data not shown) of CX-4945. These data
collectively demonstrate the potential of CK2 inhibition for
treatment of γδ T-ALL.















































































































+            +      +
        +     +      +
                          +
Figure 4. CK2 activity in γδ T-ALL cells is potentiated by CD27 costimulation and promotes AKT signaling. (a) CK2α activity in the γδ T-ALL cell
line, PEER (2× 106 cells per condition), after 6 h of treatment with indicated concentrations of CX-4945. (b) CK2α activity in lysates from
γδ T-ALL (PEER) cells (2× 106 cells per condition) after 6 h of stimulation under the indicated conditions (T-test, *Po0.05; **Po0.01).
(c) Western blot analysis of (phospho)proteins implicated in AKT signaling, in γδ T-ALL (PEER) cells treated for 6 h with anti-CD3 antibodies
(CD3), plus soluble CD27-ligand (CD3+CD27) or plus 5 μM CX-4945 (CD3+CD27+CX). Data are representative of five independent experiments.
(d) Flow cytometry analysis of apoptosis (Annexin-V+; left panel), cell cycle/DNA staining (middle panel) and intracellular Bcl-2 protein staining
(right panel; values indicate mean fluorescence intensity (MFI)) of γδ T-ALL (PEER) cells treated with CX-4945 (5 μM) during the indicated times.
(e, f) Western blot analysis of phospho-AKT (and calnexin loading control) (e) and cell survival after 48 h (f) of PEER cells transduced with
a bicistronic retroviral DNA construct: either empty vector (LZRS) expressing only IRES followed by eGFP (LZRS-IRES-eGFP) or vector
co-expressing myrPKB/AKT and eGFP (LZRS-myrPKB/AKT-IRES-eGFP) (AKThi) and treated with 3 μM CX-4945 or vehicle (T-test, *Po0.05).

















































































Figure 5. γδ T-ALL cells are more susceptible than αβ T-ALL to apoptosis induced by CX-4945. Flow cytometry analysis of the survival
(Annexin-V/7-AAD staining) of (a) γδ (n= 5) and αβ (n= 5) T-cell blast samples (obtained from T-ALL patients and expanded in NSG mice) or
(b) γδ (PEER) or αβ (MOLT-4) T-ALL cell lines, cultured for the indicated times with increasing concentrations of CX-4945 (T-test, *Po0.05;
***Po0.001).
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Increased CK2 activity is typically associated with cell transforma-
tion in several hematological and solid tumors,38 but few reports
have demonstrated its relevance in physiological conditions.32,39
Recent studies in mice have shown that epithelial cells and
peripheral T cells depend on CK2 for their survival and function.
CK2 was required for the survival of intestinal epithelial cells in
inflammatory colitis,40 for CD4+ T-cell activation and differentia-
tion into Th2 or Th17 cells21 and for the suppressive function of
CD4+ Foxp3+ regulatory T cells against allergy-promoting Th2
cells.22 However, no physiological role has yet been attributed to
CK2 in the human thymus or on healthy human T cells.
Here we identify a major role for CK2 that is restricted to the γδ
lineage of human thymocytes. These display approximately
twofold higher CK2 activity and are strikingly more sensitive to
CK2 inhibition than their αβ counterparts. As we show that TCR
stimulation increases (~2.5-fold) CK2 activity in γδ thymocytes, we
may speculate that the different basal levels of CK2 activity in
γδ versus αβ thymocytes are because of stronger TCR signals
received during their development. It is well established that
strong TCR signaling favors γδ over αβ T-cell lineage
commitment1,41–43 and further affects subsequent γδ thymocyte
development.44 In this line of reasoning, the high CK2 activity in
agonist-selected γδ thymocytes could be an important pro-
survival mechanism to counteract the activation-induced cell
death underlying thymocyte negative selection.
We previously showed that αβ primary T-ALL cells display
higher levels of CK2 expression and activity than immunopheno-
typically equivalent normal αβ thymocytes.18 Most interestingly,
we now demonstrate that the differential CK2 activity between
the γδ and αβ T-cell lineages extends from healthy thymocytes to
transformed T-ALL cells. Thus, primary γδ T-ALL cells displayed
more than twofold higher CK2 activity compared with αβ T-ALL
counterparts. As we previously showed that endogenous CK2
activity correlates with increased susceptibility to apoptosis upon
CK2 inhibition,14,18,19 this differential activity likely explains the
higher sensitivity of γδ T-ALL cells observed in the present study.
Although rare, γδ T-ALL accounts for up to 10% of T-ALL cases,
and this is significantly higher than the proportion (1%) of
γδ thymocytes in the healthy thymus. This raises the possibility
that γδ thymocytes have increased potential for malignant
transformation.10,11,45 A possible contributor to this phenomenon
could be CD27 costimulation, as it increases CK2 activity
(synergistically with TCR stimulation) in γδ T-ALL cells expressing
high levels of CD27. Of note, the importance of CK2 in T-cell
biology is also underscored by its modulation by the inhibitory
receptor PD-1 that decreases CK2 activity and AKT signaling in
CD4+ T cells.35
The ability of CK2 to affect AKT signaling was previously
reported in T-ALL.14,18,19 Here we showed for the first time that a
CK2-AKT link exists in γδ thymocytes and γδ T-ALL cells. Most
important, we considerably extended previous knowledge by
demonstrating that AKT is essential for CK2-mediated effects:
(1) chemical AKT inhibition (with MK-2206) mimicked CK2
inhibition (with CX-4945); (2) the latter extinguished AKT signaling
(AKT phosphorylation and downstream effects); and (3) ectopic
expression of a constitutively active form of AKT partially rescued
the apoptosis because of CK2 inhibition. These results suggest
that, although AKT activation is not sufficient to fully mimic CK2
activity, it is absolutely required for CK2-mediated effects in
γδ T cells.
Maximal AKT activation requires phosphorylation at Ser129 (as
reported in our western blot analyses) by CK2 both in vitro and
in vivo.46,47 Activated AKT promotes cell survival through direct
phosphorylation of anti-apoptotic molecules, or indirectly through
the transcriptional activation of anti-apoptotic genes and
increased metabolic capacity.48,49 AKT inhibits GSK3β activity50
by direct phosphorylation of an N-terminal regulatory serine
residue, allowing glycogen and protein synthesis.51 Inhibition of
CK2 activity in γδ thymocytes or γδ T-ALL cells abrogated the
AKT/GSK3β signaling pathway and had a major impact on cell
survival and proliferation. Interestingly, the strong dependence on
AKT may be specific for human γδ T cells, as AKT-deficient mice
were reported to have a normal γδ T-cell pool in the periphery.52
Overall, our demonstration of the high sensitivity γδ T-ALL cells
to CK2 inhibition with CX-4945 in vitro and in vivo clearly supports
its use for γδ T-ALL treatment. Importantly, CX-4945 is currently in
phase II clinical trials in patients with multiple myeloma or
advanced solid cancers.27
Finally, our study has implications, not only for hematology, but
also for cancer immunotherapy, as γδ T cells are known to play
important roles in protective (antitumor) responses.53 In particular,
we have recently documented the potent antileukemia properties
of Vδ1+ γδ T cells expressing natural cytotoxicity receptors.9
The success of their clinical application, particularly in adoptive
cell therapy, will strongly depend on the capacity to survive ex vivo





















































































Figure 6. CX-4945 treatment inhibits γδ T-ALL growth in vivo.
(a) Tumor volume following injection of 2× 106 PEER γδ T-ALL cells
subcutaneously into NRGS mice, treated with 75 mg/kg CX-4945 or
vehicle (T-test, *Po0.05, **Po0.01). Day 0 refers to the start of
treatment of mice bearing palpable tumors. (b–e) Tumor weight
(b) or percentage of CD45+ CD7+ γδ T-ALL cells in the blood
(c), bone marrow (d) or spleen (e) of mice killed after 18 days of
treatment. Each dot represents an animal; T-test P-values are
indicated.
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TCR-mediated activation and in vivo establishment and expansion.
We thus believe an increased knowledge of the molecular
determinants of γδ T-cell survival, as disclosed here for CK2, will
be key to optimize their performance in cancer immunotherapy.
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